  C l in ica l  Inves t iga t ion  P lan  
 
Ve rs ion  1B   10219498DOC  Page  1  o f  73   
20 /OCT /201 7   Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te  
 Med t ron i c  Con f iden t ia l    
 
C l in ica l  Inves t iga t ion  P lan  
C l in ica l  Inves t iga t ion  P lan /S tudy  T i t le   Va l ian t  EVO  US  C l in i ca l  T r ia l  
S tudy  P roduc t  Name  [CONTACT_851118] l ian t™  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem  
Sponso r /Loca l  Sponso r  Med t ron i c  Va scu la r  
3576  Uno ca l  P la ce  
San ta  Ro sa ,  CA  [ZIP_CODE]  
Un i ted  S ta te s  
Documen t  Ve rs ion  1B  
Lead  P r inc ipa l  Inves t iga to r  A l i  Az izzadeh ,  MD  
D i re c to r ,  Va scu la r  Su rge ry  
Ceda rs -S ina i  Med i ca l  Cen te r  
127  S .  San  V i cen te  B l vd  
Lo s  Ange le s ,  CA  [ZIP_CODE]  
 
Con f iden t ia l i ty  S ta temen t  
The  in fo rma t ion  con ta ined  in  th i s  do cumen t  i s  con f iden t ia l  and  the  p rop r ie ta ry  p rope r ty  o f  
Med t ron i c .  Any  d i s t r ibu t ion ,  copy ing ,  o r  d i sc lo su re  w i thou t  the  p r io r  w r i t ten  au tho r iza t ion  o f  
Med t ron i c  i s  s t r i c t l y  p roh ib i ted .  Pe rson s  to  whom  the  in fo rma t ion  i s  d i sc lo sed  mu s t  know  tha t  i t  i s  
con f iden t ia l  and  tha t  i t  may  no t  be  fu r the r  d i sc lo sed  by  [CONTACT_476] .  
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  2 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 App rova l  shee t  
 
   Au tho r  
(name )   ( fun c t iona l  ro le )  
 
 
   
(s igna tu re )   (da te )  (dd  MMM  y y y y )  
 
 
    
 
C l in i ca l  Leade rsh ip  &  P rog ram  Lead  
(name )   ( fun c t iona l  ro le )  
 
   
(s igna tu re )   (da te )  (dd  MMM  y y y y )  
 
 
    
 
Sa fe ty  
(name )   ( fun c t iona l  ro le )  
 
 
   
(s igna tu re )   (da te )  (dd  MMM  y y y y )  
 
 
    
 
Mon i to r  
(name )   ( fun c t iona l  ro le )  
 
 
   
(s igna tu re )   (da te )  (dd  MMM  y y y y )  
 
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  3 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 The  f o l low ing  s igna tu re s  a re  co l le c ted  e le c t ron i ca l l y  th rough  Ag i le :  
 
Ro le  Name  T i t le  
C l in i ca l  Qua l i ty   C l in i ca l  Qua l i ty  Manage r  
Regu la to ry  A f fa i rs   P r in c ipa l  Regu la to ry  A f fa i rs  Spe c ia l i s t  
S ta t i s t i c ian   P r in c ipa l  S ta t i s t i c ian  
Med i ca l  W r i te r  &   
C l in i ca l  S tudy  Manage r   P r in c ipa l  C l in i ca l  Re sea rch  Spe c ia l i s t  
De s ign  A ssu ran ce  Eng inee r   Qua l i ty  A ssu ran ce  P rog ram  Manage r  
 
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  4 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 TABLE  OF  CONTENTS  
 
A SYNOPS IS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  8  
B GENERAL  INFORMAT ION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14  
B .1  In t rodu c t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14  
B .2  De v i ce  in fo rma t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16  
 De v i ce  De sc r ip t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16  
B .2 .1 .1  Va l ian t  E vo  Tho ra c i c  S ten t  G ra f t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16  
B .2 .1 .2  Va l ian t  E vo  De l ive ry  Sy s tem  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18  
B .2 .1 .3  De v i ce  s ize s  and  con f igu ra t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20  
 Ind i ca t ion s  fo r  Use  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21  
C STUDY  PLAN  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
C .1  S tudy  ob je c t ive s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
 P r ima ry  ob je c t ive s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
 Se conda ry  ob je c t ive s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
C .2  C l in i ca l  endpo in t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
 P r ima ry  endpo in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
 Se conda ry  endpo in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23  
C .2 .2 .1  30 -day  Se conda ry  Endpo in t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23  
C .2 .2 .2  6 - mon th  Se conda ry  Endpo in t s :  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [ADDRESS_1183309] ION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27  
D .1  In c lu s ion  c r i te r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27  
D .2  E xc lu s ion  c r i te r ia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27  
E STUDY  PREPARAT ION  PR OCEDURES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29  
E .1  In ve s t iga to r / Inve s t iga t ion  s i te  se le c t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29  
 In ve s t iga to r  se le c t ion  c r i te r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29  
 In ve s t iga t ion  s i te  se le c t ion  c r i te r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  5 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  C l in i ca l  T r ia l  Ag reemen t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30  
E .2  E th i cs  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30  
 EC / IRB  app rova l  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30  
 In fo rmed  con sen t  p ro ce ss  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30  
 Re v i s ion s  in  In fo rmed  Con sen t  Fo rm  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31  
 Regu la to ry  subm i ss ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31  
E .3  Regu la to ry  comp l ian ce  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31  
E .4  T ra in ing  requ i remen t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
E . 5 C l in i ca l  s tudy  ma te r ia l s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
E .6  S tudy  dev i ce /p rodu c t  t ra ceab i l i ty  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
 Supp ly  o f  inve s t iga t iona l  dev i ce s /p rodu c t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
 S to rage  and  hand l ing  o f  inve s t iga t iona l  dev i ce s /p rodu c t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
 De v i ce  e xp lan t  and  re tu rn  p ro cedu re s /p rodu c t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
F STUDY  METHODS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
F .1  Po in t  o f  En ro l lmen t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32  
F .2  Imp lan t  o r  p ro cedu re  a spe c t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34  
 Inde x  P ro cedu re  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34  
 T rea tmen t  fa i lu re  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34  
 Ho sp i ta l  D i scha rge  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34  
 Fo l low -Up  V i s i t s  and  P ro cedu re s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34  
F .3  Da ta  co l le c t ion  requ i remen t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35  
F .4  Ro le  o f  the  spon so r ’ s  rep resen ta t i ve s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37  
F .5  Sou rce  do cumen t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37  
F .6  Adve rse  even t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37  
 De f in i t ion / c la ss i f i ca t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [ADDRESS_1183310] ing  and  repo r t ing  o f  De v i ce  De f i c ien c ie s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40  
 Adve rse  Even t  and  Dev i ce  De f i c ien cy  re v iew  p ro ce ss  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40  
 C l in i ca l  Even t  Comm i t tee  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42  
 Da ta  Mon i to r ing  Comm i t tee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42  
 Eme rgen cy  con ta c t  de ta i l s  in  ca se  o f  se r iou s  A E s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42  
F .7  Sub je c t  a ccoun tab i l i ty  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42  
 C r i te r ia  and  p ro cedu re s  fo r  e x i t  f rom  s tudy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43  
 S tudy  W i thd rawa l  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43  
 M i ssed  fo l low -up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43  
 Lo s t -to -fo l low -up  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43  
 Med i ca l  ca re  a f te r  s tudy  e x i t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  6 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 F .8  S tudy  dev ia t ion s  and  C IP  change s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43  
 Reque s t  fo r  app rova l  o f  s tudy  dev ia t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44  
 Repo r t ing  requ i remen t s  fo r  s tudy  dev ia t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44  
 Amendmen t s  to  the  C l in i ca l  In ve s t iga t ion  P lan  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44  
G QUAL ITY  CONTROL  PROC EDURES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45  
G .1  P ro cedu re s  fo r  da taba se  managemen t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45  
 Da ta  co l le c t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45  
 Sou rce  da ta  to  be  d i re c t ly  re co rded  on  the  Ca se  Repo r t  Fo rms . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45  
 T ime  w indow s  fo r  comp le t ion  and  subm i ss ion  o f  Ca se  Repo r t  Fo rms  . . . . . . . . . . . . . . . . . .  45  
 Da ta  rev iew  and  p ro ce ss ing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45  
G .2  Mon i to r ing  p ro cedu re s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45  
 A cce ss ib i l i ty  o f  in ve s t iga t ion  s i te  s ta f f  and  s tudy  ma te r ia l s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46  
 Aud i t s  and  inve s t iga t ion  s i te  in spe c t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46  
G .3  S tudy  su spen s ion  o r  ea r ly  te rm ina t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46  
 Ea r ly  s tudy  su spen s ion  o r  te rm ina t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46  
 Ea r ly  inve s t iga t ion  s i te  su spen s ion  o r  te rm ina t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46  
 Sub je c t  fo l low -up  in  ca se  o f  te rm ina t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47  
G .4  S tudy  c lo se  ou t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47  
H DATA  ANALYS IS  AND  RE PORT ING  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47  
H .1  Ana ly s i s  o f  c l in i ca l  da ta  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47  
H .2  Pub l i ca t ion  Po l i cy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49  
I STUD Y  MANAGEMENT  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49  
I .1  S tudy  s ta f f  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49  
I .2  Adv i so ry  comm i t tee s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49  
 I .2 .1  C l in i ca l  E ven t  Comm i t tee  (CEC )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [ADDRESS_1183311]  re ten t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52  
I .4  M i sce l laneou s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
 In su ran ce  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
 Sub je c t  compen sa t ion  and  indemn i f i ca t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  7 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Sub je c t  con f iden t ia l i ty  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
J R ISKS  AND  BENEF ITS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
J .1  An t i c ipa ted  C l in i ca l  Bene f i ts  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
J .2  R i sks  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54  
J .3  R i sk -to -bene f i t  ra t iona le  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55  
K REFERENCES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56  
L APPEND ICES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57  
L .1  Abb rev ia t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57  
L .2  De f in i t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59  
 P r ima ry  and  Se conda ry  Endpo in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59  
 Ma jo r  Adve rse  Even t s  (MAE s )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62  
 De v i ce  De f i c ien c ie s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64  
 Add i t iona l  De f in i t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  66  
L .3  Imag ing  Ma t r i x  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  67  
L .4  De v i ce  E xp lan t  and  Re tu rned  P rodu c t  In s t ru c t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  67  
L .5  In fo rmed  Con sen t  Temp la te  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  72  
L .6  Po s t  PMA -S  app rova l  Ana ly s i s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  72  
L .7  CMS  S tudy  C r i te r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  72  
M VERS ION  H ISTORY  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  73  
 
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  8 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 A   SYNOPS IS  
T i t le  Va l ian t  E vo  US  C l in i ca l  T r ia l  
Inves t iga t iona l  
Dev ice  Va l ian t™  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem  
S tudy  Des ign  The  Va l ian t   Evo   US   C l in i ca l   T r ia l  is   a   p ro spe c t ive ,   mu l t i -cen te r ,   p re -ma r ke t ,   no n-
random ized ,  s ing le -a rm  t r ia l .  
Pu rpose  The   pu rpo se   o f   the   Va l ian t   E vo  US  C l in i ca l   T r ia l   is   to   demon s t ra te   the   sa fe ty   and  
e f fe c t i vene ss  o f  the  Va l ian t  E vo  Tho ra c i c  S ten t  G ra f t  S y s tem  in  sub je c t s  w i th  a  descend ing  
tho ra c i c  ao r t i c  aneu ry sm  (DTAA )  who  a re  cand ida te s  fo r  endo va scu la r  repa i r .  The  c l in i ca l  
e v iden ce  co l le c ted  a s  pa r t  o f  th i s  t r ia l  w i l l  be  u sed  in  con jun c t ion  w i th  da ta  co l le c ted  du r ing  
the  con cu r ren t ly  en ro l l ing  Va l ian t  Evo  In te rna t iona l  C l in ica l  T r ia l  to  suppo r t  PMA -S  App rova l  
o f  the  Va l ian t  E vo  Tho ra c i c  S ten t  G ra f t  S y s tem .  The  c l in i ca l  e v iden ce  co l le c ted  a s  pa r t  o f  
th i s  c l in i ca l   t r ia l   may   a l so   be   u sed   to   suppo r t   ob ta in ing   comme rc ia l   app ro va l   in   o the r  
in te rna t iona l  geog raph ie s .    
P r ima ry  ob jec t ive  The   p r ima ry   ob je c t ive   i s   to   demon s t ra te   the   sa fe ty   and   e f fe c t i vene ss   o f   the  Va l ian t   Evo  
Tho ra c i c  S ten t  G ra f t  Sy s tem  in  sub je c t s  w i th  a  DTAA  who  a re  cand i da te s  fo r  endo va scu la r  
repa i r .   
Seconda ry  
ob jec t ive s  Se conda ry  ob je c t i ve s  in c lude  de sc r ip t ive  ana ly se s  o f  se conda ry  endpo in t s  a s  we l l  a s  a cu te  
p ro cedu ra l  ob se rva t ion s  and  c l in i ca l  u t i l i ty  mea su re s .   
P r ima ry  Endpo in ts  Compo s i te  sa fe ty  and  e f fe c t i vene ss  endpo in t  tha t   i s   ba sed  on  the  p ropo r t ion   o f  sub je c t s  
who  e xpe r ien ced :   
(a )  Acce ss  and /o r  dep loymen t  fa i lu re s ;  and /o r   
(b )  Ma jo r  dev i ce  e f fe c t  (MDE )  w i th in  30  day s  po s t  index  p ro cedu re  
MDE s  in c lude  the  o ccu r rence  o f  any  o f  the  fo l low ing  and  a re  de f ined  in  Append i x  L .5 :  
•  De v i ce -re la ted  se conda ry  p ro cedu re s   
•  De v i ce -re la ted  mo r ta l i ty  
•   C onve rs ion  to  open  su rge ry  
•  Tho ra c i c  a o r t i c  aneu ry sm  rup tu re  
An  independen t  C l in i ca l  Even t s  Comm i t tee  (CEC )  w i l l  be  e s tab l i shed  and  ad jud i ca te  MDE s .  
Seconda ry  
Endpo in ts  30 -day  Se conda ry  Endpo in t s :  
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted  w i th in  30  day s  po s t  t rea tmen t :  
• Pe r i -ope ra t i ve  mo r ta l i ty  
• A l l  adve rse  e ven t s  (AE )  w i th in  30  day s  in c lud ing :  
•  Ma jo r  Adve rse  Even t (s )  (MAE )   
•  Se r iou s  Ad ve rse  Even t (s )  (SAE )  
• Se conda ry  p ro cedu re s   
• Lo ss  o f  s ten t  g ra f t  pa ten cy  a t  30  day  v i s i t  ba sed  on  imag ing  f ind ing s  
• Endo lea ks  a t  30  day  v i s i t  ba sed  on  imag ing  f ind ing s  
Ma jo r  adve rse  e ven t s  in c lude  the  o ccu r ren ce  o f  any  o f  the  fo l low ing : 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  9 o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • Re sp i ra to ry  comp l i ca t ions : a te le c ta s i s /pneumon ia ,   pu lmona ry  
embo l i sm ,  pu lmona ry  edema ,  re sp i ra to ry  fa i lu re   
• Rena l  comp l i ca t ion s :  rena l  fa i lu re ,  rena l  in su f f i c ien cy   
• Ca rd ia c  comp l i ca t ion s :  Myo ca rd ia l   in fa rc t ion   (M I ) ,   uns tab le   ang ina ,  
new  a r rhy thm ia ,  e xa ce rba t ion  o f  conge s t ive  hea r t  fa i lu re  (CHF )   
• Neu ro log i ca l  comp l i ca t ion s :   new   ce reb rova scu la r   a cc iden t  
(CVA ) /embo l i c  e ven t s ,  pa rap leg ia ,  pa rapa re s i s   
• Ga s t ro in te s t ina l  comp l i ca t ion s :  bowe l  i schem ia   
• Ma jo r   b leed ing   comp l i ca t ion   (p ro cedu ra l   o r   po s t -p ro cedu ra l ) ,  
coagu lopa thy   
• Va scu la r  comp l i ca t ion s :  ao r t i c  rup tu re ,  aneu ry sm  rup tu re ,  hema toma  
a t  a cce ss  s i te ,  p seudo  o r  fa l se  aneu ry sm ,  a r te r iovenou s  (AV )  f i s tu la ,  
re t rope r i tonea l  b leed ,  l imb  i schem ia ,  t h rombo s i s  
6-mon th  Se conda ry  Endpo in t s :   
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted :  
• A l l -cau se  mo r ta l i ty  w i th in  183  day s  
• Aneu ry sm -Re la ted  Mo r ta l i ty  w i th in  183  day s  
• MDE s  w i th in  183  day s  
• A l l  AE s  w i th in  183  day s  in c lud ing :  
•  MAE s  
•  SAE s  
• Se conda ry  p ro cedu re s  w i th in  183  day s  
• Lo ss  o f  s ten t  g ra f t  pa ten cy  w i th in  6  mon th s  ba sed  on  imag ing  f ind ing s  
• Endo lea ks  a t  6  mon th s  ba sed  on  imag ing  f ind ing s  
• S ten t  g ra f t  m ig ra t ion  a t  6  mon th s  a s  compa red  to  1 -mon th  imag ing  
• Aneu ry sm   e xpan s ion   >   5mm   a t   6   mon th s   ba sed   on   imag ing   f ind ing s  
re la t i ve  to  the  1 -mon th  v i s i t  
12 -mon th  Se conda ry  Endpo in t s :  
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted :  
• A l l -cau se  mo r ta l i ty  w i th in  365  day s  
• Aneu ry sm -Re la ted  Mo r ta l i ty  w i th in  365  day s  
• MDE s  w i th in  365  day s  
• A l l  AE s  w i th in  365  day s  in c lud ing :  
•  MAE s  
•  SAE s  
• Se conda ry  p ro cedu re s  w i th in  365  day s  
• Lo ss  o f  s ten t  g ra f t  pa ten cy  w i th in  12  mon th s  ba sed  on  imag ing  f ind ing s  
• Endo lea ks  a t  12  mon th s  based  on  imag ing  f ind ing s  
• S ten t  g ra f t  m ig ra t ion  a t  12  mon th s  a s  compa red  to  1 -mon th  imag ing  
• Aneu ry sm   e xpan s ion   >   5mm   a t   12   mo n th s   ba sed   on   imag ing   f ind ing s  
re la t i ve  to  the  1 -mon th  v i s i t  
Fo r  sub je c t s  tha t  re -con sen t  to  e x tended  s tudy  fo l low  up ,  the  above  12 -mon th  se conda ry  
endpo in t s  w i l l  be  e va lua ted  a t  24 ,  36 ,  48 ,  and  60  mon th s . 
Add i t iona l  
Obse rva t ions  The  fo l low ing  a cu te  p ro cedu ra l  ob se rva t ion s  and  c l in i ca l  u t i l i ty  mea su re s  w i l l  be  ana ly zed :   
• Mean  du ra t ion  (m in )  o f  p ro cedu re  ( t ime  be tween  in i t ia l  s k in  a cce ss  to  
• f ina l  sk in  c lo su re )  
• P ropo r t ion  o f  sub je c t s  who  unde rwen t  gene ra l / lo ca l /ep idu ra l / sp ina l  
• ane s th e s ia  
• P ropo r t ion  o f  sub je c t s  who  unde rwen t  pe rcu taneou s  acce ss  
• P ropo r t ion  o f  sub je c t s  requ i r ing  b lood  t ran s fu s ion s ,  e xc lud ing  ce l l  sa ve r  
mean  vo lume  (cc )  o f  e s t ima ted  b lood  lo ss  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  10  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • Mean  du ra t ion  (m in )  o f  rad ia t ion  e xpo su re  
• Rad ia t ion  e xpo su re  (mGy )  
• Mean  leng th  o f  t ime  (hou rs )  in  in ten s ive  ca re  un i t  
• Mean  leng th  o f  t ime  (day s )  o f  ho sp i ta l  s tay  ( f rom  the  inde x  p ro cedu re  to  
ho sp i ta l  d i scha rge )  
 
Hea l th -re la ted   qua l i ty   o f   l i fe   ou t come s   w i l l   be   a sse ssed   a t   a l l   schedu led   fo l low -up   v i s i t s  
u s ing  the  EQ -5D  que s t ionna i re .   
Sub jec t  Popu la t ion  Sub je c t   popu la t ion   w i l l   inc lude  sub je c t s  d iagno sed   w i th  DTAA  who   a re   con s ide red  
cand ida te s  fo r  endo va scu la r  repa i r ,  and  who  mee t  the  In c lu s ion /E xc lu s ion  C r i te r ia  fo r  the  
Va l ian t  E vo  US  C l in i ca l  T r ia l .  
Numbe r  o f  sub jec ts  G loba l ly ,   a  to ta l   o f   100  sub je c t s   w i l l   be   con cu r ren t ly   en ro l led   in   the   Un i ted   S ta te s   and  
ou t s ide  the  Un i ted  S ta te s  to  suppo r t  the  p r ima ry  endpo in t s .  Up  to  50%  o f  sub je c t  da ta  u sed  
to  suppo r t  PMA  app ro va l  may  come  f rom  sub je c t s  en ro l led  a t  s i te s  ou t s ide  o f  the  US  unde r  
a   sepa ra te   CE   Ma rk   s tud y   p ro to co l ;   ca l led   the  Va l ian t  Evo   In te rna t iona l   C l in ica l   T r ia l  
p ro to co l .  The   p r ima ry   endpo in t   ana ly s i s   w i l l   be   comp le ted   upon   87   eva luab le   sub je c t s  
rea ch ing  the  30  day  endpo in t .  
The  da ta  ob ta ined  f rom  the se  87  eva luab le  sub je c t s  w i l l  be  u sed  to  suppo r t  PMA -S  App rova l  
o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  S y s tem .  
The  Va l ian t  Evo   US   C l in ica l   T r ia l  p ro to co l   and  Va l ian t  Evo   In te rna t iona l   C l in ica l   T r ia l  
p ro to co l  w i l l  be  iden t i ca l  w i th  re spe c t  to  the  in c lu s ion /exc lu s ion  c r i te r ia .   
Numb e r  o f  S i tes  The  Va l ian t  Evo  G loba l  C l in i ca l  p rog ram  w i l l  be  condu c ted  a t  up  to  37  s i te s  wo r ldw ide ,  w i th  
a t  lea s t  50%  o f  the  c l in i ca l  s i te s  com ing  f rom  the  Un i ted  S ta te s .   
C l in ica l  P rocedu res  
and  Fo l low  Up  
Schedu le  Sub je c t s  requ i re  fo l low -up  e va lua t ion s  a t  the  fo l low ing  t ime  po in t s :  
• 1  mon th  fo l low ing  the  inde x  p ro cedu re  (30  ±  15  day s )  
• 6  mon th s  fo l low ing  the  index  p ro cedu re  (183  ±  30  day s )  
• 12  mon th s  fo l low ing  the  inde x  p ro cedu re  (365  ±60  day s )  
• 24  mon th s  fo l low ing  the  inde x  p ro cedu re  (730  ±  6 0  day s )  
• 36  mon th s  fo l low ing  the  inde x  p ro cedu re  (1095  ±  60  day s )  
• 48  mon th s  fo l low ing  the  inde x  p ro cedu re  (1460  ±  60  day s )  
• 60  mon th s  fo l low ing  the  inde x  p ro cedu re  (1825  ±  60  day s )  
 
Fo r  sub je c t s  tha t  re -con sen t  to  e x tended  s tudy  fo l low  up ,  the  a sse ssmen t s  a s  pe r fo rmed  
du r ing  the  12 -mon th  v i s i t  a re  to  be  repea ted  a t  24 ,  36 ,  48  and  60  mon th  v i s i t s .  
P r inc ipa l  
Inves t iga to r  D r .  A l i  Az i zzadeh  
D i re c to r ,  Va scu la r  Su rge ry  
Ceda rs -S ina i  Med i ca l  Cen te r  
127  S .  San  V i cen te  B l vd  
Lo s  Ange le s ,  CA  [ZIP_CODE]  
Ind ica t ions  fo r  Use  The  Va l ian t  Evo  Tho ra c i c  S ten t  Gra f t  Sy s tem  i s  ind i ca ted  fo r  the  endo va scu la r  repa i r  o f  
fu s i fo rm  aneu ry sms  and  sa ccu la r  aneu ry sms /pene t ra t ing  u l ce rs  o f  the  
de scend ing  tho ra c i c  ao r ta  (DTA )  in  pa t ien t s  hav ing  the  app rop r ia te  ana tomy  
in c lud ing  the  fo l low ing :  
• I l ia c   o r   femo ra l   a r te ry   a cce ss   ve sse l   mo rpho logy   tha t   i s   compa t ib le  w i th  
va scu la r  a cce ss  te chn ique s ,  dev i ce s ,  o r  a cce sso r ie s  
• Nonaneu ry sma l  ao r t i c  d iame te r  f rom  16  mm  to  42  mm  
• Nonaneu ry sma l  ao r t i c  p ro x ima l  ne ck  leng th  ≥20  mm  ( fo r  F reeF lo  con f igu ra t ion )  
and  ≥25  mm  ( fo r  C lo sed  Web  con f igu ra t ion )  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  11  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • D i s ta l  ne ck  leng th  ≥20  mm  
Inc lus ion  C r i te r ia  Cand ida te s   fo r   the   Va l ian t   Evo   US  C l in i ca l   t r ia l   mu s t   be   app rop r ia te   sub je c t s   fo r  
endova scu la r   repa i r   o f   aneu ry sms   o f   the   de scend ing   tho ra c i c   ao r ta   (e v iden ced   by  
[CONTACT_851075] t ra s t -enhan ced  CT  o r  MRA )  and  have  to  fu l f i l l  a l l  o f  the  fo l low ing  in c lu s ion  
c r i te r ia  to  be  e l ig ib le  fo r  re c ru i tmen t  in  the  s tudy :  
1 .  Sub je c t  i s  ≥18  yea rs  o ld .  
2 .  Sub je c t   unde rs tand s   and   vo lun ta r i ly   ha s   s igned   and   da ted   the  In fo rmed   Con sen t  
Fo rm  app ro ved  by  [CONTACT_851076] r  and  by  [CONTACT_941]  E th i cs  Comm i t tee  fo r  th i s  s tudy .    
3 .  Sub je c t  p re sen t s  a  DTAA  wh i ch  i s  lo ca l ized  be low  the  os t ium  o f  le f t  sub c la v ian  a r te ry  
(LSA )  and  above  the  o s t ium  o f  ce l ia c  t run k  
4 .  Sub je c t  ha s  a  DTAA  tha t  i s  one  o f  the  fo l low ing :  
a .   A  fu s i fo rm  aneu ry sm  w i th  a  ma x imum  d iame te r  tha t :   
• i s  ≥  5 0  mm  and /o r :  
• i s  ≥2  t ime s  the  d iame te r  o f  the  non -aneu ry sma l  tho ra c ic  ao r ta  and /o r :   
• i s  <  50  mm  and  ha s  g rown  ≥  5  mm  w i th in  p rev iou s  12  mon th s  
b .   A  sa ccu la r  aneu ry sm  o r  a  pene t ra t ing  a the ro sc le ro t i c  u l ce r  
5 .  Sub je c t ’ s  ana tomy  mu s t  mee t  a l l  o f  the  fo l low ing  ana tom i ca l  c r i te r ia  a s  demon s t ra ted  
on  con t ra s t -enhan ced  compu te r ized  tomog raphy  (CT )  and /o r  on  con t ra s t -enhan ced  
Magne t i c   Re sonan ce   Ang iog ram   (MRA )   ob ta ined   w i th in  fou r   (4 )   mon th s   p r io r   to  
imp lan t  p ro cedu re :   
a .  P ro x ima l  and  d i s ta l  non -aneu ry sma l  ao r t i c  ne ck  d iame te r  mea su remen t s  mu s t  
be  ≥  16  mm  and  ≤  42  mm ;   
b .  P ro x ima l   non -aneu ry sma l   ao r t i c   ne ck   leng th   mu s t   be   ≥   20   mm  ( fo r   F reeF lo  
con f igu ra t ion )  and   ≥   25   mm  ( fo r   C lo sed   Web   con f igu ra t ion )  d i s ta l   to   the   le f t  
commo n  ca ro t id  a r te ry  (LCCA ) .  No te :  P ro x ima l  ao r t i c  ne ck  leng th  may  in c lude  
co ve r ing   the  LSA  (w i th   o r   w i thou t   d i sc re t iona ry  re va scu la r iza t ion )   when  
ne ce ssa ry   to   op t im i ze   dev i ce   f i xa t ion   and   ma x im i ze   ao r t i c   ne ck   leng th .   I f  
o cc lu s ion   o f   the   LSA   o s t ium   i s   requ i red  to   ob ta in   adequa te   ne ck   leng th   fo r  
f i xa t ion  and  sea l ing ,  t ran spo s i t ion  o r  by[CONTACT_851077] r ran ted .  
c .  D i s ta l  non -aneu ry sma l  ao r t ic  ne ck  leng th  mu s t  be  ≥  20  mm  
6 .  Sub je c t   ha s   adequa te   a r te r ia l   a cce ss   s i te   o r   can   to le ra te   a   condu i t   tha t   a l low s  
endova scu la r   a cce ss   to   the   aneu ry sma l   s i te   w i th   the   de l i ve ry   sy s tem   o f   the  
app rop r ia te  s ized  dev i ce  cho sen  fo r  the  t rea tmen t .  
Exc lus ion  C r i te r ia  Cand ida te s   who   mee t   any   o f   the   fo l low ing   e xc lu s ion   c r i te r ia   w i l l   no t   be   e l ig ib le   fo r  
re c ru i tmen t  in  the  s tudy :  
1 .  Sub je c t  ha s  a  l i fe  e xpe c tancy  o f  le ss  than  1  yea r .  
2 .  Sub je c t  i s  pa r t i c ipa t ing  in  ano the r  inve s t iga t iona l  d rug  o r  dev i ce  s tudy  wh i ch  wou ld  
in te r fe re  w i th  the  endpo in t s  and  fo l low -up s  o f  th i s  s tudy .  
3 .  Sub je c t  i s  p regnan t .  
4 .  Sub je c t  requ i re s  p lanned  p la cemen t  o f  the  co ve red  p rox ima l  end  o f  the  s ten t  g ra f t  to  
o ccu r  in  zone s  0  o r  1 .   
5 .  Sub je c t   ha s   a   tho ra c i c   aneu ry sm   w i th   a   con ta ined   rup tu re   o r   lo ca l ized   a t   the  
ana s tomo s i s  o f  a  p re v iou s  g ra f t  (p seudo -/ fa l se  aneu ry sm ) .  
6 .  Sub je c t  ha s  a  my co t i c  aneu ry sm .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  12  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 7 .  Sub je c t  ha s  a  d i ss e c t ion  ( type  A  o r  B )  o r  an  in t ramu ra l  hema toma  o r  an  ao r t i c  rup tu re  
in  add i t ion  to  the  tho ra c i c  aneu ry sm .   
8 .  Sub je c t  requ i re s  eme rgen t  aneu ry sm  t rea tmen t ,  e .g . ,  t rauma  o r  rup tu re .  
9 .  Sub je c t  ha s  re ce i ved  a  p rev iou s  s ten t  o r  s ten t  g ra f t  o r  p re v iou s  su rg i ca l  repa i r  in  the  
a scend ing  and /o r  de scend ing  tho ra c i c  ao r ta ,  and /o r  in  the  ao r t i c  a rch .   
10 .  Sub je c t  requ i re s  su rg i ca l  o r  endova scu la r  t rea tmen t  o f  an  in f ra -rena l  aneu ry sm  a t  
the  t ime  o f  imp lan t .   
11 .  Sub je c t  ha s  had  p rev iou s  su rg i ca l  o r  endo va scu la r  t rea tmen t  o f  an  in f r a - rena l  ao r t i c  
aneu ry sm .  
12 .  T rea tmen t   w i th   the   Va l ian t   Evo  Tho ra c i c  Sten t  Gra f t   wou ld   requ i re   in ten t iona l  
re va scu la r iza t ion  o f  the  b rach io -cepha l i c  a r te ry ,  the  le f t  common  ca ro t id  a r te ry  o r  the  
ce l ia c  t run k .  
13 .  Sub je c t  ha s  had  o r  p lan s  to  ha ve  a  ma jo r  su rg i ca l  o r  in te rven t iona l  p ro cedu re  w i th in  
30  day s  be fo re  o r  30  day s  a f te r  the  p lanned  imp lan ta t ion  o f  the  Va l ian t  Evo  Tho ra c ic  
Sten t  Gra f t .  Th i s  doe s  no t  in c lude  p lanned  p ro cedu re s  tha t  a re  needed  fo r  the  sa fe  
and   e f fe c t i ve   p la cemen t   o f   the   s ten t   g ra f t   ( i .e . ,  ca ro t id / sub c lav ian   t ran spo s i t ion ,  
ca ro t id / sub c lav ian  by[CONTACT_330843]  p ro cedu re ) .   
14 .  Sub je c t  ha s  a  s ign i f i can t  and /o r  c i rcum fe ren t ia l  ao r t i c  mu ra l  th rombu s  a t  e i the r  the  
p ro x ima l  o r  d i s ta l  a t ta chmen t  s i te s  tha t  cou ld  comp rom i se  f i xa t ion   and  sea l   o f  the  
imp lan ted  s ten t  g ra f t .  
15 .  Sub je c t   ha s   a   conne c t ive   t i ssue   d i sea se   (e .g . ,   Ma r fan ’ s   synd rome ,   ao r t i c   med ia l  
degene ra t ion ) .   
16 .  Sub je c t  ha s  a  b leed ing  d ia the s i s  o r  coagu lopa thy ,  o r  re fu se s  b lood  t ran s fu s ion .  
17 .  Sub je c t  ha s  had  a  M I  w i th in  3  mon th s  o f  the  p ro cedu re .  
18 .  Sub je c t  ha s  had  a  CVA  w i th in  3  mon th s  o f  the  p ro cedu re .  
19 .  Sub je c t  ha s  a  known  a l le rgy  o r  in to le ran ce  to  the  dev i ce  ma te r ia l s  
20 .  Sub je c t  ha s  a  known  a l le rgy  to  ane s the t i c  d rug s  
21 .  Sub je c t   ha s   a   known   hype rsen s i t i v i ty   o r   con t ra ind ica t ion   to   an t i coagu lan t s ,   o r  
con t ra s t  med ia ,  wh i ch  i s  no t  amenab le  to  p re t rea tmen t .  
22 .  Sub je c t  ha s  a c t ive  o r  sy s tem i c  in fe c t ion  a t  the  t ime  o f  the  inde x  p ro cedu re .  
S tudy  Success  
C r i te r ia  A  30 -day  p rema r ke t  sa fe ty  and  e f fe c t i vene ss  endpo in t  (a  m in imum  o f  87  e va luab le  sub je c t s  
fo r  hypo the s i s  te s t ) .  The  p r ima ry  endpo in t  w i l l  be  te s ted  aga in s t  a  pe r fo rman ce  goa l  o f  16 %  
MDE  ra te  a t  30  day s .  
Ana lys is  Se ts  The  p r ima ry  ana ly s i s  se t  w i l l  con s i s t  o f  a l l  sub je c t s  who  we re  en ro l led .  The  sub jec t  w i l l  be  
con s ide red  to  be  en ro l led  a f te r  a r te r ia l  a cce ss  i s  e s tab l i shed  and  the  Va l ian t  E vo  Tho ra c i c  
S ten t  G ra f t  Sy s tem  i s  in t rodu ced .  
 
A  se conda ry  ana ly s i s  se t  w i l l  be  the  Pe r -P ro to co l  popu la t ion .  Th i s  ana ly s i s  se t  i s  comp r i sed  
o f  a l l  en ro l led  sub je c t s  who  me t  in c lu s ion  and  e xc lu s ion  c r i te r i a ,  re ce ived  the  tes t  de v i ce  
and  comp le ted  30 -day  fo l low -up  ( in c lud ing  dea th  bu t  exc lud ing  w i thd rawa l  o r  lo s t  to  fo l low -
up  sub je c t s  w i th in  the  30 -day  fo l low -up  pe r iod ) .  
Da ta  Ove rs igh t  A   Da ta   Mon i to r ing   Comm i t tee ,   C l in i ca l   Even t s   Comm i t tee ,  and   imag ing   co re   lab   w i l l   be  
e s tab l i shed   to   independen t ly   e va lua te   sub je c t   hea l th   s ta tu s ,   dev i ce   pe r fo rman ce ,   and  
iden t i fy   any   sa fe ty   con ce rn s   rega rd ing   sub je c t s ’   we l l -be ing .   Con ta c t   de ta i l s   o f   the  
comm i t tee s  and  the  co re  lab  w i l l  be  a va i lab le  in  the  inve s t iga t iona l  s i te  f i le .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  13  o f  73   
20 /OCT /[ADDRESS_1183312]  NE  
M inneapo l i s ,  MN  [ZIP_CODE]  
 
 
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  14  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 B   GENERAL  INFORMAT ION  
B .1   I n t roduc t ion  
Ba ckg round :  
An  ao r t i c  aneu ry sm  i s  de f ined  a s  a  d i la ta t ion  o f  the  ao r t i c  ve sse l  g rea te r  than  50%  o f  i t s  no rma l  
d iame te r  fo r  a  g i ven  segmen t  o f  the  adhe r ing  no rma l  ve sse l . 1 A n  aneu ry sm  o f  the  De scend ing  
Tho ra c i c  A o r ta  (DTA )  i s  de f ined  a s  invo l v ing  any  po r t ion  o f  the  tho ra c i c  ao r ta  d i s ta l  to  the  LSA  
and  e x tend ing  to  above  the  d iaph ragm . 2 In  adu l t s ,  the  d iame te r  o f  the  ao r ta  i s  abou t  30  mm  a t  
the  ao r t i c  roo t  and  abou t  25  mm  a t  the  leve l  o f  the  d iaph ragm .  Age  i s  the  ma jo r  in f luen t ia l  fa c to r  
in  the  aneu ry sm  d iame te r  s ize  in c rea se  and  a l l  d iame te rs  in c rea se  w i th  age . 3 I t  ha s  been  repo r ted  
tha t  ao r t i c  d iame te rs  in c rease  abou t  1  mm  pe r  de cade  du r ing  adu l thood . 4 Gene ra l ly ,  a  d iame te r  
in  the  tho ra c i c  ao r ta  >  4 .5  cm  i s  con s ide red  aneu ry sma l .  1 ,  2 ,3 ,4 ,5   
A  tho ra c i c  ao r t i c  aneu ry sm  (TAA )  i s  a  l i fe -th rea ten ing  cond i t ion .  Annua l ly ,  the  in c iden ce  o f  TAA  
in  a  popu la t ion -ba sed  s tudy  i s  10 .4  pe r  100 ,000  pe rson -yea rs ,  and  the  DTA  i s  invo l ved  in  abou t  
40%  o f  tho se  ca se s . 6 The  numbe r  o f  peop le  d iagno sed  w i th  an  aneu ry sm  o f  the  DTA  i s  though t  
to  be  in c rea s ing .  Fa c to rs  tha t  con t r ibu te  to  th i s  r i se  in c lude  in c rea sed  longev i ty  o f  the  popu la t ion  
and  imp ro ved  d iagno s t i c  capab i l i ty . 6 ,7 ,8   
The  na tu ra l  h i s to ry  o f  TAA s ,  in c lud ing  aneu ry sms  o f  the  DTA ,  i s  one  o f  p rog re ss ive  en la rgemen t  
and  rup tu re ,  and  rup tu re  i s  a lmo s t  in va r iab ly  fa ta l .  An  ea r ly  s tudy  on  the  na tu ra l  h i s to ry  repo r ted  
tha t  ove r  90%  o f  pa t ien t s  su s ta ined  aneu ry sm  g row th  du r ing  the  pe r iod  o f  ob se rva t ion . [ADDRESS_1183313] rage  g row th  
ra te  o f  0 .19  cm  pe r  yea r  has  been  ob se rved  in  aneu ry sms  o f  the  DTA  in  the  pa s t . 10  An  aneu ry sm  
d iame te r  o f  6 -cm  ha s  been  gene ra l ly  con s ide red  the  u rgen t  po in t  o f  the  r i sk  fo r  rup tu re .   
Degene ra t i ve   change   o f   the   ao r t i c   wa l l   i s   the   cau se   o f   mo s t   aneu ry sms   o f   the   DTA .   Med ia l  
degene ra t ive  d i sea se  i s  re spon s ib le  fo r  mo s t  fu s i fo rm  aneu ry sms  o f  the  DTA .  The  smoo th  mu sc le  
ce l l s  and  e la s t i c  lam inae  in  the  med ia  a re  rep la ced  by  [INVESTIGATOR_70329] s t i c  spa ce s  f i l led  w i th  mu co id  ma te r ia l ,  
wh i ch  p rodu ce s  p rog re ss ive  wea ken ing  and  d i la ta t ion  o f  the  ao r t i c  wa l l ,  w i th  even tua l  aneu ry sm  
fo rma t i on   and   sub sequen t   comp l i ca t ion s   su ch   a s   rup tu re . 11  A r te r io sc le ro s i s   i s   a   p ro ce ss   tha t  
p r ima r i ly   invo l ve s   the   ao r t ic   in t ima ,   wh i ch   a ccoun t s   fo r   80%   o f   the   aneu ry sms   found   in   the  
tho ra c i c  ao r ta .  [ADDRESS_1183314]  su rg i ca l  t rea tmen t  invo l ve s  a  tho ra co tomy ,  ao r t i c  c lamp ing  to  re -se c t ion  the  aneu ry sma l  
segmen t   and   rep la cemen t   u s ing   a   Da c ron   g ra f t .   Endo va scu la r   s ten t   g ra f t   repa i r   con s i s t s   o f  
t ran s femo ra l   o r   i l ia c   in t rodu c t ion   o f   the   de v i ce .   When   the   s ten t   g ra f t   de v i ce   i s   dep loyed   and  
e xpanded  w i th in  the  aneu ry sma l  b lood  ve sse l ,  i t  c rea te s  a  new  ao r t i c  lumen  fo r  the  b lood  f low ,  
e xc lud ing  the   aneu ry sm   sa c   f rom   b lood   f low   wh i le   ma in ta in ing   pe r fu s ion   to   the   lowe r   body .  
S tud ie s   compa r ing   open   su rg i ca l   repa i r   ve rsu s   endova scu la r   repa i r   con c luded   tha t   the   la t te r  
o f fe r s  a  le ss  inva s i ve ,  le ss  e xpen s ive  a l te rna t ive ,  a  dec rea se  in  mo r ta l i ty  and  mo rb id i ty  in  h igh -
r i sk  pa t ien t s ,  a sso c ia ted  w i th  sho r te r  ho sp i ta l  s tay  and  qu i cke r  re tu rn  to  no rma l  a c t i v i t ie s  a f te r  
su rge ry . 13 ,14  
Howeve r ,  de sp i te  the  w ide  sp read  adop t ion  o f  tho ra c i c  endova scu la r  aneu ry sm  repa i r  ( TEVAR )  
in   mode rn   t rea tmen t   o f   TAA s ,   no t   a l l   pa t ien t s   a re   cand ida te s   fo r   TEVAR   due   to   ana tom i ca l  
l im i ta t ion s .   S in ce  TEVAR   de v i ce s   o f ten   requ i re   a   la rge -p ro f i le   de l ive ry   sy s tem  (o f ten   ou te r  
d iame te r   o f   22   F r   to   27   F r ) ,   the   p re sen ce   o f   la rge ,   femo ra l -i l ia c   a r te r ie s  i s   nece ssa ry .   Th i s  
rep re sen t s  a  s ign i f i can t  con t r ibu to r  to  the  r i sks  o f  a cce ss -ve sse l  in ju ry ,  wh i ch  con t inue s  to  be  a  
s ign i f i can t   cau se   o f   se r iou s   mo rb id i ty   and   e ven  mo r ta l i ty   re la ted   to   tho ra c i c   endo va scu la r  
p ro cedu re s .  Fu r the rmo re ,  fema le  pa t ien t s  ma ke  up  >30%  o f  TEVAR  sub je c t s  and  tend  to  have  
sma l l   a r te r ie s ,   wh i ch   compound s   the  ve sse l -a cce ss  p rob lems  de sc r ibed .  O the r   ana tom i ca l  
cha ra c te r i s t i cs  su ch  a s  l im i ted  p ro x ima l  and  d i s ta l  ao r t i c  ne ck  leng th s  and  angu la ted  ao r t i c  a rch e s  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  15  o f  73   
20 /OCT /[ADDRESS_1183315]  the  po te n t ia l  fo r  s ign i f i can t  
p rob lems   du r ing   TEVAR   due   to   non -con fo rmab i l i ty   o f   s ten t   g ra f t s ,  e spe c ia l ly  a long   the   le sse r  
cu rve .  Land ing  o r  f i xa t ing  in  th e  a rea  o f  the  d i s ta l  a rch  tha t  t ran s i t ion s  in to  the  descend ing  ao r ta  
can  lead  to  po ten t ia l ly  fa ta l  comp l i ca t ion s . 18   
Today ’ s   comme r c ia l ly   ava i lab le   s ten t   g ra f t   sy s tems   ha ve   ma r ked ly   imp ro ved   upon   f i rs t -and  
se cond -gene ra t ion  sy s tems  da t ing  ba ck  f rom  the  ea r ly  [ADDRESS_1183316]  been  redu ced  w i th  the  in ten t  to  m in im ize  endo the l ia l  t rauma  tha t   lead  to  a cce ss  
ve sse l  comp l i ca t ion s  and  imp ro v e  a cce ss ib i l i ty  in  pa t ien t s  w i th  sma l le r  a cce ss  vesse l s .   De sp i te  
the se   enhan cemen t s ,   cha l lenge s   rema in   in   te rms   o f  TEVAR   app l i cab i l i ty .     Nex t -gene ra t ion  
sy s tems  a re  fa ced  w i th  the  cha l lenge  o f  m in im i z ing  comp l i ca t ion s  and  se conda ry -p ro cedu re  ra te s  
wh i le  sa fe ly  t rea t ing  in c reas ing ly  comp le x  and  cha l leng ing  ana tom ie s .    
Med t ron i c  ha s  a  long  h i s to ry  w i th  the  de s ign  and  com me rc ia l iza t ion  o f  tho ra c i c  ao r t i c  s ten t  g ra f t s ,  
mo s t  re cen t ly  w i th  the  Va l ian t  Cap t iv ia  S ten t  G ra f t  Sy s tem .   
The  Va l ian t  s ten t  g ra f t  on  the  Xce le ran t  De l ive ry  Sy s tem  wa s  CE  ma r ked  in  Ma rch ,  2005  fo l lowed  
by  [CONTACT_851078] r k ing  o f  the  Va l ian t  Cap t i v ia  s ten t  g ra f t  Sy s tem  in  Sep tembe r ,  2009 .  Va l ian t  Cap t iv ia  
wa s  comme r c ia l ly  re lea sed  in  the  Eu ropean  Un ion  in  Oc tobe r ,  2009 .  The  same  s ten t  g ra f t  sy s tem  
re ce i ved   FDA   comme r c ia l   app rova l   in   Ap r i l   2011   le ve rag ing   da ta   f rom   the   VALOR   I I   C l in i ca l  
S tudy ,   the   Ta len t   Tho ra c i c   s te n t   g ra f t   w i th   Cap t iv ia   De l i ve ry   Sy s tem   C l in i ca l   S tudy ,   and   the  
Va l ian t  Cap t iv ia  Po s t -Ma rke t  Reg i s t ry .  To  da te ,  ove r  75 ,000  pa t ien t s  (ca .  92 ,500  un i t s  u sed )  have  
been   imp lan ted   wo r ldw ide   w i th   th i s   comme rc ia l ly   ava i lab le   dev i ce   s in ce   i t s   launch   in   Oc tobe r  
20 09 .  Med t ron i c ’ s   ne x t   gene ra t ion  tho ra c i c  ao r t i c  s ten t  g ra f t   i s  the   Va l ian t   E vo  Tho ra c i c  S ten t  
G ra f t .  
The  Va l ian t   Evo  Tho ra c i c  S ten t   G ra f t   Sy s tem  in co rpo ra te s  de s ign   change s   f rom   the   Va l ian t  
Cap t i v ia  S ten t  G ra f t  Sy s tem  tha t  a re  ta rge ted  to  b roaden  pa t ien t  app l i cab i l i ty ,  enhan ce  ea se  o f  
u se ,  and  imp ro ve  va scu la r  a cce ss  by  [CONTACT_247252]  o f  a  redu ced  p ro f i le  o f  the  de l ive ry  sy s tem .  Th i s  de v i ce  
w i l l   add re ss   an   impo r tan t  TEVAR  need :   a   s ign i f i can t   redu c t ion   o f   the   de l i ve ry   sy s tem   p ro f i le  
(p ro f i le  o f  18F r  fo r  s ten t  g ra f t  d ia me te rs  ≤25  mm ,  p ro f i le  o f  20F r  fo r  s ten t  g ra f t  d iame te rs  ≤37  mm  
and   p ro f i le   o f   22F r   fo r   s ten t   g ra f t  d iame te rs  ≥  40   mm ) .   A   lowe r   p ro f i le   w i l l   be t te r   fa c i l i ta te   the  
endova scu la r   t rea tmen t   o f   pa t ien t s   w i th   sma l le r   ve sse l   d iame te rs   a s   we l l   a s   na r row ,   to r tuou s  
and /o r  ca l c i f ied  i l ia c  a r te r ie s .  Lowe r  p ro f i le  w i l l  po ten t ia l ly  enab le  a  pe rcu taneou s  app roa ch  wh i ch  
cou ld   redu ce   comp l i ca t ions   re la ted   to   cu t   down ,   sho r ten   p ro cedu re   t ime ,   b lood   lo ss ,   imp ro ve  
pa t ien t  com fo r t  and  redu ce  the  t ime  to  ambu la t ion .   
The  Va l ian t  Evo  Tho ra c i c  Sten t  Gra f t  Sy s tem  ha s  in co rpo ra ted  o the r  de s ign  change s  f rom  the  
Va l ian t  Cap t i v ia  S ten t  G ra f t  Sy s tem  w i th  the  fo l low ing  o f  no tab le  impo r tan ce :   
• In t rodu c t ion   o f   the   C lo sed   Web   con f igu ra t ion   w i th   the   t ip   cap tu re   me chan i sm   a s   the  
p ro x ima l  o r  d i s ta l  de v i ce  
• Redu ced  leng th  o f  tape red  t ip  o f  the  de l i ve ry  sy s tem   
• S ten t  g ra f t  con f igu ra t ion s  w i th  longe r  leng th  (up  to  225  mm )  and  in c rea sed  tape r  (5  –  6  
mm )  
•  A n  op t im ized  s ize  ma t r i x ,  inc lud ing  [ADDRESS_1183317] s  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  16  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 e s tab l i shed  w i th  Va l ian t  we re  ma in ta ined .  A l l  de s ign  change s  and  dev i ce  a t t r ibu te s  in co rpo ra ted  
w i th in  the  Va l ian t  Evo  de s ign  w i l l  be  eva lua ted  v ia  the  fu l l  su i te  o f  p lanned  de s ign  ve r i f i ca t ion  and  
va l ida t ion  te s t ing ,  wh i ch  in c lude s  ben ch  and  in  v ivo  te s t ing ,  to  en su re  the  dev i ce  w i th  the  de s ign  
mod i f i ca t ion s  mee t s  the  p re -e s tab l i shed  de s ign  and  pe r fo rman ce  spe c i f i ca t ion s   and  to  en su re  
tha t  p rodu c t  pe r fo rman ce  w i l l  be  c l in i ca l ly  a ccep tab le .  
B .2  Dev ice  in fo rma t ion  
The  s tudy  de v i ce  be ing  eva lua ted  in  th i s  c l in i ca l  s tudy  i s  the  Va l ian t  E vo  Tho rac i c  S ten t  G ra f t  
Sy s tem  wh i ch  i s  an  inve s t iga t iona l  dev i ce  manu fa c tu red  by  [CONTACT_851079] t ron i c .   
 De v i ce  De s c r ip t ion  
The  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem  i s  de s igned  fo r  the  endo va scu la r  repa i r  o f  le s ion s  
in  the  DTA .  When  p la ced  w i th in  the  ta rge t  le s ion ,  the  s ten t  g ra f t  p ro v ide s  an  a l te rna t ive  condu i t  
fo r   b lood   f low   w i th in   the  sub je c t ’ s  va scu la tu re   by   e xc lud ing   the   le s ion   f rom   b lood   f low   and  
p re ssu re .  
The  Va l ian t   E vo  Tho ra c i c  S ten t   G ra f t   S y s tem   i s  compo sed   o f   two   ma in   componen t s :  the  
imp lan tab le  Va l ian t  Evo  Tho ra c i c  S ten t  Gra f t  and  the   d i spo sab le  de l i ve ry  sy s tem .  The  Va l ian t  
E vo  Tho ra c i c  S ten t  Gra f t  i s  p re loaded  in to  the  de l ive ry  sy s tem ,  wh i ch  i s  in se r ted  endo lum ina l ly  
v ia  the  femo ra l  o r  i l ia c  a r te ry  and  t ra cked  th rough  the  sub je c t ’ s  va scu la tu re  to  de l i ve r  the  s ten t  
g ra f t  to  the  ta rge t  s i te .  
B .2 .1 .1  Va l ian t  E vo  Tho ra c i c  S ten t  G ra f t  
 
A  s ing le ,  p r ima ry  s ten t  g ra f t  may  be  u sed  by  i t se l f  i f  i t s  s i ze  i s  su f f i c ien t  to  p rov ide  the  de s i red  
co ve rage .  A l te rna t ive ly ,  i t   ma y  be  u sed  in  comb ina t ion  w i th  add i t iona l  s ten t  g ra f t  se c t ion s  tha t  
in c rea se s  the  g ra f t  leng th  d i s ta l ly  o r  p ro x ima l ly  to  the  p r ima ry  se c t ion .   
A l l  Va l ian t  Evo  Tho ra c i c  Sten t  Gra f t   componen t s   a re   compo sed   o f   a   se l f -e xpand ing ,   sp r ing  
sca f fo ld  made  f rom  n i t ino l  w i re  sewn  to  a  po lye s te r  fab r i c  g ra f t  w i th  non -re so rbab le  su tu re s  (see  
F igu re  B -1  and  F igu re  B -2  be low ) .  The  me ta l  sca f fo ld ing  i s  compo sed  o f  a  se r ie s  o f  se rpen t ine  
s ten t s  s ta cked  in  a  tubu la r  con f igu ra t ion .  P la t inum -I r id ium  rad iopaque  (RO )  ma r ke rs  a re  sewn  to  
the  fab r i c  fo r  rad iog raph i c  v isua l iza t ion  o f  the  edge  o f  the  g ra f t  ma te r ia l  and  the  m in imum  o ve r lap  
requ i red   when   mu l t ip le   s ten t   g ra f t s   a re   u sed .   The   th ree   p ro x ima l   ma r ke rs ,   and   the   two   d i s ta l  
ma r ke rs ,  ind i ca te  the  e x t rem i t ie s  o f  the  co ve red  s ten t  g ra f t .  The  s ing le  “m id -ma r ke r ”  ind i ca te s  the  
m in imum  amoun t  o f  o ve r lap  requ i red  fo r  mu l t ip le  componen t s .  The  ma te r ia l s  u sed  in  the  Va l ian t  
E vo  Tho ra c i c  S t en t  G ra f t  a re  l i s ted  in  Tab le  B -1 .  
Tab le  B -1 :  Va l ian t  Evo  Tho rac ic  S ten t  G ra f t  Ma te r ia ls  
Componen t   Ma te r ia l  
Sp r ing s  N i t ino l  w i re  (55%  N i cke l ,  45%  T i tan ium  w i th  
t ra ce  e lemen t s )  
G ra f t  Fab r i c  H igh -den s i ty  woven  mu l t i f i lamen t  po lye s te r  
Su tu re s  U l t ra -h igh -mo le cu la r -we igh t  po lye thy lene  
(UHMWPE )  and  po lye s te r  
RO  Ma rke rs  P la t inum -I r id ium  
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  17  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  
F igu re  B - 1 :  Va l ian t  Evo  F reeF lo  Con f igu ra t ion  
 
 
  
F igu re  B - 2 :  Va l ian t  Evo  C losed  Web  Con f igu ra t ion  
 
Du r ing  manu fa c tu r ing ,  the   Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  w i l l  be  p re -loaded   in to  the   Va l ian t  
E vo  De l ive ry  Sy s tem .  The  n i t ino l  s ten t s  a re  a l so  v i s ib le  unde r  f luo ro scopy .   
The  Va l ian t   E vo  Tho ra c i c  S ten t   G ra f t   S y s tem  i s   a va i lab le   in  fou r  d i f fe ren t   con f igu ra t ion s   (see  
F igu re  B -3 ) :  F reeF lo  S t ra igh t ,  F ree F lo  Tape red ,  C lo sed  Web  S t ra igh t ,  and  C lo sed  Web  Tape red .  
A l l  con f igu ra t ion s  can  be  u sed  e i the r  a s  a  p ro x ima l  o r  d is ta l  componen t  when  mu l t ip le  s ten t  g ra f t s  
a re  imp lan ted .  Ea ch  s ten t  g ra f t  con s i s t s  o f  a  fab r i c  tube  on  wh i ch  a  se r ie s  o f  6 -peak  (18  F r  o r  20  
F r )  o r  7 -pea k  (22  F r )  s ten ts  and  a  suppo r t  sp r ing  a re  sewn .  The  suppo r t  sp r ing  con t r ibu te s  to  
d iame te r   re co ve ry   o f   the   s ten t   g ra f t   fo l low ing   dep loymen t   and   p reven t s   the   s ten t   g ra f t   f rom  
in fo ld ing  du r ing  and  a f te r  dep loymen t .  S ten t  g ra f t  d iame te rs  range  f rom  20  –  46  mm  w i th  cove red  
leng th  f rom  60  –  225  mm  ( re fe r  to  Se c t ion  B .2 .1 .3  fo r  fu l l  s ize  ma t r i x ) .  
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  18  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  
 
1 .  F reeF lo  S t ra igh t  
2 .  F reeF lo  Tape red  
3 .  C lo sed  Web  S t ra igh t  
4 .  C lo sed  Web  
Tape red  
5 .  P ro x ima l  End  
6 .  D i s ta l  End  7 .  F reeF lo  
8 .  C lo sed  Web  
9 .  Suppo r t  Sp r ing  
10 .  RO  ma r ke r  
11 .  Co ve red  Leng th  
12 .  To ta l  Leng th  
F igu re  B -3 :  S ten t  G ra f t  Con f igu ra t ion  Componen ts  
F reeF lo  S t ra igh t  Con f igu ra t ion  
Th i s  con f igu ra t ion  in c lude s  a  F reeF lo  p ro x ima l  end  and  a  C lo sed  Web  d i s ta l  end .  A t  the  p ro x ima l  
end ,  a  6 -pea k  (18  F r  o r  20  F r )  o r  7 -pea k  (22  F r )  ba re  s ten t  e x tend s  pa s t  the  cove red  s ten t  g ra f t  
to  p ro v ide  add i t iona l  f i xa t ion  wh i le  ma in ta in ing  t ran svesse l  f low .  The  p ro x ima l -end  and  d i s ta l -end  
d iame te rs  o f  the  F reeF lo  S t ra igh t  con f igu ra t ion  a re  cons tan t  th roughou t  the  cove re d  leng th  o f  the  
de v i ce .  A  F reeF lo  end  shou ld  no t  be  p la ced  in s id e  the  fab r i c -co ve red  se c t ion  o f  ano the r  s ten t  
g ra f t .  
F reeF lo  Tape red  Con f igu ra t ion  
Th i s  con f igu ra t ion  in c lude s  a  F reeF lo  p ro x ima l  end  and  a  C lo sed  Web  d i s ta l  end .  A t  the  p ro x ima l  
end ,  a  6 -pea k  (18  F r  o r  20  F r )  o r  7 -pea k  (22  F r )  ba re  s ten t  e x tend s  pa s t  the  cove red  s ten t  g ra f t  
to  p ro v ide  add i t iona l  f i xa t ion  wh i le  ma in ta in ing  t ran svesse l  f low .  The  p ro x ima l  end  o f  the  F reeF lo  
Tape red  con f igu ra t ion  i s  la rge r  in  d iame te r  than  i t s  d i s ta l  end .  A  F reeF l o  end  shou ld  no t  be  p la ced  
in s id e  the  fab r i c -co ve red  sec t ion  o f  ano the r  s ten t  g ra f t .  
C losed  Web  S t ra igh t  Con f igu ra t ion  
Th i s  con f igu ra t ion  in c lude s  C lo sed  Web  p ro x ima l  and  d i s ta l  end s .  The  p ro x ima l  and  d i s ta l  end  
d iame te rs  o f  the  C lo sed  Web  S t ra igh t  con f igu ra t ion  a re  con s tan t  th roughou t  the  co ve red  leng th  
o f  the  dev i ce .  
C losed  Web  Tape red  Con f igu ra t ion  
Th i s  con f igu ra t ion  in c lude s  C lo sed  Web  p ro x ima l  and  d i s ta l  end s .  The  p ro x ima l  end  o f  the  C lo sed  
Web  Tape red  con f igu ra t ion  i s  la rge r  in  d iame te r  than  i ts  d i s ta l  end .  
B .2 .1 .2  Va l ian t  E vo  De l ive ry  Sy s tem  
The  Va l ian t  Evo  de l ive ry  sy s tem  con s i s t s  o f  a  s ing le -use ,  d i spo sab le  ca the te r  w i th  an  in teg ra t ed  
hand le  to  p ro v ide  con t ro l led  dep loymen t .  I t  i s  ava i lab le  in  an  ou te r  d iame te r  o f  18 ,  20 ,  o r  22  F r  
and  a  wo rk ing  leng th  o f  93  cm .  The  ca the te r  a ssemb ly  i s  f le x ib le  and  e xc lu s ive ly  compa t ib le  w i th  
a  0 .035 -in  (0 .89 -mm )  gu idew i re .   
The  Va l ian t   Evo  De l ive ry  Sy s tem  fea tu re s  a  t ip  cap tu re  me chan i sm  in  wh i ch  the   s ten t  g ra f t  i s  
dep loyed  in  two  s tage s  –  (1 )  re t ra c t ion  o f  the  g ra f t  co ve r ,  g radua l ly  e xpo s ing  the  s ten t  g ra f t  wh i le  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  19  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 a l low ing  re -po s i t ion ing  o f  the  imp lan t  p r io r  to  fu l l  dep loymen t  (2 )  re lea se  o f  the  f i rs t  (cap tu red )  
s ten t  wh i ch  a l low s  the  g ra f t  to  fu l ly  open  in to  po s i t ion .  
The  Va l ian t   E vo  De l ive ry   Sy s tem  i s  a  mu l t i -lume n  de v i ce ,   w i th  ea ch   lumen  se rv ing  a  d i f fe ren t  
fun c t ion :  
• The  PEEK  gu idew i re  tube  ( inne r  membe r )  p ro v ide s  a  lumen  to  a l low  the  sy s tem  to  t ra c k  
o ve r  a  Ø0 .035 "  gu ide  w i re .   
• The  cap tu re  tube  p ro v ide s  a  lumen  to  a c tua te  the  t ip  cap tu re  re lea se  me chan i sm .    
• The  m idd le  membe r  w i th  f le x ib le  s ten t  s top   and  s ten t  t ran s i t ion  tube  he lp s  the  de v i ce  
t ra ck  th rough  to r tuou s  ana tomy ,  ma in ta in s  s ten t  g ra f t  po s i t ion  du r ing  dep loymen t ,  and  
imp ro ve s  k in k  re s i s tan ce  o f  the  ca the te r .  
• The   g ra f t   co ve r   (w i th   s ta in le ss   s tee l   b ra id )   p rov ide s   a   lumen   tha t   con s t ra in s   the   s ten t  
g ra f t  and  f le x ib le  s ten t  s top  du r ing  t ra ck ing  and  f ina l  pos i t ion ing  o f  the  sy s tem .  The  s ten t  
g ra f t  i s  re lea sed  f rom  the  g ra f t  co ve r  tube  du r ing  dep loymen t .   
 
 
 
 
1 .  Lue r  Conne c to r  
2 .  S c rew  Gea r  
3 .  Re t ra c to r  Hand le  
4 .  T r igge r  
5 .  F ron t  G r ip  
6 .  G ra f t  Co ve r / In t rodu ce r  
Shea th  
7 .  S ten t  S top  8 .  T ip  Cap tu re  Me chan i sm  
9 .  RO  Ma rke r  Band  
10 .  Tape red  T ip  
11 .  Ba ck  End  Lo ck  
12 .  T ip  Cap tu re  Re lea se  
Hand le  
13 .  S c rew  Gea r  Re ta ine r  
14 .  F lu sh  Po r t  
 
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  20  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  
F igu re  B -4 :  Va l ian t  Evo  S ten t  G ra f t  De l ive ry  Sys tem  
 
The  Va l ian t   E vo   Tho ra c i c   S ten t  G ra f t   S y s tem   i s   an   in ve s t iga t iona l   c la ss   I I I   dev i ce   in   a l l  
geog raph ie s  and  i s  labe led  w i th  a l l  the  requ i red  s ta temen t s  pe r  geog raphy :   
 
• Un i ted   S ta te s :   “CAUT ION :   In ve s t iga t iona l  Dev i ce .   L im i ted   by   [CONTACT_851080] l   Law   ([LOCATION_003] )   to  
In ve s t iga t iona l  Use ”  
 
The  u se  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  S y s tem  i s  l im i ted  to  th i s  c l in i ca l  inve s t iga t ion  and  
ha s  to  be  done  a cco rd ing  to  the  c l in i ca l  i n ve s t iga t iona l  plan  and  the  In s t ru c t ion s  fo r  Use  ( IFU ) .  
Requ i red   Inve s t iga to r   t ra in ing   fo r   the   u se   o f   the   Va l ian t   Evo   Tho ra c i c  S ten t   G ra f t   S y s tem  i s  
de sc r ibed  in  Se c t ion  E .  4 .  
B .2 .1 .3  De v i ce  s ize s  and  con f igu ra t ion s  
Tab le  B -2  p re sen t s  the  p ropo sed  s ize s  and  con f igu ra t ion s  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  
Sy s tem ,  and  the  s iz ing  gu ide l ine s  p rov ided  in  Tab le  B -3 .   
De ta i led  in fo rma t ion  on  de v i ce  s ize s  and  con f igu ra t ions  w i l l  be  in c luded  in  the  IFU .  The  IFU  w i l l  
be  p rov ided  w i th  ea ch  in ves t iga t iona l  dev i ce .  
Tab le  B -2 :  Va l ian t  Evo  Tho rac ic  S ten t  G ra f t  Sys tem  S i ze  Ma t r ix  
F reeF lo  and  C lo sed  Web  S t ra igh t  con f igu ra t ion s  
 
OD  
(F r )  D iame te r  (mm )  Cove red  Leng th  
(mm )  
 
18  20  100  
22   
100 ,  175  25  
 
 
20  28  
31  100 ,  175 ,  225  
34   
 
 
60 ,  100 ,  175 ,  225  37  
 
22  40  
43  
46  
F reeF lo  Tape red  con f igu ra t ion s  
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  21  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 OD  
(F r )  P rox ima l  ×  D is ta l  
D iame te r  (mm )  Cove red  Leng th  
(mm ) 
18  25 x20 
  
 
 
 
 
175   
 
20  28×22  
31×25  
34×28  
37×31  
 
22  40×34  
43×37  
46×40  
C lo sed  Web  Tape red  con f igu ra t ion s  
 
OD  
(F r )  P rox ima l  ×  D is ta l  
D iame te r  (mm )  Cove red  Leng th  
(mm )  
18  25×20  175  
 
 
20  28×22   
 
 
 
200  31×25  
34×28  
37×31  
 
22  40×34  
43×37  
46×40  
 
 
Tab le  B -3 :  S i z ing  gu ide l ines  fo r  the  t rea tmen t  o f  aneu rysms  
 
G ra f t  D iame te r  (mm )  Vesse l  D iame te r  Ind ica t ion  (mm )  
20  16 –17  
22  18 –19  
25  20 –22  
28  23 –25  
31  26 –28  
34  28 –31  
37  30 –33  
40  33 –36  
43  36 –39  
46  39 –42  
 
 Ind i ca t ion s  fo r  U se   
The  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  S y s tem  i s  ind i ca ted  fo r  the  endo va scu la r  repa i r  o f  fu s i fo rm  
aneu ry sms  and  sa ccu la r  aneu ry sms /pene t ra t ing  u l ce rs  o f  the  de scend ing  tho ra c i c  ao r ta  (DTA )  
in  pa t ien t s  ha v ing  the  app rop r ia te  ana tomy  in c lud ing  the  fo l low ing :  
• I l ia c  o r  femo ra l  a r te ry  a cce ss  ve sse l  mo rpho logy  tha t  i s  compa t ib le  w i th  va scu la r  a cce ss  
te chn ique s ,  dev i ce s ,  o r  a cce sso r ie s  
• Nonaneu ry sma l  ao r t i c  d iame te r  f rom  16  mm  to  42  mm  
• Nonaneu ry sma l  ao r t i c  p ro x ima l  ne ck  leng th  ≥20  mm  ( fo r  F reeF lo  con f igu ra t ion )  and  ≥25  
mm  ( fo r  C lo sed  Web  con f igu ra t ion )  
• D i s ta l  ne ck  leng th  ≥20  mm   
De ta i led  in fo rma t ion  on  in tended  u se  o f  the  dev i ce ,  ind ica t ion s  and  con tra ind i ca t ion s ,  a s  we l l  a s  
a  comp le te  l i s t  o f  wa rn ing s ,  p re cau t ion s  and  po ten t ia l  ad ve rse  even t s ,  w i l l  be  in c luded  in  the  IFU .  
The  IFU  w i l l  be  p rov ided  w i th  ea ch  inve s t iga t iona l  de v ice .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  22  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 C   STUDY  PLAN  
C .1   S tudy  ob jec t ives  
The  pu rpo se  o f  the  Va l ian t  E vo  US  C l in i ca l  T r ia l  i s  to  demon s t ra te  the  sa fe ty  and  e f fe c t i vene ss  
of   the   Va l ian t   Evo   Tho ra c ic   S ten t   G ra f t  Sy s tem   in   sub je c t s   w i th   a   de scend ing   tho ra c i c   ao r t i c  
aneu ry sm  (DTAA )  who  a re  cand ida te s  fo r  endova scu la r  repa i r .   
The  c l in i ca l  e v iden ce  co l le c ted  a s  pa r t  o f  th i s  t r ia l  w i l l  be  u sed  in  con jun c t ion  w i th  da ta  co l le c ted  
du r ing  the  con cu r ren t ly  en ro l l ing  Va l ian t  Evo  In te rna t iona l  C l in i ca l  T r ia l  to  suppo r t  PMA  App rova l  
o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  S y s tem .     
C l in i ca l  fo l low  up  requ i remen t s  w i l l  con t inue  to  60  mon th s  to  p rov ide  longe r -te rm  e v iden ce  on  
the  de v i ce ’ s  pe r fo rman ce ,  pe rm i t t ing  a ccumu la t ion  o f  add i t iona l  de v i ce  u se  e xpe r ien ce  and  
c l in i ca l  ou t come s  to  suppo r t  po s t -ma r ke t ing  su rve i l lan ce .  
The  c l in i ca l  ev iden ce  co l le c ted  th rough  60  mon th s  may  be  u sed  in  con jun c t ion  w i th  the  da ta  
co l le c ted  f rom  the  con cu r ren t ly  en ro l l ing  Va l ian t  E vo  In te rna t iona l  C l in i ca l  T r ia l  to  suppo r t  
comme rc ia l  app rova l s  in  geog raph ie s  wo r ldw ide .  
 P r ima ry  ob je c t i ve s  
The  p r ima ry  ob je c t ive  i s  to  demon s t ra te  the  sa fe ty  and  e f fe c t i vene ss  o f  the  Va l ian t  Evo  Tho ra c i c  
S ten t  G ra f t  Sy s tem  in  sub je c t s  w i th  a  DTAA  who  a re  cand ida te s  fo r  endova scu la r  repa i r .   
 Se conda ry  ob je c t i ve s  
Se conda ry   ob je c t ive s   in c lude   de sc r ip t i ve   ana ly se s   o f   se conda ry   endpo in t s   a s   we l l   a s   a cu te  
p ro cedu ra l  ob se rva t ion s  and  c l in i ca l  u t i l i ty  mea su re s .  A  hypo the s i s  d r i ven  endpo in t  i s  p lanned  fo r  
12  mon th s  a s  de sc r ibed  in  Append i x  L6 .  
C .2  C l in ica l  endpo in ts  
 P r ima ry  endpo in ts  
The  p r ima ry  ob je c t ive  w i l l  be  a sse ssed  by  [CONTACT_851081] s i te  sa fe ty  and  e f fe c t i vene ss  endpo in t  tha t  
i s  ba sed  on  the  p ropo r t ion  o f  sub je c t s  who  e xpe r ien ced :   
(a )  Acce ss  and /o r  dep loymen t  fa i lu re s ;  and /o r   
(b )  MDE  w i th in  30  day s  po s t  inde x  p ro cedu re  
MDE s  in c lude  the  o ccu r rence  o f  any  o f  the  fo l low ing :  
• De v i ce -re la ted  se conda ry  p ro cedu re s   
• De v i ce -re la ted  mo r ta l i ty  
• Conve rs ion  to  open  su rge ry  
• Tho ra c i c  a o r t i c  aneu ry sm  rup tu re  
De ta i led  de f in i t ion s  o f  MDEs  a re  de f ined  in  Append i x  L .5 .  
An  independen t  CEC  w i l l  be  e s tab l i shed  and  ad jud i ca te  MDE s .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  23  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Se conda ry  endpo in ts  
C .2 .2 .1  30 -day  Se conda ry  Endpo in t  
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted  w i th in  30  day s  po s t  t rea tmen t :  
• Pe r i -ope ra t i ve  mo r ta l i ty  
• A l l  adve rse  e ven t s  (AE )  w i th in  30  day s  in c lud ing :  
• Ma jo r  Adve rse  Even t (s )  (MAE )   
• Se r iou s  Ad ve rse  Even t (s )  (SAE )  
• Se conda ry  p ro cedu re s   
• Lo ss  o f  s ten t  g ra f t  pa ten cy  a t  30  day  v i s i t  ba sed  on  imag ing  f ind ing s  
• Endo lea ks  a t  30  day  v i s i t  ba sed  on  imag ing  f ind ing s  
Ma jo r  adve rse  e ven t s  in c lude  the  o ccu r ren ce  o f  any  o f  the  fo l low ing :  
• Re sp i ra to ry   comp l i ca t ion s :  a te le c ta s i s /pneumon ia ,   pu lmona ry   embo l i sm ,   pu lmon a ry  
edema ,  re sp i ra to ry  fa i lu re  
• Rena l  comp l i ca t ion s :  rena l  fa i lu re ,  rena l  in su f f i c ien cy  
• Ca rd ia c  comp l i ca t ion s :  M I ,  un s tab le  ang ina ,  new  a r rhy thm ia ,  e xa ce rba t ion  o f  CHF .   
• Neu ro log i ca l  comp l i ca t ion s :  new  CVA ,  embo l i c  e ven t s ,  pa rap leg ia ,  pa rapa r e s i s .   
• Ga s t ro in te s t ina l  comp l i ca t ion s :  bowe l  i schem ia  
• Ma jo r  b leed ing  comp l i ca t ion  (p ro cedu ra l  o r  po s t -p ro cedu ra l ) ,  coagu lopa thy .   
• Va scu la r   comp l i ca t ion s :   ao r t i c   rup tu re ,   aneu ry sm   rup tu re ,   hema toma   a t   a cce ss   s i te ,  
pseudo   o r   fa l se   aneu ry sm ,   a r te r io venou s  (AV )   f i s tu la ,   re t rope r i tonea l   b leed ,   l imb  
i schem ia ,  t h rombo s i s  
De ta i led  de f in i t ion s  o f  MAEs  a re  de f ined  in  Append i x  L .2 .2  
C .2 .2 .2   6 - mon th  Se conda ry  Endpo in t s :    
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted :  
• A l l -cau se  mo r ta l i ty  w i th in  183  day s  
• Aneu ry sm -Re la ted  Mo r ta l i ty  w i th in  183  day s  
• MDE s  w i th in  183  day s  
• A l l  AE s  w i th in  183  day s  in c lud ing :  
•  MAE s  
•  SAE s  
• Se conda ry  p ro cedu re s  w i th in  183  day s  
• Lo ss  o f  s ten t  g ra f t  pa ten cy  w i th in  6  mon th s  ba sed  on  imag ing  f ind ing s  
• Endo lea ks  a t  6  mon th s  ba sed  on  imag ing  f ind ing s  
• S ten t  g ra f t  m ig ra t ion  a t  6  mon th s  a s  compa red  to  1 -mon th  imag ing  
• Aneu ry sm  e xpan s ion  >  5mm  a t  6  mon th s  ba sed  on  imag ing  f ind ing s  re la t ive  to  the  1 -
mon th  v i s i t  
C .2 .2 .3  12 -mon th  Se conda ry  Endpo in t s  
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted :  
• A l l -cau se  mo r ta l i ty  w i th in  365  day s  
• Aneu ry sm -Re la ted  Mo r ta l i ty  w i th in  365  day s  
• MDE s  w i th in  365  day s  
• A l l  AE s  w i th in  365  day s  in c lud ing :  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  24  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • MAE s  
• SAE s  
• Se conda ry  p ro cedu re s  w i th in  365  day s  
• Lo ss  o f  s ten t  g ra f t  pa ten cy  w i th in  12  mon th s  ba sed  on  imag ing  f ind ing s  
• End o lea ks  a t  12  mon th s  based  on  imag ing  f ind ing s  
• S ten t  g ra f t  m ig ra t ion  a t  12  mon th s  a s  compa red  to  1 -mon th  imag ing  
• Aneu ry sm  e xpan s ion  >  5mm  a t  12  mon th s  ba sed  on  imag ing  f ind ing s  re la t i ve  to  the  1 -
mon th  v i s i t  
C .2 .2 .4  24 ,  36 ,  48  and  60 -mon th  Se conda ry  Endpo in t s  
The  fo l low ing  se conda ry  endpo in t s  w i l l  be  eva lua ted :  
• A l l -cau se  mo r ta l i ty  up  to  each  t imepo in t  
• Aneu ry sm -Re la ted  Mo r ta l i ty  up  to  ea ch  t imepo in t  
• MDE s  up  to  ea ch  t imepo in t  
• A l l  AE s  up  to  ea ch  t imepo in t :  
• MAE s  
• SAE s  
• Se conda ry  p ro cedu re s  up  to  ea ch  t imepo in t   
• Lo ss  o f  s te n t  g ra f t  pa ten cy  (s i te -repo r ted )  up  to  ea ch  t imepo in t  ba sed  on  imag ing  f ind ing s  
• Endo lea ks  (s i te -repo r ted )  a t  ea ch  t imepo in t  ba sed  on  imag ing  f ind ing s  
• S ten t  g ra f t  m ig ra t ion  (s i te -repo r ted )  a t  ea ch  t imepo in t  a s  compa red  to  1 -mon th  imag ing  
• Aneu ry sm  e xpan s ion  >  5mm  ( s i te -repo r ted )  a t  ea ch  t imepo in t  ba sed  on  imag ing  f ind ing s  
re la t i ve  to  the  1 -mon th  v i s i t  
 Add i t iona l  ob se rva t ion s  
The  fo l low ing  a cu te  p ro cedu ra l  ob se rva t ion s  and  c l in i ca l  u t i l i ty  mea su re s  w i l l  be  ana ly zed :   
• Mean  du ra t ion  (m in )  o f  p ro cedu re   
• P ropo r t i on  o f  sub je c t s  who  unde rwen t  gene ra l  ane s thes ia   
• P ropo r t ion  o f  sub je c t s  who  unde rwen t  pe rcu taneou s  acce ss   
• P ropo r t ion  o f  sub je c t s  requ i r ing  b lood  t ran s fu s ion s   
• Mean  numbe r  o f  un i t s  o f  b lood  t ran s fu sed ,  i f  requ i red   
• Mean  vo lume  (cc )  o f  e s t ima ted  b lood  lo ss   
• Mean  leng th  o f  t ime  (hou rs )  in  in ten s ive  ca re  un i t   
• Me an   leng th   o f   t ime   (day s )   o f   ho sp i ta l   s tay   ( f rom   the   inde x   p ro cedu re   to   hosp i ta l  
d i scha rge )  
Hea l th -re la ted  qua l i ty  o f  l i fe  ou t come s  w i l l  be  a sse ssed  a t  a l l  schedu led  fo l low -up  v i s i t s  u s ing  the  
EQ -5D  que s t ionna i re .   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  25  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 C .3  S tudy  Hypo thes is  
The  Va l ian t  Evo  US  C l in i ca l  T r ia l   w i l l  fo cu s  on  ba lanc ing  p re -  and  po s t -ma r ke t  c l in i ca l  da ta  to  
e s tab l i sh  sa fe ty  and  e f fe c t i vene ss .  
The  p r ima ry  s tudy  endpo in t  w i l l  be  te s ted  aga in s t  a  pe r fo rman ce  goa l  o f  16%  a t  30  day s :  
H0:  p ≥  16%  v s .  H a:  p <16% ,  
whe re  p  deno te s  the  t rue  even t  ra te  o f  p r ima ry  s tudy  endpo in t  in  the  ta rge t  popu la t ion .   
I f   the   nu l l   hypo the s i s   (H 0)   is   re je c ted   a t   the   one -s ided   0 .025   s ta t i s t i ca l   s ign i f i cance   lev e l ,   i t   i s  
con s ide red  tha t  the  pe r fo rman ce  goa l  fo r  the  p r ima ry  endpo in t  ha s  been  rea ched .  
IDE  coho r t  w i l l  be  fo l lowed  up  to  1 -yea r  and  the  p r ima ry  endpo in t  w i l l  be  te s ted  aga in s t  a  20%  
pe r fo rman ce  goa l  a t  1  yea r  fo r  the  po s t -app rova l  ana ly s i s .  Re fe r  to  App end i x  L -6 -  PMA -S  Po s t  
App rova l  ana ly s i s .  
C .4  S tudy  popu la t ion  
The  s tudy  popu la t ion  w i l l  in c lude  tho se  sub je c t s  who  a re  app rop r ia te  cand ida te s  fo r  endova scu la r  
repa i r  o f  DTAA ,  and  who  mee t  the  In c lu s ion /E xc lu s ion  c r i te r ia  (de f ined  in  Se c t ion  D ) .  
C .5  S tudy  des ign  
Th e   Va l ian t   E vo   US   C l in i ca l   T r ia l   i s   a   p ro spe c t i ve ,   mu l t i -cen te r ,   p re -ma r ke t ,   non -random ized ,  
s ing le -a rm  t r ia l .  The  t r ia l  i s  de s igned  to  a sse ss  the  sa fe ty  and  e f fe c t i vene ss  o f  the  Va l ian t  E vo  
Tho ra c i c  S ten t  G ra f t  Sy s tem  in  sub je c t s  w i th  a  de scend ing  tho ra c i c  ao r t i c  aneu ry sm  (DTAA )  who  
a re  cand ida te s  fo r  endo va scu la r  repa i r .   
The  c l in i ca l  pe r fo rman ce  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  w i l l  be  eva lua ted  in  a  to ta l  o f  
100   sub je c t s   w i th   a   hypo the s i s -ba sed   30 -day   p rema r ke t   compo s i te   sa fe ty   and   e f fe c t i vene ss  
endpo in t .   
 
The  p ropo sed  p r ima ry  compo s i te  sa fe ty  and  e f fe c t i vene ss  endpo in t  i s  ba sed  on  the  p ropo r t ion  
o f  sub je c t s  who  e xpe r ien ced :  
 
(a )  A cce ss  and /o r  dep loymen t  fa i lu re s ;  and /o r  
(b )  Ma jo r  Dev i ce  E f fe c t  (MDE )  w i th in  30  day s  po s t  inde x  p ro cedu re  
 
MDE s  in c lude  the  o ccu r rence  o f  any  o f  the  fo l low ing :  
 
• De v i ce -re la ted  se conda ry  p ro cedu re s  
• De v i ce -re la ted  mo r ta l i ty  
• Conve rs ion  to  open  su rge ry  
• Tho ra c i c  ao r t i c  aneu ry sm  rup tu re  
Th i s  p r ima ry  compo s i te  endpo in t  w i l l  be  compa red  to  a  PG  o f  16 %  MDE  ra te  a t  [ADDRESS_1183318]  requ i red  fo l low -
up  eva lua t ion s  a t  the  fo l low ing  t ime  po in t s :  
•  1 - mon th  fo l low ing  the  inde x  p ro cedu re  
•  6 - mon th s  fo l low ing  the  index  p ro cedu re    
• 12 ,  24 ,  36 ,  48  and  60 -mon th s  fo l low ing  the  inde x  p ro cedu re  
A l l  sub je c t s  we re  con sen ted  fo r  up  to  2  yea rs  o f  fo l low -up .  Th i s  wa s  to  a ccommoda te  any  g loba l  
c l in i ca l  in ve s t iga t io na l  requ i remen t s ,  i f  requ i red .  Sub jec t s  a l ready  en ro l led  and  w i l l ing  to  e x tend  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  26  o f  73   
20 /OCT /[ADDRESS_1183319] ing   sub je c t s ’   we l l -be ing .  An   imag ing   co re   lab   w i l l   no t   be   u sed   to  
pe r fo rm  independen t  imag ing  a sse ssmen ts  rega rd ing  de v i ce  pe r fo rman ce  beyond  12  mon th s  o f  
fo l low -up .  
C .6  Random iza t ion  and  b l ind ing  
The  s tudy  i s  a  s ing le  a rm  s tudy ,  the re fo re  ne i the r  r andom i za t ion  no r  b l ind ing  a re  app l i cab le  to  
th i s  c l in i ca l  t r ia l .  
 
C .7  Samp le  s ize  
G loba l ly ,  a  to ta l  o f  100  sub je c t s  w i l l  be  con cu r ren t ly  en ro l led  in  the  Un i ted  S ta te s  and  ou t s ide  the  
Un i ted  S ta te s  to  suppo r t  the  p r ima ry  endpo in t s .  Up  to  50%  o f  sub je c t  da ta  u sed  to  suppo r t  PMA  
app rova l  may  come  f rom  sub j e c t s  en ro l led  a t  s i te s  ou ts ide  o f  the  US  unde r  a  sepa ra te  CE  Ma rk  
s tudy  p ro to co l ;  ca l led  the  Va l ian t  Evo  In te rna t iona l  C l in i ca l  T r ia l  p ro to co l .   
The  Va l ian t  Evo  In te rna t iona l  C l in i ca l  T r ia l  p ro to co l  and  Va l ian t  E vo  US  C l in i ca l  T r ia l  p ro to co l  w i l l  
be  iden t i ca l  w i th  re spe c t  to  the  in c lu s ion /e xc lu s ion  c r i te r ia .  
One  hund red  (100 )  en ro l led  sub je c t s  w i l l  en su re  87  eva luab le  sub je c t s  a t  30  day s .  The  p r ima ry  
endpo in t  ana ly s i s  w i l l  be  comp le ted  upon  87  e va luab le  sub je c t s  rea ch ing  the  30  day  endpo in t .  
The  da ta  f rom  the se  87  e va luab le  sub je c t s  a t  30 -day s  w i l l  be  u sed  to  f i le  the  PMA  subm i ss ion .  
Ba sed   on  Va lo r   I I  s tudy   resu l t s,   Va l ian t   Evo   i s   e xpe c ted   to   pe r fo rm   s im i la r ly   and   ha ve   6%   o f  
MDE s   comb ined   w i th   a ccess   and /o r   dep loymen t   fa i lu re s   a t   30   day s .   The   samp le   s ize   o f  87  
e va luab le  sub je c t s  w i l l  p rov ide  85%  s ta t i s t i ca l  powe r  fo r  the  s tudy  hypo the s i s .   The  type  I  e r ro r  i s  
con t ro l led  a t  the  one -s ided  0 .025  le ve l .   
Tab le  C -1 :  Powe r  Ana lys is   
T rue  ra te  o f  MDE s  comb ined  w i th  a c ce s s  
and /o r  dep lo ymen t  fa i lu re s  a t  30  da y  w i th  
Va l ian t  E vo  6%  
Pe r fo rman ce  Goa l   16%  
S ign i f i can ce  le ve l  0 .025  
S ta t i s t i ca l  te s t  One -s ided  b inom ia l  te s t  
E va luab le  samp le  s i ze  n=87  
En ro l lmen t  M in imum  o f  100  sub je c ts  
en ro l led  to  en su re  87  
e va luab le  sub je c ts  
S ta t i s t i ca l  powe r  f rom  the  87  e va luab le  
sub je c ts  85%  
C .8  Numbe r  o f  Inves t iga t iona l  s i tes  and  s tudy  du ra t ion  
The  Va l ian t  Evo  G loba l  C l in i ca l  p rog ram  w i l l  be  condu c ted  a t  up  to  37  s i te s  wo r ldw ide ,  w i th  a t  
lea s t  50%  o f  the  c l in i ca l  s i te s  com ing  f rom  the  Un i ted  S ta te s .  In c lu s ion  w i l l  be  ha l ted  a t  s i te s  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  27  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 tha t  rea ch  the  20%  in c lu s ion  cap .  The re  w i l l  be  no  m in imum  numbe r  o f  sub je c t s  fo r  a  s ing le  
inve s t iga t iona l  s i te .  
The  to ta l  en ro l lmen t  pe r iod  i s  e xpe c ted  to  be  app ro x ima te ly  [ADDRESS_1183320] ION  
D .1  Inc lus ion  c r i te r ia  
Cand ida te s  fo r  the  Va l ian t  E vo  US  C l in i ca l  t r ia l  mu s t  be  app rop r ia te  sub je c t s  fo r  endo va scu la r  
repa i r  o f  aneu ry sms  o f  the  de scend ing  tho ra c i c  ao r ta  (ev iden ced  by  [CONTACT_851075] t ra s t -enhan ced  
CT  o r  MRA )  and  ha ve  to  fu l f i l l  a l l  o f  the  fo l low ing  in c lu s ion  c r i te r ia  to  be  e l ig ib le  fo r  re c ru i tmen t  in  
the  s tudy :  
1 .  Sub je c t  i s  ≥18  yea rs  o ld .  
2 .  Sub je c t  unde rs tand s  and  vo lun ta r i ly  ha s  s igned  and  da ted  the  In fo rmed  Con sen t  Fo rm  
app roved  by  [CONTACT_851076] r  and  by  [CONTACT_941]  E th i cs  Comm i t tee  fo r  th i s  s tudy .    
3 .  Sub je c t   p re sen t s  a   DTAA  wh i ch   i s   lo ca l ized   be low   the   o s t ium   o f  LSA  and   above   the  
o s t ium  o f  ce l ia c  t run k  
4 .  Sub je c t  ha s  a  DTAA  tha t  i s  one  o f  the  fo l low ing :  
a .   A  fu s i fo rm  aneu ry sm  w i th  a  ma x imum  d iame te r  tha t :  
• i s  ≥  5 0  m m  and /o r :  
• i s  >  2  t ime s  the  d iame te r  o f  the  non -aneu ry sma l  tho ra c i c  ao r ta  and /o r :  
• i s  <  50  mm  and  ha s  g rown  ≥  5  mm  w i th in  p rev iou s  12  mon th s  
b .   A  sa ccu la r  aneu ry sm  o r  a  pen e t ra t ing  a the ro sc le ro t i c  u l ce r  
5 .  Sub je c t ’ s  ana tomy  mu s t  mee t  a l l  o f  the  fo l low ing  ana tom i ca l  c r i te r ia  a s  demon s t ra ted  on  
con t ra s t -enhan ced   CT   and /o r   on   con t ra s t -enhan ced   MRA   ob ta ined   w i th in   fou r   (4 )  
mon th s  p r io r  to  imp lan t  p rocedu re :   
a .  P ro x ima l  and  d i s ta l  non -aneu ry sma l  ao r t i c  ne ck  d iame te r  mea su remen t s  mu s t  be  
≥  16  mm  and  ≤  42  mm ;   
b .  P ro x ima l   non -aneu ry sma l  ao r t i c   ne ck   leng th   mu s t   be   ≥   20   mm  ( fo r   F reeF lo  
con f igu ra t ion )  and   ≥   25   mm  ( fo r   C lo sed   Web   con f igu ra t ion )  d i s ta l   to   the   le f t  
common   ca ro t id   a r te ry   (LCCA ) .   No te :   P ro x ima l   ao r t i c   ne ck   leng th   may   in c lude  
co ve r ing  the  LSA  (w i th  o r  w i thou t  d i sc re t iona ry  reva scu la r iza t ion )  when  ne ce ssa ry  
to  op t im i ze  dev i ce  f i xa t ion  and  ma x im i ze  ao r t i c  ne ck  leng th .  I f  o cc lu s ion  o f  the  LSA  
o s t ium   i s   requ i red   to   ob ta in   adequa te   ne ck   leng th   fo r   f i xa t ion   and   sea l ing ,  
t ran spo s i t ion  o r  by[CONTACT_851077] r ran ted .  
c .  D i s ta l  n on -aneu ry sma l  ao r t ic  ne ck  leng th  mu s t  be  ≥  20  mm  
6 .  Sub je c t   ha s   adequa te   a r te r ia l   a cce ss   s i te   o r   can   to le ra te   a   condu i t   tha t   a l low s  
endova scu la r  a cce ss  to  the  aneu ry sma l  s i te  w i th  the  de l ive ry  sy s tem  o f  the  app rop r ia te  
s ized  dev i ce  cho sen  fo r  the  t rea tmen t .  
D .2   E xc lus ion  c r i te r ia  
Cand ida te s  who  mee t  any  o f  the  fo l low ing  e xc lu s ion  c r i te r ia  w i l l  no t  be  e l ig ib le  fo r  re c ru i tmen t  in  
the  s tudy :  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  28  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 1 .  Sub je c t  ha s  a  l i fe  e xpe c tancy  o f  le ss  than  1  yea r  
2 .  Sub je c t   i s   pa r t i c ipa t ing   in   ano the r   in ve s t iga t iona l   d rug   o r   dev i ce   s tudy  wh i ch   wou ld  
in te r fe re  w i th  the  endpo in t s  and  fo l low -up s  o f  th i s  s tudy .  
3 .  Sub je c t  i s  p regnan t .  
4 .  Sub je c t   requ i re s   p lanned   p la cemen t   o f   the   co ve red   p ro x ima l   end  o f   the   s ten t   g ra f t   to  
o ccu r  in  zone s  0  o r  1 .   
 
F igu re  D -1 :  Land ing  zones  o f  the  tho rac ic  ao r ta  
(See  append i x  L .2 .4  fo r  de f in i t ion s  o f  zone s ) 
5 .  Sub je c t  ha s  a  tho ra c i c  aneu ry sm  w i th  a  con ta ined  rup tu re  o r  lo ca l ized  a t  the  ana s tomo s i s  
o f  a  p re v iou s  g ra f t  (p seudo -/ fa l se  aneu ry sm ) .  
6 .  Sub je c t  ha s  a  my co t i c  aneu ry sm .  
7 .  Sub je c t  ha s  a  d i sse c t ion  ( type  A  o r  B )  o r  an  i n t ramu ra l  hema toma  o r  an  ao r t i c  rup tu re  in  
add i t ion  to  the  tho ra c i c  aneu ry sm .   
8 .  Sub je c t  requ i re s  eme rgen t  aneu ry sm  t rea tmen t ,  e .g . ,  t rauma  o r  rup tu re .  
9 .  Sub je c t   ha s   re ce ived   a   p re v iou s   s ten t   o r   s ten t   g ra f t   o r   p re v iou s   su rg i ca l   repa i r   in   the  
a scend ing  and /o r  de scend ing  tho ra c i c  ao r ta ,  and /o r  in  the  ao r t i c  a rch .   
10 .  Sub je c t   requ i re s   su rg i ca l   o r   endova scu la r   t rea tmen t   o f   an   in f ra -rena l   aneu ry sm  a t   the  
t ime  o f  imp lan t   
11 .  Sub je c t   ha s   had   p re v iou s   su rg i ca l   o r   endova scu la r   t rea tmen t   o f   an  in f ra -rena l   ao r t i c  
aneu ry sm .  
12 .  T re a tmen t   w i th   the   Va l ian t   E vo   Tho ra c i c   S ten t   G ra f t  wou ld   requ i re   in ten t iona l  
re va scu la r iza t ion  o f  the  b rach io -cepha l i c  a r te ry  o r  the  le f t  common  ca ro t id  a r te ry  o r  the  
ce l ia c  t run k .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  29  o f  73   
20 /OCT /[ADDRESS_1183321]  a  ma jo r  su rg i ca l  o r  in te rven t iona l  p ro cedu re  w i th in  30  
day s  be fo re  o r  30  day s  a f te r  the  p lanned  imp lan ta t ion  o f  the  Va l ian t  E vo  Tho ra c i c  S ten t  
G ra f t .   Th i s   doe s   no t   in c lude   p lanned   p ro cedu re s   tha t   a re   needed   fo r   the   sa fe   and  
e f fe c t i ve   p la cemen t   o f   the   s ten t   g ra f t   ( i .e . ,   ca ro t id / sub c la v ian   t ran spos i t ion ,  
ca ro t id / sub c lav ian  by[CONTACT_330843]  p ro cedu re ) .  
14 .  Sub je c t   ha s   a   s ign i f i can t  and / o r   c i rcum fe ren t ia l   ao r t i c   mu ra l   th rombu s   a t   e i the r   the  
p ro x ima l   o r   d i s ta l   a t ta chmen t   s i te s   tha t   cou ld   comp rom i se   f i xa t ion   and   sea l   o f   the  
imp lan ted  s ten t  g ra f t .  
15 .  Sub je c t   ha s   a   conne c t ive   t i ssue   d i sea se   (e .g . ,   Ma r fan ’ s   synd rome ,   ao r t i c   med ia l  
degene ra t ion ) .   
16 .  Sub je c t  ha s  a  b leed ing  d ia the s i s  o r  coagu lopa thy ,  o r  re fu se s  b lood  t ran s fu s ion .  
17 .  Sub je c t  ha s  had  a  M I  w i th in  3  mon th s  o f  the  p ro cedu re .  
18 .  Sub je c t  ha s  had  a  CVA  w i th in  3  mon th s  o f  the  p ro cedu re .  
19 .  Sub je c t  ha s  a  known  a l le rgy  o r  in to le ran ce  to  the  dev i ce  ma te r ia l s  
20 .  Sub je c t  ha s  a  known  a l le rgy  to  ane s the t i c  d rug s  
21 .  Sub je c t  ha s  a  known  hype rsen s i t iv i ty  o r  con t ra ind i ca t ion  to  an t i coagu lan t s ,  o r  con t ra s t  
me d ia ,  wh i ch  i s  no t  amenab le  to  p re t rea tmen t .  
22 .  Sub je c t  ha s  a c t ive  o r  sy s tem i c  in fe c t ion  a t  the  t ime  o f  the  inde x  p ro cedu re .  
E   STUDY  PREPARAT ION  PROCEDURES  
E .1  Inves t iga to r / Inves t iga t ion  s i te  se lec t ion  
 In ve s t iga to r  se le c t ion  c r i te r ia  
The  ro le  o f  the  p r in c ipa l  inve s t iga to r  i s  to  imp lemen t  and  manage  the  day -to -day  condu c t  o f  the  
c l in i ca l  s tudy  a s  we l l  a s  en su re  da ta  in teg r i ty  and  the  r igh t s ,  sa fe ty  and  we l l -be ing  o f  the  sub je c t s  
invo lved  in  t he  c l in i ca l  s tudy .  
An  inve s t iga to r  may  be  in c luded  in  the  c l in i ca l  s tudy  i f  comp l ian t  w i th  the  fo l low ing  requ i remen t s :    
• In ve s t iga to rs  a re  app rop r ia te ly  qua l i f ied  p ra c t i t ione rs  and  e xpe r ien ced  in  the  d iagno s i s  
and  t rea tmen t  o f  sub je c t s  requ i r ing  an  endova scu la r  p rocedu re  w i th  a  tho ra c i c  s ten t  g ra f t  
•  I n ve s t iga to rs  have  adequa te  t ime  to  fo l low  up  on  the  c l in i ca l  s tudy  
• In ve s t iga to rs  a re  w i l l ing  to  comp ly  w i th  the  cl in i ca l  in ve s t iga t ion  plan  
• In ve s t iga to rs  a re  w i l l ing  to  s ign  the  app rop r ia te  cl in i ca l  t r ia l  a g reemen t  
• In ve s t iga to rs   ha ve   pa s t   expe r ien ce   w i th   condu c t ing   c l in i ca l   s tud ie s   o r   app rop r ia te  
t ra in ing  
• In ve s t iga to rs  a re  fam i l ia r  w i th  FDA / ICH -GCP  requ i remen t s  
• In ve s t iga to rs  a re  w i l l ing  to  unde rgo  aud i t ing  by  [CONTACT_851082] r  o r  regu la to ry  bod ie s  
• In ve s t iga to rs  a re  w i l l ing  to  unde rgo  s tudy  spe c i f i c  t ra in ing  
 In ve s t ig a t ion  s i te  se le c t ion  c r i te r ia  
An  in ve s t iga t ion  s i te  may  be  se le c ted  fo r  pa r t i c ipa t ion  in  the  c l in i ca l  s tudy  i f  comp l ian t  w i th  the  
fo l low ing  requ i remen t s :   
• Adequa te  s ta f f  ( sub -in ve s t iga to r  and /o r  re sea rch  coo rd ina to r )  tha t  i s  a cce ss ib le  and  ha s  
t ime  to  manage  the  t r ia l  and  da ta  repo r t ing  requ i remen t s  
• S i te  pe rsonne l  ha s  demon s t ra ted  e xpe r ien ce  w i th  condu c t ing  c l in i ca l  (spe c i f i ca l ly  de v i ce )  
t r ia l s  tha t  comp ly  w i th  app l icab le  regu la to ry  s tanda rd s  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  30  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • S i te  ha s  su f f i c ien t  annua l  ca se  vo lume  o f  DTAA  s ten t  g ra f t  p ro ced u re s  
• Ab i l i ty  to  se cu re ly  s to re  de v i ce s  a cco rd ing  to  the  In s t ruc t ion s  fo r  Use   
• Ab i l i ty  to  pe r fo rm  requ i red  imag ing  a sse ssmen t s  a t  s i te  
 C l in i ca l  T r ia l  Ag reemen t  
A  c l in i ca l  t r ia l  ag reemen t  sha l l  be  in  p la ce ,  s igned  by  [CONTACT_301849] r t i c ipa t ing  inve s t iga t iona l  s i te  an d /o r  
p r in c ipa l  in ve s t iga to r  o f  ea ch  in ve s t iga t iona l  s i te ,  a s  pe r  the  lo ca l  lega l  requ i remen t s ,  and  re tu rned  
to   Med t ron i c   p r io r   to   the   commen cemen t   o f   any  c l in i ca l  s tudy   a c t iv i t ie s .   The   inve s t iga to r   i s  
ind i ca t ing   app rova l   o f   the   c l in i ca l   in ve s t iga t ion   p lan   and   sub sequen t   amendmen t s ,   w i th   a   fu l ly  
e xe cu ted  ag reemen t .  
E .2  E th ics  
 EC / IRB  app ro va l  
P r io r  to  en ro l l ing  sub je c t s  in  th i s  c l in i ca l  s tudy ,  ea ch  in ve s t iga t iona l  s i te ’ s  EC / IRB  w i l l  be  requ i red  
to  app rove  the  cu r ren t  C l in i ca l  Inve s t iga t ion  P lan ,  the  In fo rmed  Con sen t  Fo rm ,  in c lud ing  any  o the r  
w r i t ten   in fo rma t ion   to   be   p ro v ided   to   the   sub je c t s   and ,  i f   app l i cab le ,  ma te r ia l s   u sed   to   re c ru i t  
sub je c t s .  EC / IRB  app ro va l  o f  the  c l in i ca l  s tudy  mu s t  be  re ce ived  in  the  fo rm  o f  a  le t te r  and  a  copy  
p ro v ided  to  Med t ron i c  be fo re  commen cemen t  o f  the  c l in i ca l  s tudy  a t  an  inve s t iga t iona l  s i te .  The  
app rova l  le t te r  mu s t  con ta in  enough  in fo rma t ion  to  iden t i fy  the  ve rs ion  o r  da te  o f  the  do cumen t s  
app roved .  I f  th i s  in fo rma t ion  i s  no t  con ta ined  in  the  app ro va l  le t te r ,  i t  mu s t  be  re t r ie vab le  f rom  the  
co r re spond ing  subm i ss ion  le t te r .  In  add i t ion  the  app rova l  le t te r  need s  to  be  a ccompan ied  by  [CONTACT_851083] / IRB  ro s te r  o r  le t te r  o f  comp l ian ce ,  to  a l low  ve r i f i ca t ion  tha t  the  inve s t iga to r ,  o the r  inve s t iga t ion  
s i te  pe rsonne l ,  and /o r  Med t ron i c  pe rsonne l  a re  no t  membe rs  o f  the  EC / IRB .  I f  they  a re  membe rs  
o f   the   EC / IRB ,   w r i t ten   do cumen ta t ion   i s   requ i red   s ta t ing   tha t   he / she   d id   no t   pa r t i c ipa te   in   the  
app rova l   p ro ce ss .   I f   the   EC / IRB   impo se s   any   add i t iona l   requ i remen t s   (e .g .   sa fe ty   repo r t s ,  
p rog re ss   repo r t s ) ,   the   s i te   mu s t   reque s t   the se   add i t iona l   requ i remen t s   in   w r i t ing ,   and   then  
Med t ron i c  w i l l  p repa re  the  requ i red  do cumen t s  and  send  them  to  the  inve s t iga to r  fo r  repo r t ing  to  
the   EC / IRB .   Inve s t iga to rs   mu s t   in fo rm   Med t ron i c   o f   any   change   in   s ta tu s   o f   EC / IRB   app rova l  
on ce   the   in ve s t iga t iona l   s i te   ha s   s ta r ted   en ro l lmen t .   I f   any   a c t ion   i s   ta ken   by   [CONTACT_851084] / IRB   w i th  
re spe c t   to   the   inve s t iga t ion ,   tha t   in fo rma t ion   w i l l   be   fo rwa rded   to   Med t ron i c   by   [CONTACT_851085] c t i ve  
inve s t iga to r .  
 In fo rmed  con sen t  p ro ce s s  
The  in ve s t iga to r  o r  au tho r ized  de s ignee  mu s t  ob ta in  w r i t ten  in fo rmed  con sen t  be fo re  any  c l in i ca l  
s tudy  re la ted  a c t iv i ty  ta ke s  p la ce .    
We l l   in   advan ce   o f   the   con sen t   d i scu ss ion ,   the  sub je c t  shou ld   re ce ive   the   EC / IRB   app roved  
Pa t ien t  In fo rma t ion  and  In fo rmed  Con sen t  Fo rm .  Du r ing  the  con sen t  d i scu ss ion  the  inve s t iga to r  
o r  h i s /he r  au tho r ized  de s ignee  mu s t  fu l ly  in fo rm  the  sub je c t  o f  a l l  a spe c t s  o f  the  c l in ica l  s tudy  tha t  
a re  re le van t  to  the  sub je c t ’ s  de c i s ion  to  pa r t i c ipa te  in  the  c l in i ca l  s tudy .   
 
I f  a  sub je c t  i s  unab le  to  read  and /  o r  w r i te ,  an  impa r t ia l  w i tne ss  mu s t  be  p re sen t  du r ing  the  en t i re  
in fo rmed   con sen t   d i scu ss ion .   A l l   i tems   add re ssed   in   the   In fo rmed   Con sen t   Fo rm   mu s t   be  
e xp la ined .  The  language  u sed  sha l l  be  a s  non -te chn i ca l  a s  po ss ib le  and  mu s t  be  unde rs tandab le  
to  the  sub je c t  and  the  impa r t ia l  w i tne ss ,  whe re  app l i cab le .   
 
The  sub je c t  mu s t  ha ve  amp le  t ime  and  oppo r tun i ty  to  read  and  unde rs tand  the  In fo rmed  Con sen t  
Fo rm ,  to  inqu i re  abou t  de ta i l s  o f  the  c l in i ca l  s tudy ,  and  to  de c ide  whe the r  o r  no t  to  pa r t i c ipa te  in  
the  c l in i ca l  s tudy .  A l l  que s t ion s  abou t  the  c l in i ca l  s tudy  shou ld  be  an swe red  to  the  sa t i s fa c t ion  o f  
the  sub je c t .  
Ne i the r  the  inve s t iga to r ,  no r  the  inve s t iga t ion  s i te  s ta f f  sha l l  coe rce  o r  undu ly  in f luen ce  a  sub je c t  
to  pa r t i c ipa te  o r  to  con t inue  to  pa r t i c ipa te  in  the  c l in i ca l  s tudy .  The  in fo rmed  con sen t  p ro ce ss  sha l l  
no t  wa ive  o r  appea r  to  wa ive  the  sub je c t ’ s  r igh t s .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  31  o f  73   
20 /OCT /[ADDRESS_1183322]  s igned  and  da ted  the  In fo rmed  Con sen t  Fo rm  the  inve s t iga to r  mu s t  p ro v ide  
the  sub je c t  w i th  a  copy  o f  the  s igned  and  da ted  In fo rmed  Con sen t  Fo rm .  
 Re v i s ion s  in  In fo rmed  Con sen t  Fo rm  
Med t ron i c   rev i sed   the   w r i t ten   in fo rmed   con sen t   temp la te   to   in c lude   the   e x ten s ion   o f   fo l low -up  
th rough  5  yea rs  po s t  imp lan t  p ro cedu re .  Sub je c t s  who  a re  cu r ren t ly  pa r t i c ipa t ing  in  the  c l in i ca l  
s tudy  sha l l  be  a sked  to  s ign  the  upda ted  in fo rmed  con sen t  to  con f i rm  the i r  con t inu ing  in fo rmed  
con sen t  in  w r i t ing  fo r  up  to  5  yea rs  o f  fo l low -up .  The  rev i sed  in fo rmed  con sen t  do cumen t s  w i l l  be  
p ro v ided  to  the  inve s t iga t iona l  s i te s  fo r  app rova l  by  [CONTACT_851086] l  EC / IRB .  
Med t ron i c   w i l l   in fo rm   the   in ve s t iga to rs   wheneve r   in fo rma t ion   be come s   a va i lab le   tha t   may   be  
re levan t  to  the  sub je c t ’ s  con f i rmed  pa r t i c ipa t ion  in  the  c l in i ca l  s tudy .  The  inve s t iga to r  o r  h i s /he r  
au tho r ized  de s ignee  shou ld  in fo rm  the  sub je c t  in  a  t ime ly  manne r .   
I f  new  in fo rma t ion  be come s  a va i lab le  tha t  can  s ign i f i can t ly  a f fe c t  the  sub je c t ’ s  fu tu re  hea l th  and  
med i ca l  ca re ,  Med t ron i c  w i l l  rev i se  the  w r i t ten  In fo rmed  Con sen t  Fo rm .  The  re v i sed  in fo rma t ion  
w i l l   be   sen t   to   the   inve s t iga to r   fo r   app ro va l   by   [CONTACT_851087] / IRB .     A f te r   app ro va l   by   [CONTACT_851087] / IRB ,   i f  
re levan t ,   a l l   a f fe c ted   sub jec t s   sha l l   be   a sked   to   con f i rm   the i r   con t inu ing   in fo rmed   con sen t   in  
w r i t ing .    
 Regu la to ry  subm i s s ion  
In  coun t r ie s  whe re  subm i ss ion  to  the  Regu la to ry  Au tho r i ty  i s  requ i red  pe r  lo ca l  law ,  no  sub je c t s  
w i l l   be   en ro l led   in   the  c l in ica l  s tudy   un t i l   the   pa r t i cu la r   Regu la to ry   Au tho r i ty   ha s   app roved   the  
cu r ren t  Cl in i ca l  Inve s t iga t ion  Plan  o f  the  c l in i ca l  s tudy  and  o the r  do cumen t s  a s  requ i red  a cco rd ing  
to  the  lo ca l  requ i remen t s .  
I f   the   R egu la to ry   A u tho r i ty   impo se s   any   add i t iona l   requ i remen t s   (e .g .   sa fe ty   repo r t s ,   p rog re ss  
repo r t s   e t c . ) ,   Med t ron i c   w i l l   p repa re   the   requ i red   do cumen t s   and   send   them   to   the   re spe c t ive  
au tho r i ty .  
O the r  do cumen t s  tha t  a re  re fe r red  to  in  th i s  C l in i ca l  Inve s t iga t ion  P lan  a re  l i s ted  be low  and  w i l l  
be  made  a va i lab le  upon  reque s t :  
• Mon i to r ing  P lan  
• Da ta  Managemen t  P lan  
• In fo rmed  Con sen t  Fo rm  
• Ca se  Repo r t  Fo rms  
E .3  Regu la to ry  comp l iance  
The  Va l ian t  Evo  US  C l in i ca l  T r ia l  w i l l  be  condu c ted  unde r  an  FDA  Inve s t iga t iona l  De v i ce  
E xemp t ion  ( IDE )  in  comp l ian ce  w i th  ICH -GCP ,  ISO  [ZIP_CODE] :2011  3 .1 ,  3 .15 ,  3 .2 ,  3 .36 ,  3 .37 ,  3 .42   
and  21  CFR  Pa r t s  11 ,  50 ,  54 ,  56  and  812 .  21CFR  803  Med i ca l  Dev i ce  Repo r t ing ,  21CFR  814  
P rema r ke t  App rova l  o f  Med i ca l  De v i ce s  
 
Th i s  s tudy  w i l l  be  pub l i c ly  reg i s te red  be fo re  re c ru i tmen t  o f  the  f i rs t  en ro l lmen t   in  acco rdan ce  
w i th  the  2007  Food  and  D rug  Adm in i s t ra t ion  Amendmen t s  A c t  (FDAAA )  and  De c la ra t ion  o f  
He l s in k i  (Oc tobe r  2013 )  on  www . c l in i ca l t r ia l s .go v  (PL  110 -85 ,  Se c t ion  810 (a ) ) .  
In  ca se  o f  con f l i c t ing  requ i remen t s ,  the  regu la t ion  a f fo rd ing  the  g rea te s t  p ro te c t ion  to  the  
sub je c t  w i l l  be  fo l lowed .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  32  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 E .4   T ra in ing  requ i remen ts  
P r io r   to   inve s t iga t ion   s i te   ac t i va t ion   o r   sub sequen t   invo lvemen t   in   c l in i ca l   s tudy   a c t i v i t ie s ,   the  
spon so r  w i l l  p ro v ide  c l in i ca l  s tudy  t ra in ing  re levan t  and  pe r t inen t  to  the  invo l vemen t  o f  pe r sonne l  
condu c t ing  c l in i ca l  s tudy  a c t i v i t ie s .  A t  a  m in imum ,  in ves t iga to r  re spon s ib i l i t ie s ,  T i t le  21  CFR ,  the  
c l in i ca l   inve s t iga t ion   p lan ,   In fo rmed   Con sen t   Fo rm ,   u se   o f   da ta   co l le c t ion   too l ,   a s   we l l   a s  
app l i cab le   lo ca l  regu la t ion s  a re  requ i red .  Fu r the rmo re  in ve s t iga to rs  tha t   w i l l  pe r fo rm  the  inde x  
p ro cedu re  and  imp lan ta t ion  o f  the  dev i ce  w i l l  be  t ra ined  on  the  Va l ian t  Evo  Tho ra c i c  Sten t  Gra f t  
Sy s tem .  S tudy -spe c i f i c  t ra in ing  w i l l  be  do cumen ted  p r io r  to  in ve s t iga t ion a l  s i te  a c t i va t ion .    
Med t ron i c   and /o r   i t s   de s ignee s   a re   re spon s ib le   fo r   the   t ra in ing   o f   app rop r ia te   c l in i ca l   s i te  
pe rsonne l ,  in c lud ing  the  inve s t iga to r ,  co -in ve s t iga to r (s ) ,  s tudy  coo rd ina to r (s ) ,  and  a s  ne ce ssa ry  
o the r   s i te   pe rsonne l .   In i t ia l   t ra in ing   w i l l   be   condu c ted   by   [CONTACT_851079] t ron i c   o r   i t s   de s ignee s   a t   a   s i te  
in i t ia t ion  v i s i t  and /o r  In ve s t iga to r  mee t ing  to  en su re  p rope r  repo r t ing  o f  ad ve rse  even t s ,  un i fo rm  
da ta  co l le c t ion  and  comp l ian ce  w i th  the  p ro to co l ,  con sen t  p ro ce sse s  and  app l i cab le  regu la t ion s .    
A l so  a f te r  in i t ia l  t ra in ing ,  Med t ron i c  w i l l  p ro v ide  t ra in ing  to  o the r  c l in i ca l  s i te  s tudy  team  membe rs .  
A l l  s tudy  spe c i f i c  t ra in ing  mu s t  be  do cumen ted  on  a  fo rma l  t ra in ing  re co rd  tha t  w i l l  be  p ro v ided  
by  [CONTACT_851079] t ron i c .  
E .5  C l in ica l  s tudy  ma te r ia ls   
Med t ron i c  w i l l  p rov ide  s tudy  ma te r ia l s  to  the  s i te  a f te r  app ro va l  o f  the  s i te  fo r  pa r t i c ipa t ion .  Be fo re  
a  s tudy  s i te  can  en ro l l  a  sub je c t  o r  ha ve  a cce ss  to  the  e le c t ron i c  da ta  cap tu re  (EDC )  sy s tem ,  the  
inve s t iga to r   mu s t   be   in   rece ip t   o f   a   “ Go   le t te r ”   ( th i s   may   be   an   ema i l ,   fa x   o r   o the r   w r i t ten  
commun i ca t ion  mean s )  f rom  Med t ron i c .   
E .6  S tudy  d ev ice /p roduc t  t raceab i l i ty  
 Supp l y  o f  in ve s t iga t iona l  de v i ce s /p rodu c ts  
On ce   the   s i te   ha s   been   ac t i va ted   and   an   e l ig ib le   sub je c t   ha s   been   iden t i f ied   and   con sen ted  
th rough  the  p ro to co l  requ i red  sc reen ing  p ro ce ss  inve s t iga t iona l  dev i ce s /p rodu c t s  w i l l  be  o rde red  
and  sh ipped  to  the  s i te .  
 S to rage  and  hand l ing  o f  in ve s t iga t iona l  de v i ce s /p rodu c ts  
In ve s t iga t iona l  dev i ce s /p rodu c t s  mu s t  be  s to red  in  a  se cu red  a rea .  The  me thod  o f  s to rage  sha l l  
p re ven t  the  u se  o f  inve s t iga t iona l  dev i ce s /p rodu c t s  fo r  o the r  app l i ca t ion s  than  men t ioned  in  th i s  
cl in i ca l  inve s t iga t ion  plan .   In  add i t ion ,   a l l   in fo rma t ion  fo r  the  u se ,  s to rage ,  and  hand l ing   o f  the  
inve s t iga t iona l  de v i ce /p rodu c t  a s  ind i ca ted  in  the  In s t ruc t ion s  fo r  Use  mu s t  be  ta ken  in to  a ccoun t .  
 De v i ce  e xp lan t  and  re tu rn  p ro cedu re s /p rodu c ts  
A l l  non -fun c t ion ing  o r  e xp lan ted  inve s t iga t iona l  dev i ce s /p rodu c t s  shou ld  be  re tu rned  to  Med t ron i c  
fo r  ana ly s i s .  In fo rma t ion  pe r ta in ing  to  the  e xp lan t  p ro cedu re  shou ld  be  re co rded .  I f  a  p rodu c t  i s  
e xp lan ted  and  no t  re tu rned  to  Med t ron i c ,  an  e xp lana t ion  shou ld  be  p rov ided .  The  f ina l  d i spo s i t ion  
o f  the  dev i ce  mu s t  be  re co rded  on  the  de v i ce  d i spo s i t ion  log .  Re levan t  in fo rma t ion  shou ld  a l so  
be  re co rded  on  a sso c ia ted  ca se  repo r t  fo rms ,  e .g . ,  Adve rse  E ven t  and  S tudy  E x i t  Fo rm .  D e ta i led  
in s t ru c t ion s  fo r  the  re tu rn  o f  non -fun c t ion ing  dev i ce s  and  e xp lan t  o f  the  de v i ce  w i l l  be  p ro v ided  in  
the  inve s t iga t iona l  s i te  f i le  and  in  append i x  L .4 .  
F   STUDY  METHODS  
F .1  Po in t  o f  En ro l lmen t   
P re  S c reen ing :  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  33  o f  73   
20 /OCT /[ADDRESS_1183323] /MRA .  I f  the  
sub je c t  appea rs  to  mee t  the  e l ig ib i l i ty  c r i te r ia ,  then  the  in ve s t iga to r  w i l l  d i scu ss  the  s tudy  w i th  the  
sub je c t  and  p ro v i de  in fo rma t ion  re la t ing  to  the  po ten t ia l  r i sks  and  bene f i t s ,  and  requ i red  fo l low -
up  p ro cedu re s  pe r  the  in fo rmed  con sen t  p ro ce ss .   
Te s t  re su l t s  tha t  a re  w i th in  the  t ime f rame s  spe c i f ied  be low  may  be  u sed  even  though  the  a c tua l  
te s t  wa s  done  p r io r  to  a  sub je c t’ s  in fo rmed  con sen t .   Th i s  may  be  done  on ly  fo r  s tanda rd  o f  ca re  
te s t s  w i th  the  in ten t  to  m in im i ze  s t re ss  and  d i scom fo r t  to  the  sub je c t  and  redu ce  co s t s .  
 Requ i red  sc reen ing  eva lua t ion s  in c lude  the  fo l low ing .  
• P regnan cy  te s t  ( fo r  fema le  sub je c t s  o f  ch i ldbea r ing  po ten t ia l ) .  Te s t  mu s t  be  comp le ted  
pe r  in s t i tu t iona l  s tanda rd  o f  ca re  a t  the  t ime  o f  sc reen ing  (p r io r  to )  the  inde x  p ro cedu re .  
Re su l t s  mu s t  be  nega t i ve .  
• S c reen ing  CT  o r  MRA  w i th  con t ra s t  o f  the  che s t ,  abdomen  and  pe lv i s  comp le ted  w i th in  
fou r  mon th s  p r io r  to  the  inde x  p ro cedu re .  Th i s  w i l l  be  u sed  to  v i sua l ize  and  a ssess  the  
cha ra c te r i s t i cs ,  leng th ,  and  d iame te rs  o f  the  DT AA  and  the  su r round ing  ana tomy .  
S c reen ing /  Ba se l ine  A sse ssmen t s :  
A f te r  the  sub je c t  ha s  vo lun ta r i ly  s igned  and  da ted  the  In fo rmed  Con sen t  Fo rm ,  the  sub je c t  w i l l  
be  con s ide red  a  s tudy  cand ida te .  I f  a  sub je c t  doe s  no t  s ign  the  In fo rmed  Con sen t  Fo rm ,  then  no  
fu r the r  s tudy  spe c i f i c  sc reen ing  p ro cedu re s  can  o ccu r .    
 
Co l le c t ion  o f  s c reen ing  and  ba se l ine  in fo rma t ion  w i l l  take  p la ce  on ly  a f te r  the  sub je c t  ha s  g iven  
vo lun ta ry ,  do cumen ted  in fo rmed  con sen t  and  w i l l  in c lude  the  fo l low ing :  
 
• Sub je c t  demog raph i cs  
• Med i ca l  h i s to ry  
• Cu r ren t  hea l th  s ta tu s  
• R i sk  fa c to rs  
• ASA  Phy s i ca l  S ta tu s  C la ss i f i ca t ion  
• EQ -5D  Que s t ionna i re  
 
S c reen ing  CT /MRA  image s  w i l l  be  rev iewed  by  [CONTACT_851088] s t iga to r  to  con f i rm  e l ig ib i l i ty .  The  imag ing  
w i l l   a l so   be  sen t   to   a   co re   lab   to   a sse ss   the   ana tom i ca l   in c lu s ion /e xc lu s ion   requ i remen t s .   An  
Independen t   P hy s i c ian  Re v iewe r   ( IPR )  w i l l   rev iew  sc reen ing   CT /MRA  image s  to   con f i rm  
e l ig ib i l i ty .  App rova l  by  [CONTACT_851089] s t  be  ob ta ined  p r io r  to  a  sub je c t ’ s  a c tua l  in c lu s ion  in  the  s tudy .  
The  de c i s ion  o f  the  IPR  w i l l  be  commun i ca ted  to  the  inve s t iga t iona l  s i te  by  [CONTACT_851076] r .  Tho se  
sub je c t s  who   s ign   and   da te   the  In fo rmed  Con sen t ,   mee t   a l l   s tudy   e l ig ib i l i ty   c r i te r ia ,   and  a re  
app roved  by  [CONTACT_851090]  w i l l  be  e l ig ib le  fo r  in c lu s ion  in  the  s tudy .  Sub je c t s  tha t  a re  no t  app roved  by  
[CONTACT_851090]  a re  con s ide red  sc reen  fa i lu re s  and  w i l l  no t  be  fo l lowed  pe r  s tudy  p ro to co l .   
 
Sub je c t s  who  do  no t  qua l i fy  fo r  en ro l lmen t  w i l l  be  do cumen ted  a s  ine l ig ib le  on  the  S c reen ing  and  
En ro l lmen t  log .  
En ro l lmen t :   
Tho se  sub je c t s  who  s ign  and  da te  the  in fo rmed  con sen t  do cumen t ,  mee t  a l l  o f  the  s tudy  e l ig ib i l i ty  
c r i te r ia ,  and  a re  app roved  by  [CONTACT_3433] e  IPR   w i l l  be  e l ig ib le  fo r  in c lu s ion  in to  the  Va l ian t  E vo  US  C l in i ca l  
T r ia l .  The  sub je c t   w i l l  on ly   be  con s ide red  en ro l led  when   a r te r ia l   a cce ss  i s  e s tab l i shed  and   an  
a t temp t  to  in t rodu ce  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  i s  made .  
En ro l led  sub je c t s  w i l l  be  documen ted  on  the  e le c t ron i c  S c reen ing  and  En ro l lmen t  Log .  Sub je c t s  
who  a re  en ro l led ,  bu t  no t  imp lan ted  w i th  the  dev i ce ,  w i l l  be  fo l lowed  th rough  the  1  mon th  fo l low -
up  on ly .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  34  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  
The   in ve s t iga to r   w i l l   ma in ta in   a   log   o f   a l l   sub je c t s   sc reened   and  en ro l led   in   the   c l in i ca l  s tudy ,  
a ss ign ing  an  iden t i f i ca t ion  code  l in ked  to  the i r  name s ,  a l te rna t ive  sub je c t  iden t i f i ca t ion  o r  con ta c t  
in fo rma t ion .  
 
F .2  Imp lan t  o r  p rocedu re  aspec ts  
 Inde x  P ro cedu re  
A l l   inve s t iga to rs   w i l l   read ,   unde rs tand   and   be   t ra ined   to   the   Va l ian t   Evo  Tho ra c i c  S ten t   G ra f t  
Sy s tem  IFU  p r io r  to  in i t ia t ion  o f  the  p ro cedu re .  The  IFU  i s  pa ckaged  w i th  the  de v i ce  and  mu s t  be  
fo l lowed  fo r  imp lan ta t ion  o f  the  s ten t  g ra f t  sy s tem .  The  inde x  p ro cedu re  w i l l  in c lude  the  fo l low ing :  
• A r te r ia l  a cce ss  and  i mp lan ta t ion  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t (s )  pe r  the  IFU .   
• F luo ro scop i c   gu idan ce   w i l l   be   u sed   fo r   p la cemen t   o f   the   s ten t   g ra f t   th roughou t   the  
p ro cedu re .  
• Add i t iona l   p ro cedu re s   pe r fo rmed   du r ing   the   t rea tmen t   w i l l   be   do cumen ted   on   the  
app rop r ia te  eC RF s .  
• Upon  comp le t ion  o f  the  index  p ro cedu re ,  a  f ina l  run -o f f  ang iog raphy  shou ld  be  pe r fo rmed  
to   do cumen t   the   s ta tu s   o f   the  Va l ian t  Evo   dev i ce (s ) ,   the   aneu ry sma l   sa c ,   and   the  
su r round ing  va scu la tu re .  
Iden t i f i ca t ion   and /o r   se r ia l   numbe rs   fo r   a l l   in ve s t iga t iona l   componen t s   o f   the   Va l ian t   Evo  
Tho ra c i c  S ten t  G ra f t  Sy s tem  u sed  o r  opened  du r ing  the  inde x  p ro cedu re  w i l l  be  reco rded .  
Adve rse   e ven t   a sse ssmen t   shou ld   be   done   fo r   a l l   sub je c t s   a s   o f   the   momen t   the   sub je c t   i s  
con s ide red  to  be  en ro l led  in  the  s tudy .   
 T rea tmen t  fa i lu re  
Inab i l i ty  to  imp lan t  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem  fo l low ing  a r te r ia l  acce ss  due  to  
dep loymen t  i ssue s  o r  en t rapmen t  o f  the  de l ive ry  sy s tem  w i l l  be  con s ide red  a  t rea tmen t  fa i lu re .  
The se   sub je c t s   w i l l   be   fo l lowed  fo r   [ADDRESS_1183324]  o f  ca re .   
 Ho sp i ta l  D i s cha rge  
The  fo l low ing  a sse ssmen t s  w i l l  be  pe r fo rmed  a t  ho sp i ta l  d i scha rge  and  re spe c t ive  da ta  w i l l  be  
co l le c ted  on  eCRF s :  
• Adve rse  even t  a sse ssmen t  
• Du ra t ion  o f  in ten s i ve  ca re  un i t  s tay  af te r  inde x  p ro cedu re  ( in  hou rs )  
 Fo l low -Up  V i s i ts  and  P ro cedu re s  
Ea ch  sub je c t  w i l l  have  requ i red  po s t -imp lan ta t ion  fo l low -up  v i s i t s  a t  30 -day s ,  6 ,  12 ,  24 ,  36 ,  48  
and  60  mon th s .  Fo l low -up  v i s i t s  and  a sso c ia ted  t ime f rame  w indow s  a re  summa r i zed  in  Tab le  
F - 1 .         
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  35  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Tab le  F -1 :   Pos t -Imp lan ta t ion  Fo l low -Up  V is i t  Schedu le  and  W indows  
Fo l low -Up  V is i t  W indow  S ta r t  Day  Ta rge t  Day  W indow  C lose  Day  
1  Mon th  (±  15  days )  15  30  45  
6  Mon th  (183  ±30  days )  153  183  213  
12  Mon ths  (365  ±60  
days )  305  365  425  
24  Mon ths  (730  ±60  
days )  670  730  790  
36  Mon ths  (1095  ±60  
days )  1035  1095  1155  
48  Mon ths  (1460  ±60  
days )  1400  1460  1520  
60  Mon ths  (1825  ±60  
days )  1765  1825  1885  
A t  a l l  requ i red  fo l low -up  v i s i t s  sub je c t s  w i l l  unde rgo  the  fo l low ing  a sse ssmen t s  and  p ro cedu re s :  
• Phy s i ca l  E xam ina t ion  
• Che s t  CT /MR I  w i th  con t ra s t  
• EQ -5D  que s t ionna i re    
• Adve rse  even t  a sse ssmen t  
A  CT /MR I  w i th  con t ra s t  a c qu i red  a t  d i scha rge  (o r  be fo re  day  15 )  due  to  med i ca l  ne ce ss i ty  may  
be  u sed  to  mee t  the  [ADDRESS_1183325] /MR I  requ i remen t  i f  a  CT /MR I  w i th  con t ra s t  canno t  
be  ob ta ined  w i th in  the  1 -mon th  fo l low -up  w indow  due  to  the  sub je c t ’ s  hea l th  s ta tus  ba sed  upon  
phy s i c ian  d i sc re t ion .   
I f  con ve rs ion   to   open   repa i r   i s   requ i red   du r ing   the  fo l low -up   pe r iod ,   then   the   sub je c t   w i l l   be  
fo l lowed  fo r  30  day s  a f te r  the  conve rs ion ,  a t  wh i ch  t ime  the  sub je c t  w i l l  be  e x i ted  f rom  the  s tudy .  
  
F .3  Da ta  co l lec t ion  requ i remen ts  
C l in i ca l  da ta  w i l l  be  co l le c ted  p reope ra t i ve ly  to  e s tab l ish  e l ig ib i l i ty ,  a t  ba se l ine ,  du r ing  the  inde x  
p ro cedu re ,   th roughou t   the   ho sp i ta l   s tay ,   an d   po s tope ra t i ve ly   a t   the   requ i red   (and   any   in te r im  
imag ing )  fo l low -up  v i s i t s  desc r ibed  in  Se c t ion  F .2 .   The  da ta  co l le c t ion  schedu le  is  summa r i zed  
in  Tab le  F -2 .   Imag ing  sou rce  da ta  w i l l  be  sen t  to  a  Co re  Lab  fo r  ana ly s i s  up  to  the  12 -mon th  
fo l low -up  v i s i t .  Any  in te r im  imag ing  o f  the  s ten t  g ra f t  reg ion  bu t  no t  l in ked  to  a  s tudy  v i s i t  shou ld  
be  re co rded  on  the  In te r im  Image  eCRF  (e .g .  imag ing  pe r fo rmed  a s  s tanda rd  o f  ca re  beyond  the  
p ro to co l  requ i red  t ime  po in t s  and /o r  when  pe r fo rmed  fu r the r  to  any  i ssue  ob s e rved  a t  p rev iou s  
imag ing  Fo l low -up ) .  
Imag ing  sou rce  da ta  beyond  [ADDRESS_1183326]  
o f  ca re  and  in  l ine  w i th  lo ca l  and  s i te  requ i remen t s  d i rec t ly  on  the  e -CRF .   Rou t ine ly  a cqu i red  
image s  may  be  requ i red  fo r  ad jud i ca t ion  pu rpo se s  in  ca se  o f  CEC  ad jud i ca t ion  o r  any  o the r  
sa fe ty  even t .   
S tudy  da ta  w i l l  be  co l le c ted  u s ing  e le c t ron i c  ca se  repo r t  fo rms  (eCRFs )  a s  de sc r ibed  in  Se c t ion  
G .1 .   C l in i ca l  inve s t iga to rs  mu s t  e le c t ron i ca l ly  re v iew  and  app rove  a l l  eCRFs .  Med t ron i c  
mon i to rs  w i l l  pe r fo rm  sou rce  do cumen t  ve r i f i ca t ion  o f  the  eCRFs .  The  mon i to r ing  s t ra tegy  w i l l  
be  de f ined  in  the  mon i to r ing  p lan .   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  36  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Tab le  F - 2 :   Da ta  Co l lec t ion  Schedu le  
DATA   Sc reen ing  /  
Base l ine  
 Index  
P rocedu re  Hosp i ta l  
D ischa rge  1 - Mo .  F /U  
(±15  days )  6 - Mo .  F /U d 
(+ 30  days )  12 -Mo .  F /U  
(+ 60  days )  24 ,  36 ,  48  &  
60 -Mo .  F / U  
(+ 60  days )  
GENERAL    
In fo rmed  
Con sen t         
In c lu s ion  
C r i te r ia /  
Ex c lu s ion  
C r i te r ia       
  
Ph y s i ca l  
Exam ina t ion          
Med ica l  
H is to r y         
Cu r ren t  Hea l th  
S ta tu s  and  
R isk  Fa c to r s         
De v ice  and  
P ro cedu re  
In fo rma t ion          
P re -imp lan t  
Ad jun c t ive  
P ro cedu re s         
Ho sp i ta l  
D ischa rge  
In fo rma t ion         
Ad ve r se  e ven t   
a sse ssmen t  a       
EQ -5D  
que s t ionna i re         
IMAG ING   
CT /MR I  w i th  
con t ra s t  b g    c , e , g  e , g  e,g  e,h  
Ang iog raph y   f      
a In  ca se  o f  s c reen  fa i lu re s ,  inve s t iga to rs  w i l l  be  reque s ted  to  en te r  sa fe ty  in fo rma t ion  in  the  eCRF  f rom  
t ime  po in t  o f  en ro llmen t  un t i l  t ime  po in t  o f  sc reen  fa i lu re  
b  CT  e va lua t ion   may   in c lude   “3 -pha se   te chn ique ” ,   vo lume   s tud ie s ,   [ADDRESS_1183327] /MR I  w i th  con t ra s t  acqu i red  a t  d i scha rge  (o r  be fo re  Day  15 )  due  to  med i ca l  ne ce ss i ty  may  be  
u sed   to   mee t   the   [ADDRESS_1183328] /MR I  requ i remen t   i f   a   CT /MR I   w i th   con t ra s t   canno t   be  
ob ta ined  w i th in  the  1 -mon th  fo l low -up  w indow  due  to  the  sub je c t ’ s  hea l th  s ta tu s  ba sed  upon  phy s i c ian  
d i sc re t ion .  
d  Fo r  sub je c t s  en ro l led  in  the  Va l ian t  Evo  In te rna t iona l  C l in i ca l  T r ia l  in  Eu ropean  coun t r ie s ,  a  s i x  mon th  
fo l low  up  v i s i t  i s  no t  requ i red  pe r  p ro to co l .   
e  MR I   w i th   con t ra s t   may   be   u sed   fo r   tho se   pa t ien t s   e xpe r ien c ing   rena l   fa i lu re   o r   who   a re   o the rw i se  
unab le  to  unde rgo  con t ra s t -enhan ced  CT  scan ,  w i th  T ran se sophagea l  e cho ca rd iog raphy  ( TEE )  be ing  
an  add i t iona l  op t ion  in  the  even t  o f  subop t ima l  MR  imag ing .  
f Requ i red  to  comp le te  P rocedu re  eCRF  bu t  no t  e xpec ted  to  be  subm i t ted  to  Med t ron i c  o r  Co re  Lab  
un le ss  fu r the r  ana ly s i s  i s  needed .  
g  Imag ing  a sse ssed  by  [CONTACT_851091] .            
h  Upon  spon so r  reque s t ,  co re  lab  ana ly s i s  o f  imag ing  ma y  be  requ i red .   
 
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  37  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 F .4  Ro le  o f  the  sponso r ’s  rep resen ta t ives  
Spon so r ’ s  rep re sen ta t ive s  may   p rov ide   suppo r t   a s   requ i red   fo r   the  c l in i ca l  s tudy ,   in c lud ing  
te chn i ca l  suppo r t  du r ing  imp lan t .  The  spon so r  rep re sen ta t i ve  i s  an  e xpe r ien ced  expe r t  o f  dev i ce  
s iz ing ,  p la cemen t  and  the  techn i ca l  fea tu re s  o f  the  de v i ce  and  w i l l  ad v i se  the  imp lan t ing  phy s i c ian  
du r ing  the  imp lan t  p ro cedu re  i f  needed .  The  spon so r  rep re sen ta t ive  w i l l  no t  be  invo l ved  a c t ive ly  
du r ing  the  p la cemen t  and  dep loymen t  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  Gra f t  Sy s tem . 
F .5  Sou rce  documen ts  
In ve s t iga to rs  a re  requ i red  to  ma in ta in  sou rce  da ta  o f  ea ch  sub je c t ’ s  ca se  h i s to ry ,  e xpo su re  to  the  
de v i ce  and  c l in i ca l  fo l low -up s .  Sou rce  da ta  i s  a l l  in fo rma t ion  in  o r ig ina l  re co rd s ,  ce r t i f ied  cop ie s  
o f  o r ig ina l  re co rd s  o f  c l in i ca l  f ind ing s ,  ob se rva t ion s ,  o r  o the r  a c t i v i t ie s  in  a  c l in i ca l  in ve s t iga t ion ,  
ne ce ssa ry  fo r  the  re con s t ruc t ion  and  e va lua t ion  o f  the  c l in i ca l  inve s t iga t ion .   
E xamp le s  o f  the se  o r ig ina l  do cumen t s  and  da ta  re co rds  in c lude ,  bu t  a re  no t  l im i ted  to :   
• ho sp i ta l  re co rd  (pape r  and  e le c t ron i c ,  a s  app l i cab le ) ,   
• sub je c t ’ s  sc reen ing  do cumen ta t ion ,   
• re co rd ing  med ia  su ch  a s  CD ,  DVD ,  CT  o r  o the r  imag ing  repo r t s ,   
• labo ra to ry  repo r t s ,   
• de v i ce  a ccoun tab i l i ty  re co rd s ,   
• wo rkshee t s  and  sub je c t  f i les  a t  o the r  depa r tmen t s .   
Whe re  pape r  no te s  and  wo rkshee t s  a re  re ta ined ,  the se  sha l l  be  s igned  and  da ted  by  [CONTACT_851092] r  
o f  the  inve s t iga t iona l  s i te  team .  Whe re  cop ie s  o f  the  o r ig ina l  sou rce  do cumen t  a s  we l l  a s  p r in t  
ou t s  o f  o r ig ina l  e le c t ron i c  sou rce  do cumen t s  a re  re ta ined ,  the se  sha l l  be  s igned  and  da ted  by  a  
membe r  o f   the   inve s t iga t iona l   s i te   team   w i th   a   s ta temen t   tha t   i t   i s   a   t rue   rep rodu c t ion   o f   the  
o r ig ina l  sou rce  do cumen t .   
Sou rce  do cumen t s  w i l l  be  used  fo r  ve r i f i ca t ion  o f  the  da ta  do cumen ted  in  sub je c t ’s  eCRF  du r ing  
mon i to r ing  v i s i t s ,  aud i t s  and  in spe c t ion s ,  and  fo r  the  ad jud i ca t ion  o f  AE s  and  mu s t  be  a cce ss ib le  
to  the  Med t ron i c  f ie ld  c l in i ca l  suppo r t  and  the  c l in i ca l  s tudy  team  
The  inve s t iga to r  w i l l  a l low  in spe c t ion s  o f  the  s tudy  s i te  and  do cumen ta t ion  by  C l in i ca l  Re sea rch  
and  aud i t  pe rsonne l  f rom  Med t ron i c  o r  de s ignee ,  EC / IRB ,  e x te rna l  aud i to rs ,  o r  rep re sen ta t ive s  
o f  regu la to ry  au tho r i t ie s .  The  pu rpo se  o f  the se  in spe c t ion s  i s  to  ve r i fy  and  co r robo ra te  the  da ta  
co l le c ted   on   the   eCRFs .   In   o rde r   to   do   th i s ,   d i re c t   a cce ss   to   med i ca l   o r   c l in ica l   re co rd s   i s  
ne ce ssa ry .  
F .6  Adve rse  even ts  
 De f in i t ion /c la s s i f i ca t ion   
Fo r  the  pu rpo se  o f  th i s  c l in i ca l  in ve s t iga t ion  Med t ron i c  w i l l  de f ine  and  c la ss i fy  the  fo l low ing  even t s  
pe r  ISO14155 :2011  and  T i t le  21  CFR  pa r t  812 .3  
 
A l l  adve rse  e ven t s  tha t  mee t  the  s tudy  de f in i t ion s  w i l l  be  repo r ted  to  the  spon so r  and  do cumen ted  
on  the  Ad ve rse  Even t  eCRF  and  in  the  sub je c t ’ s  med i ca l  re co rd s .    
 
C l in i ca l  e ven t s  tha t  a re  inhe ren t  to  a  su rg i ca l  p ro cedu re  and  e xpe c ted  to  o ccu r  in  the  ma jo r i ty  o f  
sub je c t s  fo r  a  p ro je c ted  du ra t ion  may  be  con s ide red  una vo idab le .  Su ch  even t s  inc lude ,  bu t  a re  
no t  l im i ted  to ,  tho se  l i s ted  in  Tab le  F -3 .  The se  even t s  shou ld  no t  be  to  be  repo r ted  a s  adve rse  
e ven t s  du r ing  th i s  s tudy .  
Tab le  F -3 :  Expec ted  and  unavo idab le  adve rse  even ts  re la ted  to  the  su rg ica l  p rocedu re .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  38  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Desc r ip t ion  o f  the  Even t  T ime  F rame  f rom  the  Index  P rocedu re  
Endo lea ks  ob se rved  and  reso l ved  du r ing  
the  inde x  p ro cedu re  Re so lved  by  [CONTACT_941]  t ime  the  sub je c t  lea ve s  
the  OR  
Ane s the s ia -re la ted  nau sea  and /o r  vom i t ing  W i th in  24  hou rs  
Low -g rade  fe ve r  (<  100 °  F  o r  <  37 .8 °  C )  W i th in  48  hou rs  
Ba ck  pa in  re la ted  to  lay ing  on  OR  tab le  W i th in  72  hou rs  
In c i s iona l  pa in  (pa in  a t  a cce ss  s i te )  W i th in  72  hou rs  
S leep  p rob lems  o r  in somn ia  W i th in  72  hou rs  
M i ld  to  mode ra te  b ru i s ing  o r  e cchymo s i s  W i th in  168  hou rs  
 
Whe re  the  de f in i t ion  ind i ca te s  “de v i ce ” ,  i t  re fe rs  to  any  de v i ce  u sed  in  the  s tudy .  Th i s  m igh t  be  
the  de v i ce  unde r  inve s t iga t ion ,  o r  any  ma r ke t  re lea sed  componen t  o f  the  sy s tem .  
Adve rse  Even t  (AE ) :  ( ISO14155 :2011  3 .2 )  
Any  un towa rd  med i ca l  o ccu r ren ce ,  un in tended  d i sea se  o r  in ju ry ,  o r  un towa rd  c l in i ca l  s ign s  
( in c lud ing  abno rma l  labo ra to ry  f ind ing s )  in  sub je c t s,  u se rs  o r  o the r  pe rson s ,  whe the r  o r  no t  
re la ted  to  the  in ve s t iga t iona l  med i ca l  de v i ce  
 
NOTE  1 :  Th i s  de f in i t ion  in c lude s  e ven t s  re la ted  to  the  in ve s t iga t iona l  med i ca l  de v ice  o r  the  
compa ra to r .  
NOTE  2 :   Th i s  de f in i t ion  in c lude s  e ven t s  re la ted  to  the  p ro cedu re s  invo lved .  
NOTE  3 :   Fo r  u se rs  o r  o the r  pe rson s ,  th i s  de f in i t ion  i s  re s t r i c ted  to  even t s  re la ted  to  
inve s t iga t iona l  med i ca l  dev ice s .  
Adve rse  Dev ice  E f fec t  (ADE ) :  ( ISO14155 :20 11  3 .1 )  
Adve rse  even t  re la ted  to  the  u se  o f  an  inve s t iga t iona l  med i ca l  dev i ce  
 
NOTE  1 :  Th i s  de f in i t ion  in c lude s  ad ve rse  even t s  re su l t ing  f rom  in su f f i c ien t  o r  inadequa te  
in s t ru c t ion s  fo r  u se ,  dep loymen t ,  imp lan ta t ion ,  in s ta l la t ion ,  o r  ope ra t ion ,  o r  any  ma l fun c t ion  o f  
the  inve s t iga t iona l  med i ca l  de v i ce .  
NOTE  2 :  Th i s  de f in i t ion  in c lude s  any  e ven t  re su l t ing  f rom  u se  e r ro r  o r  f rom  in ten t iona l  m i su se  
o f  the  in ve s t iga t iona l  med i ca l  de v i ce  
Se r ious  Adve rse  Even t  (SAE ) :  ( ISO  [ZIP_CODE] :20 11  3 .37 ) 
Adve rse  even t  tha t   
a )  led  to  dea th ,  
b )  led  to  se r iou s  de te r io ra t ion  in  the  hea l th  o f  the  sub je c t ,  tha t  e i the r  re su l ted  in   
1 )  a  l i fe -th rea ten ing  i l lne ss  o r  in ju ry ,  o r   
2 )  a  pe rmanen t  impa i rmen t  o f  a  body  s t ru c tu re  o r  a  body  fun c t ion ,  o r  
3 )  in -pa t ien t  o r  p ro longed  ho sp i ta l iza t ion ,  o r   
4 )  med i ca l  o r  su rg i ca l  in te rven t ion  to  p re ven t  l i fe -th rea ten ing  i l lne ss  o r  in ju ry  o r  
pe rmanen t  impa i rmen t  to  a  body  s t ru c tu re  o r  a  body  fun c t ion ,  
c )  led  to  fe ta l  d i s t re ss ,  f e ta l  dea th  o r  a  congen i ta l  abno rma l i ty  o r  b i r th  de fe c t .    
 
NOTE :   P lanned  hosp i ta l iza t ion  fo r  a  p re -ex is t ing  cond i t ion ,  o r  a  p rocedu re  requ i red  by  [CONTACT_941]  C IP ,  w i thou t  
se r ious  de te r io ra t ion  in  hea l th ,  is  no t  con s ide red  a  se r iou s  ad ve r se  even t .  
Se r ious  Adv e rse  Dev ice  E f fec t  (SADE ) :  (ISO  [ZIP_CODE] :20 11  3 .36 ) 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  39  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Adve rse  de v i ce  e f fe c t  tha t  ha s  re su l ted  in  any  o f  the  con sequen ce s  cha ra c te r i s t i c  o f  a  Se r iou s  
Adve rse  Even t   
Unan t ic ipa ted  Se r ious  Adve rse  Dev ice  E f fec t  ([LOCATION_003]DE ) :  ( ISO  [ZIP_CODE] :2011  3 .42 )  
Se r iou s  adve rse  dev i ce  e f fe c t  wh i ch  by  i t s  na tu re ,  in c iden ce ,  seve r i ty  o r  ou t come  ha s  no t  been  
iden t i f ied  in  the  cu r ren t  ve rs ion  o f  the  r i sk  ana ly s i s  repo r t  
 
NOTE :   An t i c ipa ted  se r iou s  adve rse  dev i ce  e f fe c t  (ASADE )  i s  an  e f fe c t  wh i ch  by  i t s  na tu re ,  
in c iden ce ,  seve r i ty  o r  ou t come  ha s  been  iden t i f ied  in  the  r i sk  ana ly s i s  repo r t .  
 
Unan t ic ipa ted  Adve rse  Dev ice  E f fec t  (UADE ) :  (21  CFR  812 .3 )  
Any  se r iou s  adve rse  e f fe c t  on  hea l th  o r  sa fe ty  o r  any  l i fe -th rea ten ing  p rob lem  o r  dea th  cau sed  
by ,  o r  a sso c ia ted  w i th ,  a  dev i ce ,  i f  tha t  e f fe c t ,  p rob lem ,  o r  dea th  wa s  no t  p re v iou s ly  iden t i f ied  in  
na tu re ,  se ve r i ty ,  o r  deg ree  o f  in c iden ce  in  the  in ve s t iga t iona l  p lan  o r  app l i ca t ion ,  o r  any  o the r  
unan t i c ipa ted  se r iou s  p rob lem  a sso c ia ted  w i th  a  dev i ce  tha t  re la te s  to  the  r igh t s ,  sa fe ty ,  o r  
we l fa re  o f  su b je c t s .  
Dev ice  de f ic iency :  ( ISO  [ZIP_CODE] :2011  3 .15 )  
Inadequa cy  o f  a  med i ca l  dev i ce  w i th  re spe c t  to  i t s  iden t i ty ,  qua l i ty ,  du rab i l i ty ,  re l iab i l i ty ,  sa fe ty  o r  
pe r fo rman ce  
 
NOTE :  Dev i ce  de f i c ien c ie s  in c lude  ma l fun c t ion s ,  u se  e r ro rs ,  and  inadequa te  labe l l ing .  
 
Fo r  the  Va l ian t  Evo  US  C l in ica l  T r ia l  Med t ron ic  has  de f ined  Ma jo r  Dev ice  E f fec ts  (MDEs )  
wh ich  w i l l  be  used  to  assess  the  p r ima ry  endpo in t .    
MDE s  in c lude  the  o ccu r rence  o f  any  o f  the  fo l low ing  and  a re  de f ined  in  Append i x  L .2 .1 :  
• De v i ce -re la ted  se conda ry  p ro cedu re s   
• De v i ce -re la ted  mo r ta l i ty  
• Conve rs ion  to  open  su rge ry  
• Tho ra c i c  ao r t i c  aneu ry sm  rup tu re  
Fo r  the  Va l ian t  Evo  US  C l in ica l  t r ia l  Med t ron ic  has  de f ined  Ma jo r  Adve rse  Even ts  wh ich  
w i l l  be  used  to  assess  the  seconda ry  endpo in ts .    
MAE s  in c lude  the  o ccu r ren ce  o f  any  o f  the  fo l low ing  and  a re  de f ined  in  Append i x  L . 2 .2 :  
• Re sp i ra to ry   comp l i ca t ion s :   a te le c ta s i s ,   pneumon ia ,   pu lmona ry   embo l i sm ,   pu lmo na ry  
edema ,  re sp i ra to ry  fa i lu re   
• Rena l  comp l i ca t ion s :  rena l  fa i lu re ,  rena l  in su f f i c ien cy   
• Ca rd ia c  comp l i ca t ion s :  M I ,  un s tab le  ang ina ,  new  a r rhy thm ia ,  e xa ce rba t ion  o f  CHF .   
• Neu ro log i ca l   comp l i ca t ion s :   new   ce reb rova scu la r   a cc iden t   (CVA ) ,   ce reb ro va scu la r  
embo l i c  e ven t s ,  pa rap leg ia ,  pa rapa re s i s  
• Ga s t ro in te s t ina l  comp l i ca t ion s :  bowe l  i schem ia   
• Ma jo r  b leed ing  comp l i ca t ion  (p ro cedu ra l  o r  po s t -p ro cedu ra l ) ,  coagu lopa thy .  
• Va scu la r   comp l i ca t ion s :   ao r t i c   rup tu re ,   aneu ry sm   rup tu re ,   hema toma   a t   a cce ss   s i te ,  
pseudo   o r   fa l se   aneu ry sm ,   a r te r io venou s   (AV )   f i s tu la ,   re t rope r i tonea l   b leed ,   l imb  
i schem ia ,  t h rombo s i s  
 Re co rd ing  and  repo r t ing  o f  Ad ve rse  E ven ts  
Adve rse  E ven t  (AE )  in fo rma t ion  w i l l  be  co l le c ted  th roughou t  the  s tudy  and  repo r ted  to  Med t ron i c  
on  the  Adve rse  E ven t  eCRF .  A l l  Ad ve rse  Even t s  (e xcep t  the  one s  l i s ted  in  tab le  F -3 ) ,  rega rd le ss  
o f  re la tedne ss  o r  ou t come ,  mu s t  be  repo r ted .  The  inves t iga to r  i s  re spon s ib le  fo r  repo r t ing  a l l  AE  
to  Med t ron i c .  See  the  Adve rse  E ven t  eCRF  fo r  the  in fo rma t ion  to  be  repo r ted  fo r  ea ch  Adve rse  
E ven t .  
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  40  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Fo r   Ad ve rse   Even t s   tha t   requ i re   immed ia te   repo r t ing   (see   Tab le   F -4 ) ,   in i t ia l   repo r t ing   m ay  be  
done  by  [CONTACT_648] ,  e -ma i l  (con ta c t  de ta i l s  w i l l  be  p rov ided  in  the  inve s t iga t iona l  s i te  f i le ) ,  o r  on  the  
eCRF  w i th  a s  mu ch  in fo rma t ion  a s  i s  a va i lab le .  In  ca se  the  inve s t iga to r  requ i re s  in fo rma t ion  f rom  
the  Spon so r  in  an  eme rgency  s i tua t ion ,  the  con ta c t  de ta i l s  fo r  eme rgen cy  s i tua t ions  a re  g iven  in  
the  inve s t iga t iona l  s i te  f i le .  
 
 Re co rd ing  and  repo r t ing  o f  De v i ce  De f i c ien c ie s  
De v i ce  De f i c ien cy  in fo rma t ion  w i l l  be  co l le c ted  th roughou t  the  s tudy  and  repo r ted  to  Med t ron i c .  
De v i ce  De f i c ien c ie s  shou ld  be  repo r ted  on  a  Dev i ce  De f i c ien cy  Fo rm  in  the  eCRF .  In  ca se  the  
eCRF  i s  no t  ava i lab le  th e  De v i ce  De f i c ien cy  fo rm  need s  to  be  comp le ted  manua l ly  and  mu s t  be  
sen t   to   Med t ron i c .  Con ta c t   de ta i l s   a re   g i ven  in  the   inve s t iga t iona l   s i te   f i le .  The   in ve s t iga to r   i s  
re spon s i b le  fo r  repo r t ing  a l l  De v i ce  De f i c ien c ie s  to  Med t ron i c .  
See  the  Dev i ce  De f i c ien cy  eCRF  fo r  the  in fo rma t ion  to  be  repo r ted  fo r  ea ch  Dev i ce  De f i c ien cy .   
De v i ce  de f i c ien c ie s  tha t  d id  no t  lead  to  an  Adve rse  Even t  bu t  cou ld  have  led  to  an  SAE  
a )  i f  e i the r  su i tab le  a c t ion  had  no t  been  ta ken ,  
b )  i f  in te rven t ion  had  no t  been  made ,  o r  
c )  i f  c i rcums tan ce s  had  been  le ss  fo r tuna te ,  
requ i re  immed ia te  repo r t ing  (see  Tab le  F -4 ) .  In i t ia l  repo r t ing  may  be  done  by  [CONTACT_152847] ,  phone ,  e -
ma i l ,  w i th  a s  mu ch  in fo rma t ion  a s  ava i lab le .   
 Ad ve rse  E ven t  and  De v i ce  De f i c ien c y  re v iew  p ro ce s s  
A l l  Adve rse  Even t s  and  Dev i ce  De f i c ien c ie s  w i l l  be  rev iewed  by  [CONTACT_851079] t ron i c  S tudy  Managemen t  
and /  o r  de s ignee .  Th i s  re v iew  w i l l  in c lude  the  de te rm ina t ion  whe the r  the  Ad ve rs e  Even t /Dev i ce  
De f i c ien cy  mee t s  regu la to ry  repo r t ing  requ i remen t s  (see  tab le  F -4 ) .  The  spon so r  w i l l  en su re  
t ime ly  Adve rse  E ven t /Dev i ce  De f i c ien cy  repo r t ing  to  mee t  g loba l  and  coun t ry  spe c i f ic  regu la to ry  
requ i remen t s .  
A  l i s t  o f  an t i c ipa ted  adve rse  e ven t s  tha t  a re  e xpe c ted  in  na tu re  i s  in c luded  in  se c t ion  J .2 .  
In  ca se  the  Adve rse  Even t /De v i ce  De f i c ien cy  i s  re la ted  to  a  Med t ron i c  ma r ke t  re lea sed  dev i ce  
u sed  du r ing  the  s tudy ,  Med t ron i c  S tudy  Managemen t  and /  o r  de s ignee  w i l l  immed ia te ly  repo r t  
th i s  dev i ce  re la ted  Adve rse  E ven t /De v i ce  De f i c ien cy  to  the  P rodu c t  E xpe r ien ce  Managemen t  
(PXM )  g roup .  The  PXM  g roup  w i l l  en su re  p romp t  re v iew ,  and  app rop r ia te  repo r t ing .  
 
Tab le  F -4 :  Adve rse  Even t  Repo r t ing  Requ i remen ts  
Se r ious  Adve rse  Dev ice  E f fec ts  (SADE ) ,  inc lud ing  Unan t ic ipa ted  Se r ious  Adve rse  Dev ice  
E f fec t  ([LOCATION_003]DE ) :  
Inves t iga to r  subm i t  to :   
Med t ron ic  A s  soon  a s  pos s ib le ,  bu t  in  no  case  la te r  than  3  ca lenda r  day s  a f te r  the  
c l in ica l  s i te  s tudy  team  f i r s t  lea rns  o f  the  even t  o r  o f  new  in fo rma t ion  in  
re la t ion  w i th  an  a l ready  repo r ted  even t .  
Regu la to r y  Au tho r i ty  A s  pe r  lo ca l  repo r t ing  requ i remen t  
EC / IRB  Repo r t ing  t ime f rame  as  pe r  lo ca l  EC / IRB  requ i remen t .  
Sponso r  subm i t  to :   
Regu la to r y  Au tho r i t ies  Repo r t ing  t ime f rame  as  pe r  lo ca l  requ i remen t .  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
Se r ious  Adve rse  Even ts  (SAE )  and  Unan t ic ipa ted  Adve rse  Dev ice  E f fec ts  (UADE )  
Inves t iga to r  subm i t  to :   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  41  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Med t ron ic  A s  soon  a s  pos s ib le ,  bu t  in  no  case  la te r  than  3  ca lenda r  day s  a f te r  the  
c l in ica l  s i te  s tudy  team  f i r s t  lea rns  o f  the  even t  o r  o f  new  in fo rma t ion  in  
re la t ion  w i th  an  a l ready  repo r ted  even t .  
Regu la to r y  Au tho r i ty  A s  pe r  lo ca l  repo r t ing  requ i remen t  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
Sponso r  subm i t  to :   
Regu la to r y  Au tho r i t ies  Repo r t ing  t ime f rame  as  pe r  lo ca l  requ i remen t .  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
Adve rse  Dev ice  E f fec ts  (ADE )  
Inves t iga to r  subm i t  to :   
Med t ron ic  A s  soon  a s  pos s ib le ,  bu t  in  no  case  la te r  than  3  ca lenda r  day s  a f te r  the  
c l in ica l  s i te  s tudy  team  f i r s t  lea rns  o f  the  even t .  
Regu la to r y  Au tho r i ty  A s  pe r  lo ca l  repo r t ing  requ i remen t  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
Sponso r  subm i t  to :   
Regu la to r y  Au tho r i t ies  Repo r t ing  t ime f rame  as  pe r  lo ca l  requ i remen t  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
 
A l l  o the r  AEs  
Inves t iga to r  subm i t  to :   
Med t ron ic  Subm i t  in  a  t ime ly  manne r  a f te r  the  c l in ica l  s i te  s tudy  team  f i r s t  lea rn s  o f  
the  even t .  
Regu la to r y  Au tho r i ty  A s  pe r  lo ca l  repo r t ing  requ i remen t  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
Dev ice  De f ic iency  w i th  SADE  po ten t ia l  
Inves t iga to r  subm i t  to :   
Med t ron ic  A s  soon  a s  pos s ib le ,  bu t  in  no  case  la te r  than  3  ca lenda r  day s  a f te r  the  
c l in ica l  s i te  s tudy  team  f i r s t  lea rns  o f  the  de f ic iency  o r  o f  new  in fo rma t ion  
in  re la t ion  w i th  an  a l ready  repo r ted  de f ic ien cy .  
Regu la to r y  Au tho r i ty  A s  pe r  lo ca l  repo r t ing  requ i remen t  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
Sponso r  subm i t  to :   
Regu la to r y  Au tho r i t ies  Repo r t ing  t ime f rame  as  pe r  lo ca l  requ i remen t  
EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
A l l  o the r  Dev ice  De f ic ienc ies  
Inves t iga to r  subm i t  to :   
Med t ron ic  Subm i t  in  a  t ime ly  manne r  a f te r  the  c l in ica l  s i te  s tudy  team  f i r s t  lea rn s  o f  
the  de f ic ien cy .  
Regu la to r y  Au tho r i ty  A s  pe r  lo ca l  repo r t ing  requ i remen t  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  42  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 EC / IRB  Subm i t  to  EC / IRB  pe r  loca l  repo r t ing  requ i remen t .  
 
In   add i t ion ,   Inve s t iga to rs   a re   ob l iga ted   to   repo r t   ad ve rse   even t s   in   a cco rdan ce   w i th   the  
requ i remen t s  o f  the i r  IRB /EC  and  lo ca l  regu la t ion s .  The  Spon so r  i s  ob l iga ted  to  repo r t  ad ve rse  
e ven t s   and   dev i ce   de f i c ienc ie s   tha t   o ccu r   du r ing   th i s   t r ia l   to   the   Regu la to ry   Au tho r i t ie s   and  
IRB /EC  a s  pe r  lo ca l  requ i remen t s .  The  app l i cab le  t ime f rame s  a re  de sc r ibed  in  the  Va l ian t  E vo  
C l in i ca l  T r ia l  sa fe ty  p lan .   
 C l in i ca l  E ven t  Comm i t tee  
A  c l in i ca l  e ven t  comm i t tee  (CEC )  w i l l  be  e s tab l i shed .  The  CEC  i s  an  independen t  comm i t tee  
made  up  o f  c l in i c ian s  ( in te rven t iona l )  w i th  pe r t inen t  e xpe r t i se  who  a re  no t  pa r t i c ipan t s  in  the  
s tudy  and  who  do  no t  have  any  o the r  rea l  o r  po ten t ia l  con f l i c t s  o f  in te re s t .  The  CEC  w i l l  mee t  
pe r iod i ca l ly   to   rev iew   and   ad j ud i ca te  a l l   MDE s ,   UADE s ,  dea th s   and   a l l   DTAA   rup tu re s  tha t  
o ccu r  th roughou t  the  conduc t  o f  the  c l in i ca l  t r ia l .  A  cha r te r  w i l l  be  deve loped  tha t  w i l l  de ta i l  the  
cr i te r ia  fo r  se le c ted  comp l i ca t ion s  and  c l in i ca l  even t s  tha t  need  to  be  ad jud i ca ted  as  we l l  a s  the  
CEC  compo s i t ion ,  du t ie s ,  p ro cedu re s  and  ad jud i ca t ion  ru le s  and  mee t ing  f requency .  
 
 Da ta  Mon i to r ing  Comm i t tee  
A   Da ta   Mon i to r ing   Comm i t tee   (DMC )   w i l l   be   e s tab l i shed .   The   DMC   i s   compo sed   o f   se ve ra l  
membe r s  w i th  pe r t inen t  e xpe r t i se  who  a re  no t  pa r t i c ipan t s  o r  d i re c t ly  invo l ved  in  the  condu c t  o f  
the  t r ia l .  
The  re spon s ib i l i ty  o f  the  DMC  i s  to  eva lua te  sa fe ty  da ta  du r ing  the  cou rse  o f  the  t r ia l  and  to  
ad v i se  Med t ron i c  abou t  the  con t inu ing  sa fe ty  o f  the  t r ia l ,  to  en su re  the  we l lbe ing  o f  the  cu r ren t  
pa r t i c ipan t s  and  tho se  ye t  to  be  en ro l led  a s  we l l  a s  the  con t inu ing  va l id i ty  and  sc ien t i f i c  me r i t  o f  
the  t r ia l .   
Med t ron i c  w i l l  p rov ide  l i s t ing s  o f  a l l  Adve rse  Even t s  and  Dev i ce  De f i c ien c ie s  to  the  Independen t  
Med i ca l  Mon i to r  to  e va lua te  sa fe ty  o f  the  s tudy  dev i ce .  A l l  even t s ,  in c lud ing  any  dev i ce  re la ted  
e ven t s  wi l l  be  re v iewed  on  a  ca se  by  [CONTACT_851093] t  Med i ca l  Mon i to r .  In  ca se  
o f  a  sa fe ty  con ce rn  the  Independen t  Med i ca l  Mon i to r  can  t r igge r  a  DMC  mee t ing .  
Tr ia l  da ta  w i l l  be  rev iewed  on  a  pe r iod i c  ba s i s  a s  de f ined  in  the  DMC  Cha r te r .  
 
Ba sed  on  the  sa fe ty  da ta ,  the  DMC  may  re commend  tha t  Med t ron i c  mod i fy  o r  s top  the  t r ia l .  
DMC  compo s i t ion ,  du t ie s ,  p ro cedu re s ,  de l ibe ra t ion  ru les  a re  de ta i led  and  do cumen ted  in  the  
DMC  Cha r te r .  
 Eme rgen c y  con ta c t  de ta i l s  in  ca se  o f  se r iou s  AE s  
In  ca se  o f  an  immed ia te ly  repo r tab le  Adve rse  E ven t  the  inve s t iga to rs  can  con ta c t  the  Med t ron i c  
S tudy   Manage r .  Con ta c t   de ta i l s   o f   Med t ron i c   S tudy   Managemen t  a re   g iven  in  the  
In ve s t iga t iona l  S i te  F i le .   
 
In  ca se  the  inve s t iga to r  requ i re s  in fo rma t ion  in  a  med i ca l  eme rgen cy  s i tua t ion  the  in ve s t iga to r  
can   con ta c t   the   Med i ca l   E xpe r t .  Con ta c t   de ta i l s   o f   Med i ca l   E xpe r t  a re   g iven  in  the  
In ve s t iga t iona l  S i te  F i le .  
F .[ADDRESS_1183329]  comp le ted  the  requ i red  
fo l low  up  pe r  the  s tudy  p ro to co l .  
I f  a  sub je c t  i s  w i thd rawn  f rom  the  c l in i ca l  s tudy ,  the  rea son  fo r  w i thd rawa l  sha l l  be  re co rded  on  
the  app rop r ia te  eCRF  and  in  the  sub je c t ’ s  ho sp i ta l  re co rd .  I f  d i scon t inua t ion  i s  becau se  o f  sa fe ty  
o r  la ck  o f  e f fe c t i vene ss ,  the  sub je c t  sha l l  be  a sked  to  be  fo l lowed  fo r  co l le c t ing  sa fe ty  da ta  ou t s ide  
the  c l in i ca l  s tudy .  Sub je c t s  w i l l  no t  be  rep la ced  in  ca se  o f  p rema tu re  s tudy  d i scon t inua t ion .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  43  o f  73   
20 /OCT /[ADDRESS_1183330]  e x i ted  f rom  the  s tudy  fo r  any  o f  the  fo l low ing  rea son s :  
• Sub je c t  comp le te s  fo l low -up s  requ i red  by  [CONTACT_851088] s t iga t iona l  p lan .  
• Sub je c t  d ie s .  
• Sub je c t  reque s t s  to  be  w i thd rawn .  
• In ve s t iga to r  reque s t s  tha t  sub je c t  be  w i thd rawn  to  p ro te c t  the  we l fa re  o f  the  sub jec t .  
• Sub je c t  i s  lo s t  to  fo l low -up .  
• O the r  (spe c i fy ) .  
 S tud y  W i thd rawa l   
Sub je c t s   may   w i thd raw   f rom   the   s tudy   a t   any   t ime   and   fo r   any   rea son .   I f   a   sub je c t   de c ide s   to  
w i thd raw  f rom  the  s tudy ,  the  in ve s t iga to r  w i l l  do cumen t  the  rea son  fo r  w i thd rawa l  and  ind i ca te  any  
re la t ion sh ip  o f  the  w i thd rawa l  to  the  s tudy  o r  p rodu c t s  be ing  inve s t iga ted  in  the  sub je c t ’ s  ho sp i ta l  
re co rd  in   the  sub je c t ’ s   f i le .   I f   d i scon t inua t ion   i s   be cause   o f   sa fe ty   o r   la ck   o f   e f fe c t i vene ss ,   the  
sub je c t  sha l l  be  a sked  to  be  fo l lowed  fo r  co l le c t ing  sa fe ty  da ta  ou t s ide  the  c l in i ca l  s tudy  a s  fu r the r  
de sc r ibed  in  se c t ion  F .[ADDRESS_1183331] .  
 Lo s t -to -fo l low -up   
A  sub je c t  may  be  con s ide red   lo s t   to  fo l low -up   on ce  the   inve s t iga to r  and /o r  re sea rch  s ta f f  ha s  
made  th ree  do cumen ted  a t temp t s  to  con ta c t  the  sub jec t .  The  th i rd  a t temp t  shou ld  be  made  by  
[INVESTIGATOR_6125] r t i f ied  ma i l  to  the  sub je c t .  
 Med i ca l  ca re  a f te r  s tud y  e x i t  
A f te r  s tudy  e x i t  the  sub je c t s  w i l l  be  fo l lowed  a s  pe r  rou t ine  s tanda rd  o f  ca re  by  [CONTACT_851094] s t iga t ion a l  
s i te  o r  a  t rea t ing  phy s i c ian .  
F .[ADDRESS_1183332] ing  to  the  c l in i ca l  inve s t iga t iona l  p lan ,  app l i cab le  law s  o r  regu la t ion s ,  
o r  the  Inve s t iga to r  Ag reemen t .  E ve ry  a t temp t  mu s t  be  made  to  avo id  de v ia t ion s .  A l l  de v ia t ion s  
a re  re co rded   on   a   P ro to co l   Dev ia t ion   Ca se  Repo r t   Fo rm .  Un i ted  S ta te s   regu la t ion s   (21   CFR  
812 .140 )  requ i re  tha t  inve s t iga to rs  ma in ta in  a ccu ra te ,  comp le te ,  and  cu r ren t  re co rd s  re la t ing  to  
the  c l in i ca l  s tudy .  Th i s  in c lude s  do cumen t s  show ing  the  da te s  and  rea son s  fo r  ea ch  de v ia t ion  
f rom  the  c l in i ca l  inve s t iga t iona l  p lan .  Depend ing  on  the  na tu re  o f  the  p ro to co l  de v ia t ion ,  e xped i ted  
repo r t ing   and   p r io r   app rova l   f rom   Med t ron i c   may   be   requ i red .   A l l   p ro to co l   dev ia t ion s   mu s t   be  
repo r ted  to  the  In s t i tu t iona l  Re v iew  Boa rd  ( IRB )  in  a cco rdan ce  w i th  IRB  po l i c ie s  and /o r  lo ca l  law s .  
A l l  dev ia t ion s  w i l l  be  summa r ized  and  repo r ted  in  regu la r  p rog re ss  repo r t s  to  the  FDA .  
 
Med t ron i c   w i l l   a sse ss   the   s ign i f i can ce   o f   a l l   dev ia t ion s   and   eva lua te   the   need   to   amend   the  
c l in i ca l   inve s t iga t ion   p lan  o r  to  ea r ly  te rm ina te  the  in ve s t iga t ion ,  in  a cco rdan ce  w i th   Med t ron ic  
SOP s .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  44  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Reque s t  fo r  app ro va l  o f  s tud y  de v ia t ion s  
The  in ve s t iga to r  sha l l  ob ta in  do cumen ted  app ro va l  f rom  Med t ron i c ,  be fo re  imp lemen ta t ion ,  fo r  
any  change  in -  o r  de v ia t ion  f rom  the  C l in i ca l  Inve s t iga t ion  P lan .  In  ca se  o f  s tudy  de v ia t ion s  tha t  
can  a f fe c t  the  sub je c t ’ s  r igh t s ,  sa fe ty  and  we l l -be ing  o r  the  sc ien t i f i c  in teg r i ty  o f  the  c l in i ca l  s tudy ,  
app rova l   f rom   the   EC / IRB   and   Regu la to ry   Au tho r i ty   mu s t   a l so   be   ob ta ined   be fo re  
imp lemen ta t ion .  The  in ve s t iga to r  sha l l  t ime ly  con ta c t  the  C l in i ca l  S tudy  Manage r  fo r  re v iew  o f  the  
p ropo sed  change /dev ia t ion .  
P r io r  app ro va l  i s  no t  a lway s  rea l i s t i c  in  s i tua t ion s  whe re  un fo re seen  c i rcums tan ce s  a re  beyond  
the  in ve s t iga to r ’ s  con t ro l .  Howeve r ,  a l so  in  the se  ca se s ,  the  even t  i s  con s ide red  a  de v ia t ion ,  and  
sh a l l  be  repo r ted .   
In   any   eme rgen cy   s i tua t ion   the   inve s t iga to r   sha l l   e xe rc i se   h i s /he r   judgmen t   to   sa fegua rd   the  
sub je c t ’ s  in te re s t .  Su ch  dev ia t ion s  f rom  the  C l in i ca l  In ve s t iga t ion  P lan  do   no t  requ i re   the   p r io r  
app rova l   o f   Med t ron i c .   The   inve s t iga to r   sha l l   repo r t   the   dev ia t ion   a s   soon   as   po ss ib le   to  
Med t ron i c   and   the   rev iew ing   EC / IRB ,   i f   app l i cab le .   Med t ron i c   w i l l   in fo rm   the   Regu la to ry  
Au tho r i t ie s ,  i f  requ i red .  
 Repo r t ing  requ i remen ts  fo r  s tud y  de v ia t ion s  
The   inve s t iga to r   sha l l   adhe re   to   EC / IRB   requ i remen t s   and   p ro cedu re s   fo r   repo r t ing   s tudy  
de v ia t ion s .  
Med t ron i c   i s   re spon s ib le   fo r   ana ly z ing   de v ia t ion s ,   a sse ss ing   the i r   s ign i f i can ce ,   and   iden t i fy ing  
any   add i t iona l   co r re c t i ve   and /o r   p reven t ive   a c t ion s   (e .g .   amend   the   C IP ,   add i t iona l   t ra in ing ,  
te rm ina te  the  s tudy ,  e t c . ) .  Repe t i t i ve  o r  se r iou s  inve s t iga to r  comp l ian ce  i ssue s  may  re su l t  in  the  
need   to   in i t ia te   a   co r re c t ive   a c t ion   p lan ,   and   in   some   ca se s   f reeze   en ro lmen t   o r   u l t ima te ly  
te rm ina te  the  inve s t iga to r ’ s  pa r t i c ipa t ion  in  the  c l in i ca l  s tudy :  
• Non -comp l ian ce  to  o b ta in  sub je c t ’ s  in fo rmed  con sen t  
• Non -comp l ian ce  to  the  in c lu s ion /e xc lu s ion  c r i te r ia  
• Fa i lu re  to  fo l low  sub je c t s  pe r  schedu led  fo l low -up s  
• Fa i lu re  to  subm i t  da ta  in  a  t ime ly  manne r  
• Fa i lu re  to  fo l low -up  w i th  f ind ing s  on  mon i to r ing  repo r t s  
• EC  app rova l  e xp i ra t ion  
• EC  su spen s ion  o f  the  cen te r  
I f  a  cen te r  i s  te rm ina ted  o r  su spended ,  no  add i t iona l  en ro l lmen t s  w i l l  be  a l lowed  a t  the  cen te r .   
Unu sed  inve s t iga t iona l  p rodu c t  a l lo ca ted  to  the  cen te r  w i l l  be  re tu rned  to  Med t ron i c .  
Med t ron i c  w i l l  p rov ide  inves t iga t ion  s i te -spe c i f i c  repo r ts  to  the  in ve s t iga to rs  on  a  pe r iod i c  ba s i s  
summa r i z ing  in fo rma t ion  on  dev ia t ion s  tha t  o ccu r red  a t  the  in ve s t iga t ion  s i te .   
 Amendmen ts  to  the  C l in ica l  In ve s t iga t ion  Plan  
The  in ve s t iga to r  w i l l  p ropo se  any  app rop r ia te  mod i f i ca t ion (s )  o f  the  C l in i ca l  In ve s t iga t ion  P lan  o r  
inve s t iga t iona l   dev i ce /p rodu c t  o r   inve s t iga t iona l   de v i ce /p rodu c t  u se .   Med t ron i c   w i l l   rev iew   th i s  
p ropo sa l  and  de c ide  whe the r  the  mod i f i ca t ion (s )  w i l l  be  imp lemen ted .   
Med t ron i c  w i l l  subm i t  any   s ign i f i can t  amendmen t  to  the  C l in i ca l  Inve s t iga t ion  P lan ,  in c lud ing  a  
ju s t i f i ca t ion  fo r  th i s  amendmen t ,  to  the  app rop r ia te  Regu la to ry  Au tho r i t ie s  and  to  the  inve s t iga to rs  
to  ob ta in  app rova l  f rom  the i r  EC / IRB .  The  inve s t iga to r  w i l l  on ly  imp lemen t  the  amendmen t  a f te r  
app rov a l  o f  the  EC / IRB ,  Regu la to ry  Au tho r i ty   and  spon so r .  Adm in i s t ra t i ve  amendmen t s  to  the  
C l in i ca l  Inve s t iga t ion  P lan  w i l l  be  subm i t ted  to  the  EC / IRB  and  Regu la to ry  Au tho r i ty  ( i f  requ i red )  
fo r  no t i f i ca t ion .  Fu r the rmo re  inve s t iga to rs  sha l l  s ign  any  app roved  amendmen t  fo r  ag reemen t .   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  45  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 G   QUAL ITY  CONTROL  PROCEDURES  
G .1  P rocedu res  fo r  da tabase  managemen t  
 Da ta  co l le c t ion  
The  in ve s t iga to r  mu s t  en su re  a ccu ra cy ,  comp le tene ss  and  t ime l ine ss  o f  the  da ta  repo r ted  in  the  
CRFs  and  in  a l l  o the r  requ i red  repo r t s .  Da ta  repo r ted  on  the  CRFs  wh i ch  a re  de r ived  f rom  
sou rce  do cumen t s  mu s t  be  con s i s ten t  w i th  the  sou rce  do cumen t s ,  and  d i sc repan c ie s  need  to  
be  ju s t i f ied  in  a  do cumen ted  ra t iona le ,  s igned  and  da ted  by  [CONTACT_941]  (p r in c ipa l )  inve s t iga to r ,  and  f i led  
in  the  sub je c t ’ s  med i ca l  f i le .  
On ly  au t ho r ized  pe rson s  can  comp le te  CRFs .  CRFs  sha l l  be  s igned  by  [CONTACT_851095] s t iga to rs  
(phy s i c ian s  on ly )  a s  spe c i f ied  on  the  De lega ted  Ta s ks  L i s t  in c luded  in  the  Inve s t iga to r  S i te  F i le .  
The  E le c t ron i c  Da ta  Cap tu re  (EDC )  sy s tem  ma in ta in s  an  aud i t  t ra i l  on  en t r ie s ,  change s  o r  
co r re c t ion s  in  CRFs .  I f  a  pe rson  i s  on ly  au tho r ized  to  comp le te  CRFs  o r  to  ma ke  change s  to  an  
a l ready  s igned  CRF ,  the  inve s t iga to r  sha l l  re -s ign  th i s  CRF .  
Any  sou rce  do cumen ta t ion ,  a s  we l l  a s  any  imag ing  (e .g . ,  p ro cedu re  repo r t s ,  imag ing  ma te r ia l ,  
lab  repo r t s ,  dea th  ce r t i f i ca te s ,  au top sy  repo r t s )  tha t  i s  sen t  to  the  spon so r ,  shou ld  have  a l l  
sub je c t  iden t i f ie rs  remo ved  and  rep la ced  w i th  the  sub jec t ’ s  s tudy  ID .  
A  pape r  copy  o f  the  eCRF s ,  a s  we l l  a s  a cce ss  to  th e  EDC  sy s tem ,  w i l l  be  p rov ided  to  the  
inve s t iga t ion  s i te  p r io r  to  sub je c t  en ro l lmen t .  
 Sou rce  da ta  to  be  d i re c t l y  re co rded  on  the  C a se  Repo r t  Fo rm s  
A l l  da ta  repo r ted  on  the  eCRF s  sha l l  be  de r ived  f rom  sou rce  do cumen t s  and  be  con s i s ten t  w i th  
the se   sou rce ;  an y   d i sc repan c ie s   sha l l   be   e xp la ined   in   w r i t ing .   The re   a re   no   da ta   tha t   w i l l   be  
re co rded  d i re c t ly  on  the  eCRF  w i thou t  co r robo ra t ing  sou rce  do cumen ta t ion .  
 T ime  w indows  fo r  comp le t ion  and  subm i s s ion  o f  C a se  Repo r t  Fo rms  
A l l  da ta  en t ry  shou ld  be  comp le ted  a s  soon  a s  po ss ib le  a f te r  the  v i s i t  ta ke s  p la ce .  Adve rse  e ven t  
and  dev i ce  de f i c ien c ie s  shou ld  be  repo r ted  a s  de sc r ibed  in  the  se c t ion  F .[ADDRESS_1183333] ing  to  Med t ron i c  SOP s  and  the  Da ta  Managemen t  P lan  
fo r  th i s  c l in i ca l  s tudy .  The se  do cumen t s  w i l l  be  made  a va i lab le  up on  reque s t .  
A l l   co l le c ted   da ta   w i l l   be   re v iewed   fo r   comp le tene ss ,   co r re c tne ss   and   con s i s tency .   In   ca se   o f  
i ssue s ,  que r ie s  w i l l  be  sen t  to  the  in ve s t iga to r  to  comp le te ,  co r re c t  o r  commen t  the  da ta .   
G .2  Mon i to r ing  p rocedu res  
A  s i te  qua l i f i ca t ion  v i s i t  ma y  be  condu c ted  by  [CONTACT_851079] t ron i c  pe rsonne l  (o r  de s ignee s )  to  rev iew  the  
c l in i ca l   in ve s t iga t iona l   p lan   and ,   regu la to ry   and   s tudy   requ i remen t s   w i th   the   inve s t iga to r   and  
s tudy  pe rsonne l .  A  s i te  in i t ia t ion  v i s i t  w i l l  be  pe r fo rmed  a f te r  i t  ha s  been  ve r i f ied  tha t  the  s i te  i s  
p repa red  fo r  the  s tudy  and  tha t  the  s i te  requ i remen t s  fo r  s tudy  pa r t i c ipa t ion  a re  me t .  
Mon i to r ing  v i s i t s  w i l l  be  condu c ted  a t  the  s ta r t ,  du r ing  and  a t  the  c lo su re  o f  the  c l in i ca l  s tudy  in  
a cco rdan ce  w i th  Med t ron i c  SOP s  and  the  Mon i to r ing  P lan .  F requen cy  and  t im ing  o f  mon i to r ing  
v i s i t s  sha l l  be  de te rm ined  by  [CONTACT_851076] r  fo r  ea ch  s i te  ba sed  on  en ro l lmen t  ra te  and  vo lume ,  
s tudy  comp l ian ce  and  f ind ing s  f rom  p re v iou s  v i s i t s .   
I t  w i l l  be  ve r i f ied  whe the r  s igned  and  da ted  In fo rmed  Con sen t  Fo rms  ha ve  been  ob ta ined  f rom  
ea ch  sub je c t  be fo re  any  c l in i ca l  s tudy  re la ted  p ro cedu re s  a re  unde r ta ken .  Med t ron i c  o r  de s ignee  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  46  o f  73   
20 /OCT /[ADDRESS_1183334] s  and  do cumen t s  a re  be ing  p rope r ly  ma in ta ined  fo r  the  du ra t ion  o f  the  
s tudy .  
 A c ce s s ib i l i ty  o f  in ve s t iga t ion  s i te  s ta f f  and  s tud y  ma te r ia l s  
The  p r in c ipa l  inve s t iga to r (s ) ,  h i s /he r  de lega te (s )  and  the  s tudy  coo rd ina to r (s )  sha l l  be  a cce ss ib le  
to  Med t ron i c  f ie ld  pe rsonne l  and  the  C l in i ca l  S tudy   Manage r .   Th i s   a cce ss ib i l i ty   i s   o f   pa r t i cu la r  
impo r tan ce  fo r  re v iew ing  da ta  in  the  Ca se  Repo r t  Fo rm  (CRF ) .  D i re c t  a cce ss  to  sub je c t  med i ca l  
f i le s  fo r   sou rce   da ta   ve r i f i ca t ion   w i l l   need  to  be   g ran ted   and   p repa red   p r io r   to   any   mon i to r ing  
v i s i t s .  I f  d i re c t  a cce ss  canno t  be  p ro v ided  pe r  lo ca l  laws  and  regu la t ion s ,  ce r t i f ied  cop ie s  need  to  
be  made  a va i lab le  o r  mon i to r  need s  to  ob ta in  a cce ss  b y  rev iew ing  a long s ide  w i th  s tudy  s ta f f .   
 Aud i ts  and  in ve s t iga t ion  s i te  in spe c t ion s   
In  add i t ion  to  regu la r  mon i to r ing  v i s i t s ,  Med t ron i c  may  condu c t  aud i t s  a t  pa r t i c ipa t ing  inve s t iga t ion  
s i te s .  The  pu rpo se  o f  an  aud i t  i s  to  ve r i fy  the  adequa te  pe r fo rman ce  o f  the  c l in i ca l  s tudy  re la ted  
a c t i v i t ie s .  Independen t  o f  the  emp loyee s  in vo lved  in  the  c l in i ca l  s tudy .  Regu la to ry  bod ie s  may  
a l so  pe r fo rm  in spe c t ion s  a t  pa r t i c ipa t ing  inve s t iga t io n  s i te s .  Any  Regu la to ry  Au tho r i ty  in spe c t ion  
announ cemen t s  sha l l  be  fo rwa rded  immed ia te ly  to  the  C l in i ca l  S tudy  Manage r .   
The  in ve s t iga to r  and /o r  in s t i tu t ion  sha l l  pe rm i t  Med t ron i c  and  regu la to ry  bod ie s  d i re c t  a cce ss  to  
sou rce   da ta   and   do cumen t s ,   ta k ing   in to   a ccoun t   any   re s t r i c t ion s   due   to   lo ca l   law ,   to   pe r fo rm  
c l in i ca l  s tudy -re la ted  mon i to r ing ,  aud i t s ,  EC / IRB  rev iew ,  and  regu la to ry  in spe c t ion s .  
G .3  S tudy  suspens ion  o r  ea r ly  te rm ina t ion  
 Ea r l y  stud y  su spen s ion  o r  te rm ina t ion  
Med t ron i c  o r  Regu la to ry  Au tho r i ty  may  de c ide  to  su spend  o r  p rema tu re ly  te rm ina te  the  c l in i ca l  
s tudy  (e .g .  i f  in fo rma t ion  be come s  a va i lab le  tha t  the  r i sk  to  s tudy  sub je c t  i s  h ighe r  than  in i t ia l ly  
ind i ca ted ,  i f  in te r im  ana ly s is  ind i ca te s  tha t  the  re su l t s  s ign i f i can t ly   d i f fe r  f rom  the  c l in i ca l  s tudy  
ob je c t ive s  o r  s ta t i s t i ca l  endpo in t s ).  I f  the  c l in i ca l  s tudy  i s  te rm ina ted  p rema tu re ly  o r  su spended ,  
Med t ron i c   sha l l   p romp t ly   in fo rm   the   inve s t iga to rs   o f   the   te rm ina t ion   o r   su spen s ion   and   the  
rea son (s )  fo r  th i s .  The  in ve s t iga to r  sha l l  then  p romp t ly  in fo rm  the  re v iew ing  EC / IRB  and  the  s tudy  
sub je c t s .   
 Ea r l y  in ve s t iga t ion  s i te  s u spen s ion  o r  te rm ina t ion  
Med t ron i c ,  EC / IRB  o r  Regu la to ry  Au tho r i ty  may  de c ide  to  su spend  o r  p rema tu re ly  te rm ina te  a n  
inve s t iga t ion  s i te  (e .g .  in  case  o f  e xp i r ing  app rova l  o f  the  re v iew ing  EC / IRB ,  non -comp l ian ce  to  
the   C l in i ca l   In ve s t iga t ion   P lan   o r   la ck   o f   en ro l lmen t ) .  I f   a n   in ve s t iga t ion   s i te  i s  su spended  o r  
p rema tu re ly  te rm ina ted ,  Med t ron i c  sha l l  p romp t ly  in fo rm  the  inve s t iga to r (s )  o f  the  te rm ina t ion  o r  
su spen s ion  and  the  rea son (s )  fo r  th i s .  The  in ve s t iga to r  sha l l  then  p romp t ly  in fo rm  the  rev iew ing  
EC / IRB  and  the  s tudy  sub je c t s  o r  the i r  lega l  rep re sen ta t ive .   
I f  an  inve s t iga t ion  s i te  i s  suspended  o r  p rema tu re ly  te rm ina ted :  
• Med t ron i c   sha l l   p romp t ly   in fo rm   the   c l in i ca l   inve s t iga to r (s )   o f   the   te rm ina t ion   o r  
su spen s ion  and  the  rea son (s )  fo r  th i s  
• The  in ve s t iga to r  sha l l  then  p romp t ly  in fo rm  the  re v iew ing  EC / IRB   
• The  in ve s t iga to r  sha l l  then  p romp t ly  in fo rm  s tudy  sub jec t s  
• The  in ve s t iga to r  ag reemen t  w i l l  be  te rm ina ted  
• The   in ve s t iga to r   w i l l   in fo rm   the   in s t i tu t ion   (whe re   requ i red   by   [CONTACT_97458] l i cab le   regu la to ry  
requ i remen t s )  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  47  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • Med t ron i c   w i l l   in fo rm   the   R egu la to ry  Au tho r i ty ( ie s )   (whe re   requ i red   by   [CONTACT_97458] l i cab le  
regu la to ry  requ i remen t s )  
When  the  r i sks  a re  found  to  ou twe igh  the  po ten t ia l  bene f i t s  o r  when  the re  i s  con c lu s ive  p roo f  o f  
de f in i te  ou t come s ,  in ve s t iga to rs  mu s t  a s se ss  whe the r  to  con t inue ,  mod i fy  o r  immed ia te ly  s top  
the   c l in i ca l   s tudy   in   the   respe c t i ve   in ve s t iga t ion   s i te   and   immed ia te ly   in fo rm   the   spon so r   and  
EC / IRB ,  i f  app l i cab le .  
 Sub je c t  fo l low -up  in  ca se  o f  te rm ina t ion  
I f  the  s tudy  i s  te rm ina ted  ea r ly ,  sub je c t s  w i l l  be  fo l lowed  a s  pe r  rou t ine  s tanda rd  o f  ca re  by  [CONTACT_851096] s t iga t ion a l  s i te  o r  a  t rea t ing  phy s i c ian .  
G .4  S tudy  c lose  ou t  
P r io r  to  comp le t ion  o f  s tudy  c lo se  ou t ,  a l l  da ta  mu s t  be  en te red  and  mon i to red  in  the  EDC  sy s tem .     
Med t ron i c  and /o r  i t s  de s ignee s  w i l l  no t i fy  the  s i te  o f  the  in ten t ion  to  c lo se  the  s tudy .  S tudy  c lo se  
ou t  v i s i t s  may  be  pe r fo rmed .  Du r ing  the se  v i s i t s ,  the  mon i to rs  w i l l  en su re  tha t  the  inve s t iga to r ’ s  
regu la to ry  f i le s  a re  up  to  da te  and  comp le te  and  tha t  any  ou t s tand ing  i ssue s  f rom  p re v iou s  v i s i t s  
ha ve  been  re so lved .  Med t ron i c  w i l l  no t i fy  and  in fo rm  the  s i te (s )  tha t  a l l  requ i remen t s  have  been  
me t  w i th  a  s tudy  c lo su re  le t te r .   
I f  requ i red ,  EC / IRB  and /o r  Regu la to ry  A u tho r i ty  w i l l  be  in fo rmed  by  [CONTACT_851079] t ron i c  abou t  the  s tudy  
c lo se  ou t .  
H  DATA  ANALYS IS  AND  REPORT ING  
Any  de v ia t ion s  f rom  th i s  se c t ion  and /o r  the  S ta t i s t i ca l  Ana ly s i s  P lan  w i l l  be  de sc r ibed  and  ju s t i f ied  
in  the  F ina l  C l in i ca l  S tudy  Repo r t ,  a s  app rop r ia te .  
H .1   A na lys is  o f  c l in ica l  da ta  
A l l  endpo in t s  w i l l  be  ana ly zed  de sc r ip t ive ly .  In  gene ra l ,  qua l i ta t ive  pa rame te rs  w i l l  be  de sc r ibed  
by   [CONTACT_941] i r   d i s t r ibu t ion   f requen c ie s ;   quan t i ta t i ve   pa rame te rs   w i l l   be   de sc r ibed   by   [CONTACT_941] i r   mean ,  
s tanda rd  dev ia t ion ,  m in imum ,  ma x imum ,  med ian ,  and  numbe r  o f  sub je c t s  w i th  a sse ssab le  da ta .   
The  su rv iva l  f rom  a l l -cau se  mo r ta l i ty  o ve r  one  yea r  t ime  o r  longe r  w i l l  be  de sc r ibed  by  [CONTACT_851097] -
Me ie r  su rv iva l  cu rve  and  the  a sso c ia ted  Kap lan -Me ie r  e s t ima te  w i l l  be  ca l cu la ted  a long  w i th  i t s  
s tanda rd  e r r o r  u s ing  the  G reenwood  me thod .   
The  p r ima ry  s tudy  endpo in t  i s  a  d i cho tomou s  s tudy  ou tcome ;  hen ce ,  an  e xa c t  me thod  ba sed  on  
the  b inom ia l  d i s t r ibu t ion  w i l l  be  u sed  fo r  the  hypo the s i s  te s t ing .  
Fo r  e ven t s  su ch  a s  AE s ,  dea th s  and  se conda ry  p ro cedu re s ,  tha t  can  o ccu r  o r  a re  ob se rved  a t  
any  t ime  du r ing  the  s tudy ,  no  t ime  w indow  w i l l  be  app l ied .   Fo r  su ch  e ven t s ,  an  e ven t  tha t  o ccu rs  
“w i th in   1   mon th   o r   30   day s ”   i s   an   e ven t   tha t   ta ke s   p la ce   be tween   Day s   0   to   30 ,   i n c lu s ive .   
S im i la r ly ,  an  even t  tha t  o ccu rs  “w i th in  12  mon th s  o r  365  day s ”  i s  an  even t  o ccu r r ing  be tween  Day  
0  to  Day  365 ,  in c lu s ive .  Da te  o f  e ven t  on se t  w i l l  be  u sed  to  de te rm ine  when  the  even t  o ccu r red .  
Day  0  i s  re fe r r ing  to  the  day  o f  inde x  p ro cedu re .     
Fo r  image -ba sed  a sse ssmen t s ,  su ch  a s  s ten t -g ra f t  endo lea k ,  pa ten cy ,  and  o the r  ob se rva t ion s ,  
the  fo l low ing  t ime  w indow s  w i l l  be  app l ied  fo r  by -v i s i t  da ta  summa r ie s :  
Tab le  H -1 :   T ime  W indows  fo r  S ta t is t ica l  Ana lyses  
S tudy  V is i t  Ta rge t  Day  T ime  W indow  
Imp lan t  Day  0   Day  0   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  48  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 S tudy  V is i t  Ta rge t  Day  T ime  W indow  
1  Mon th  Day  30   1  –  90  day s  
6  Mon th s  Day  183   91  –  304  day s  
12  Mon th s  Day  365  305  –  548  day s  
24  Mon th s  Day  730  549  –  913  d ay s   
36  Mon th s  Day  1095  914  –  1278  day s  
48  Mon th s  Day  1460  1279  –1643  day s  
60  Mon th s  Day  1825  1644  –  2009  d ay s  
 
I f  the re  a re  two  o r  mo re  a sse ssmen t s  in  the  same  t ime  w indow ,  un le ss  o the rw i se  spe c i f ied ,  the  
a sse ssmen t  c lo se s t  to  the  ta rge t  day  w i l l  be  u sed  in  the  ana ly s i s  o f  e ven t  ra te  a t  a  g iven  t ime  
po in t .   
In   add i t ion   to   endpo in ts ,   summa r ie s   o f   sub je c t   d i spo s i t ion ,   demog raph i cs ,   ba se l ine  
cha ra c te r i s t i cs ,  and  sub je c t  a ccoun tab i l i ty  w i l l  be  p rov ided .    
Du r ing  s ta t i s t i ca l  ana ly s i s ,  impu ta t ion  o f  m i ss ing  da ta  w i l l  no t  be  pe r fo rmed  e xcep t  fo r  da ta  re la ted  
to  the  on se t  da te  o f  an  adve rse  e ven t  o r  a  dea th .   In  ca se s  whe re  the  on se t  da te  o f  an  e ven t  o r  
a  dea th  i s  in comp le te  and  un re so lvab le  v ia  da ta  que ry ,  the  15 th  day  o f  the  known  mon th  o r  Ju ly  
1 s t  o f  the  known  yea r  w i l l  be  u sed .   
Sen s i t iv i ty   ana ly s i s   u s ing   t ipp ing   po in t   me thod   may   be   pe r fo rmed ,   a s   needed ,   to   a sse ss   the  
impa c t  o f  m i ss ing  da ta  fo r  the  p r ima ry  endpo in t .  
S ta t i s t i ca l  ana ly se s  fo r  th i s  s tudy  w i l l  be  pe r fo rmed  u s ing  the  S ta t i s t i ca l  Ana ly s i s  Sy s tem  (SAS )  
fo r  W indow s  (Ve rs ion  9 .1  o r  h ighe r )  o r  o the r  w ide ly -a ccep ted  s ta t i s t i ca l  o r  g raph i ca l  so f twa re .  
Sub se t  ana ly se s  by -se x ,  by -ra ce  (ba sed  on  sub je c t s  en ro l led  in  the  US  on ly ,  s in ce  co l le c t ion  o f  
ra ce   and   e thn i c i ty   da ta   ma y   no t   be   a l lowed   ou t s ide   the   US   a s   pe r   lo ca l   law   and   regu la t ion ) ,  
F reeF lo  ve rsu s  C lo sed  Web  con f igu ra t ion  a s  p ro x ima l  componen t ,  pe rcu taneou s  a cce ss  ve rsu s  
non -pe rcu taneou s ,   and   by -reg ion / s tudy   s i te   w i l l   be   pe r fo rmed   on   the   p r ima ry   s tudy   endpo in t  
u s ing  de sc r ip t i ve  s ta t i s t i cs  and  rev iewed  fo r  c l in i ca l  s ign i f i can t  d i f fe ren ce .  
No   in fe ren t ia l   s ta t i s t i ca l   ana ly s i s   i s   p lanned   fo r   se conda ry   o r   add i t iona l   s tudy   endpo in t s .  
De sc r ip t ive  s ta t i s t i cs  w i l l  be  p ro v ided  fo r  a l l  endpo in t s  a s  we l l  a s  ba se l ine  va r iab les .  
Ana l ys i s  Se t s :  
The  p r ima ry  ana ly s i s  se t  w i l l  con s i s t  o f  a l l  sub je c t s  who  we re  en ro l led .  Sub je c t s  w i l l  be  con s ide red  
a s  en ro l led  in  the  s tudy  a s  de sc r ibed  in  se c t ion  F .1 .  
Poo lab i l i t y  o f  the  da ta  
The  poo lab i l i ty  o f  sub je c t s  en ro l led  in  the  Va l ian t  Evo  US  C l in i ca l  t r ia l  and  sub je c t s  en ro l led  in  
the   Va l ian t   E vo   In te rna t iona l   C l in i ca l   T r ia l   i s   a ssumed   g iven   tha t   bo th   s tudy   p ro to co l s   w i l l   be  
s im i la r  w i th  re spe c t  to ,  in c lus ion /e xc lu s ion  c r i te r ia ,  c l in i ca l  t rea tmen t ,  de f in i t ion s  o f  c l in i ca l  e ven t s ,  
one  da ta  mon i to r ing  p lan ,  Da ta  Mon i to r ing  Comm i t tee  (DMC ) ,  C l in i ca l  E ven t  Comm i t tee  (CEC ) ,  
Independen t  Phy s i c ian  Rev iewe r  ( IPR )  and  co re  imag ing  labo ra to ry .   
A t  t he  da ta  ana ly s i s  s tage ,  the  da ta  poo lab i l i ty  w i l l  be  rev iewed  fo r  the  p r ima ry  endpo in t .  Re su l t s  
f rom   Va l ian t   E vo   US   C l in i ca l   T r ia l   and   Va l ian t   E vo   In te rna t iona l   C l in i ca l   T r ia l   sub je c t s   w i l l   be  
p re sen ted  sepa ra te ly  fo r  c l in i ca l  re v iew  a s  we l l  a s  te s ted  u s ing  a  Ch i -squa re  te s t .   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  49  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 A  poo lab i l i ty  ana ly s i s  among  geog raph ie s / in ve s t iga t iona l  s i te s  w i l l  be  a sse ssed  desc r ip t i ve ly  fo r  
the  p r ima ry  endpo in t s  by  [CONTACT_851098] i c  reg ion s .  Sma l l  inve s t iga t iona l  s i te s  ( le ss  than  5  sub je c t s )  
w i l l  be  g rouped  w i th  o the r  nea rby  s i te s  fo r  the  by -reg ion  ana ly s i s .   
H .[ADDRESS_1183335]  to  be  adhe red  to  by  
a l l  pa r t i c ipa t ing  inve s t iga t ion  s i te s :  
Med t ro n i c  may  u se  the  s tudy  da ta  fo r  Regu la to ry  Au tho r i ty  subm i ss ion  re su l t s ,  ma y  pub l i sh  the  
re su l t s  in  pee r  re v iewed  sc ien t i f i c  jou rna l (s )  and  p re sen t  the  da ta  a t  ma jo r  cong re sse s .  
Au tho rsh ip  on  any  pub l i ca t ion (s )  re su l t ing  f rom  th i s  c l in i ca l  s tudy  w i l l  be  a ss igned  a cco rd ing  to  
sub s tan t ia l   con t r ibu t ion s  to  con cep t ion   and   de s ign ,   a cqu i s i t ion   o f   da ta ,   o r   ana ly s i s   and  
in te rp re ta t ion  o f  da ta ,  d ra f t ing  the  a r t i c le  o r  rev i s ing  i t  c r i t i ca l ly  fo r  impo r tan t  in te l le c tua l  con ten t  
and   f ina l   app rova l   o f   the   ve rs ion   to   be   pub l i shed .   Th i s   i s   in   a cco rdan ce   w i th   the   Van couve r  
p r in c ip le s  (The  Un i fo rm  Requ i remen t s  fo r  Manu sc r ip t s  Subm i t ted  to  B iomed i ca l  Jou rna l s :  W r i t ing  
and  Ed i t ing  fo r  B iomed i ca l  Pub l i ca t ion ,  ICM JE ,  Oc tobe r  2008 ) ,  a s  ag reed  upon  by  [CONTACT_851099] i to rs  o f  
a l l  ma jo r  med i ca l  jou rna l s .   
The   numbe r   o f   au tho rs   w i l l   be   dependen t   on   the   regu la t ion s   o f  the   con ce rn ing   jou rna l   w i th   a  
ma x imum   o f   10  au tho rs .  Name s   o f   a l l   pa r t i c ipa t ing   inve s t iga to rs   w i l l   appea r   in   the  
A cknow ledgmen t  o f  the  pape r .  
Ba sed  on  the  p r in c ip le  tha t  Med t ron i c  own s  the  da ta  o f  th i s  c l in i ca l  s tudy ,  a  s ing le  inve s t iga t ion  
s i te  may   a cce ss   and   u se   the   da ta   p rov ided   by   i t se l f   fo r   s c ien t i f i c   pub l i ca t ion s   fo l low ing   p r io r  
app rova l  by  [CONTACT_851079] t ron i c .  
Poo l ing   da ta   f rom   se ve ra l   inve s t iga t ion   s i te s   fo r   pub l i ca t ion   pu rpo se s ,   na t iona l   p ro je c t s   and  
in te rna t iona l  p ro je c t s  a l l  requ i re  p r io r  app rova l  f rom  Med t ron i c .  
Med t ron i c  a s  the  owne r  o f  the  da ta  can  u se  the  da ta  and /o r  any  re su l t s  de r ived  f rom  the  da ta  o r  
pub l i ca t ion s   ba sed   on   tha t   da ta   fo r   ma r ke t ing   pu rpo se s ,   fu r the r   re sea rch   and   de ve lopmen t   o f  
de v i ce s  o r  edu ca t iona l  u se .  
The  s tudy  spon so r  w i l l  co l le c t  da ta  in  su ch  way  tha t  no  sub je c t  can  be  iden t i f ied ,  and  mon i to r  
s tudy  re co rd s .  
Pa r t i c ipa t ing  sub je c t s  w i l l  no t  be  iden t i f ied  by  [CONTACT_851100] l i shed  repo r t s  abou t  the  c l in i ca l  
s tudy .   
I   STUDY  MANAGEMENT  
I .1  S tudy  s ta f f  
The  s tudy  i s  spon so red  by  [CONTACT_851079] t ron i c  Va scu la r .   S tudy  s ta f f  con ta c t  de ta i l s  w i l l  be  p ro v ided  in  the  
inve s t iga t iona l  s i te  f i le .  
I .2  Adv iso ry  comm i t tees  
 I .2 .1  C l in i ca l  E ven t  Comm i t tee  (CEC )  
A   c l in i ca l   even t   comm i t tee   (CEC )   w i l l   be  e s tab l i shed .   The   CEC   i s   an   independen t   comm i t tee  
made  up  o f  c l in i c ian s  ( in te rven t iona l )  w i th  pe r t inen t  e xpe r t i se  who  a re  no t  pa r t i c ipan t s  in  the  s tudy  
and  who  do  no t  ha ve  any  o the r  rea l  o r  po ten t ia l  con f l i c t s  o f  in te re s t .   P lea se  re fe r  to  se c t ion  F .[ADDRESS_1183336] ing  the  CEC .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  50  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Da ta  Mon i to r ing  Comm i t tee  
A   Da ta   Mon i to r ing   Comm i t tee   (DMC )   w i l l   be   e s tab l i shed .   The   DMC   i s   compo sed   o f   se ve ra l  
membe r s  w i th  pe r t inen t  e xpe r t i se  who  a re  no t  pa r t i c ipan t s  o r  d i re c t ly  invo l ved  in  the  condu c t  o f  
the  s tudy .  P lea se  re fe r  to  se c t ion  F .[ADDRESS_1183337] ing  the  DMC .  
 Pub l i ca t ion  Comm i t tee  
A  pub l i ca t ion  comm i t tee  w i l l  no t  be  e s tab l i shed  fo r  the  Va l ian t  Evo  US  and  In te rna t iona l  C l in i ca l  
t r ia l s.  The  pub l i ca t ion  po l i cy  fo r  th i s  t r ia l  i s  de sc r ibed  in  se c t ion  H .2 .  
 Ima g ing  Co re  Lab  
An  imag ing  co re  lab  w i l l  be  e s tab l i shed  to  independen t ly  ana ly ze  image s  ba sed  on  the  imag ing  
p ro to co l / co re  lab  gu ide l ine s .  Imag ing  gu ide l ine s  w i l l  be  p ro v ided  in  the  in ve s t iga t iona l  s i te  f i le .  
I .[ADDRESS_1183338] s  mu s t  be  kep t  by  [CONTACT_851088] s t iga to r :   
• C l in i ca l  Inve s t iga t ion  P lan  and ,  i f  app l i cab le ,  a ny  amendmen t s  
• In s t ru c t ion s  fo r  Use  
• Med t ron i c  and  EC / IRB  app ro ved  In fo rmed  Con sen t  fo rm  
• Regu la to ry  Au tho r i ty  app rova l  o r  no t i f i ca t ion  
• Fu l ly  s igne d  Cl in i ca l  Inve s t iga t ion  Ag reemen t  and  con f iden t ia l i ty  ag reemen t  ( i f  no t  
in c luded  in  the  Cl in i ca l  Inves t iga t ion  Ag reemen t )  
• F inan c ia l  d i sc lo su re s  
• Comp le ted  De lega t ion  o f  Au tho r i ty  Fo rm  and  Cu r r i cu lum  V i tae  o f  a l l  in ve s t iga t ion  s i te  
pe rsonne l  
• T ra in ing  do cumen ta t ion  o f  a l l  inve s t iga t ion  s i te  pe rsonne l  
• Re levan t  commun i ca t ion s  
• Sub je c t  sc reen ing  log  and /o r  sub je c t  iden t i f i ca t ion  log   
• S igned ,  da ted  and  fu l ly  e xecu ted  I n fo rmed  Con sen t  fo rms  
• Fu l ly  e xe cu ted  CRFs  and  co r re c t ion s  
• Repo r t s  o f  Ad ve rse  Even ts  and  De v i ce  De f i c ien c ie s  
• De v i ce  a ccoun tab i l i ty  re co rd s  
• IRB /EC  co r re sponden ce  
 In ve s t iga to r  repo r t ing  re spon s ib i l i t ie s  
 
Repo r t  Subm i t ted  to  Desc r ip t ion  
Adve rse  Even t s  Spon so r ,  EC / IRB ,  
and  lo ca l  Regu la to ry  
Au tho r i ty ,  whe re  
app l i cab le  Re fe r  to  se c t ion  F .6  fo r  repo r t ing  requ i remen t s .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  51  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Repo r t  Subm i t ted  to  Desc r ip t ion  
W i thd rawa l  o f  EC / IRB  
app rova l  Spon so r  An  inve s t iga to r  sha l l  repo r t  to  the  spon so r ,  w i th in  
5  wo rk ing  day s ,  a  w i thd rawa l  o f  app ro va l  by  [CONTACT_851101] v iew ing  IRB  o f  the  in ve s t iga to r 's  pa r t  o f  an  
inve s t iga t ion .  (21  CFR  812 .150 (a ) (2 ) ) .  
F i na l  in ve s t iga to r  repo r t   
 Spon so r ,  IRB  s  and  
Re levan t  Au tho r i t ie s   Th i s  repo r t  mu s t  be  subm i t ted  w i th in  3  mon th s  o f  
s tudy  comp le t ion  o r  te rm ina t ion  o f  the  
inve s t iga t ion  o r  the  in ve s t iga to r ’ s  pa r t  o f  the  
inve s t iga t ion .  (21  CFR  812 .150 (a ) (6 ) ) .  
S tudy  dev ia t i on s  Spon so r  and  IRB  No t i ce  o f  de v ia t ion s  f rom  the  C IP  to  p ro te c t  the  l i fe  
o r  phy s i ca l  we l l -be ing  o f  a  sub je c t  in  an  
eme rgen cy  sha l l  be  g i ven  as  soon  a s  po ss ib le ,  
bu t  no  la te r  than  5  wo rk ing  day s  a f te r  the  
eme rgen cy  o ccu r red .  (21  CFR  812 .150 (a ) (4 ) ) . 
Fa i lu re  to  ob ta in  IC  
p r io r  to  inve s t iga t iona l  
de v i ce  u se   
 Spon so r  and  IRB s   I f  an  inve s t iga to r  u se s  a  dev i ce  w i thou t  ob ta in ing  
in fo rmed  con sen t ,  the  inve s t iga to r  sha l l  repo r t  
su ch  u se  w i th in  5  wo rk ing  day s  a f te r  dev i ce  u se .  
(21  CFR  812 .150 (a ) (5 ) ) .  
O the r   IRB  and  FDA   An  inve s t iga to r  sha l l ,  upon  reque s t  by  a  rev iew ing  
IRB ,  FDA  o r  any  o the r  regu la to ry  agen cy ,  p rov ide  
a ccu ra te ,  comp le te ,  and  cu r ren t  in fo rma t ion  abou t  
any  a spe c t  o f  the  in ve s t iga t ion .  (21  CFR  
12 .150 (a ) (7 ) ) . 
 
 Spon so r  re co rd s  
A t  a  m in imum ,  the  spon so r  w i l l  keep  the  fo l low ing  re co rd s :  
• A l l  e ssen t ia l  s tudy  do cumen t s  and  co r re sponden ce  tha t  pe r ta in s  to  the  c l in i ca l  s tudy  
• C IP  and ,  i f  app l i cab le ,  any  amendmen t s  
• In s t ru c t ion s  fo r  Use  
• Samp le  o f  labe l ing  a t ta ched  to  the  inve s t iga t iona l  dev ice  
• Cu r r i cu lu m  Vi tae  o f  in ve s t iga to rs  and  inve s t iga t ion  s i te  pe rsonne l  
• De lega t ion  o f  Au tho r i ty  Fo rm  and  t ra in ing  re co rd s  o f  inve s t iga to rs  and  inve s t iga t ion  s i te  
pe rsonne l  
• EC / IRB  app rova l s /no t i f i ca t ion s  and  regu la to ry  app ro va l s /no t i f i ca t ion s  
• S igned  C l in i ca l  Inve s t iga t ion  Ag reemen t s  and  s igned  ag reemen t s  w i th  th i rd  pa r t ies  
• Sh ipp ing  re co rd s  fo r  inve s t iga t iona l  de v i ce s  and  c l in i ca l -inve s t iga t ion  re la ted  
do cumen t s  and  ma te r ia l s  
• Med t ron i c  and  EC / IRB  app ro ved  In fo rmed  Con sen t  Fo rms  
• S i te  se le c t ion  repo r t s ,  s i te  in i t ia t ion  repo r t s  and  mon i to r ing  v i s i t  repo r t s   
• Adve rse  even t  and  De v i ce  De f i c ien cy  repo r t s  
• F inan c ia l  d i sc lo su re  in fo rma t ion  
• Fu l ly  e xe cu ted  CRFs  and  co r re c t ion s  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  52  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Spon so r  repo r t ing  re spon s ib i l i t ie s  
Repo r t  Subm i t  to  Desc r ip t ion  
Adve rse  Even t s   EC / IRB ,  
In ve s t iga to rs ,  FDA  
and  re levan t  
au tho r i t ie s ,  whe re  
app l i cab le  Med t ron i c  w i l l  repo r t  ad ve rse  even t s  a s  
requ i red  and  in  comp l ian ce  w i th  lo ca l  
regu la to ry  requ i remen t s ,  a s  app l i cab le  and  
de sc r ibed  in  the  Va l ian t  Evo  Sa fe ty  P lan .  
Unan t i c ipa ted  Ad ve rse  
De v i ce  E f fe c t   In ve s t iga to rs ,  I RB ,  
FDA ,  and  re levan t  
au tho r i t ie s   No t i f i ca t ion  w i th in  ten  wo rk ing  day s  a f te r  the  
spon so r  f i rs t  re ce i ve s  no t i ce  o f  the  e f fe c t .  (21  
CFR  812 .150 (b ) (1 ) ) . 
W i thd rawa l  o f  EC / IRB  
app rova l  In ve s t iga to rs ,  IRB ,  
FDA ,  and  re levan t  
au tho r i t ie s   No t i f i ca t ion  w i th in  f i v e  wo rk ing  day s  a f te r  
re ce ip t  o f  the  w i thd rawa l  o f  app rova l .  (21  
CFR  812 .150 (b ) (2 ) ) .  
W i thd rawa l  o f  FDA  
app rova l   In ve s t iga to rs ,  
EC / IRB ,  and  re levan t  
au tho r i t ie s   No t i f i ca t ion  w i th in  f i ve  wo rk ing  day s  a f te r  
re ce ip t  o f  no t i ce  o f  the  w i thd rawa l  o f  
app rova l .  (21  CFR  812 .150 (b ) (3 ) ) .  
In ve s t iga to r  L i s t   FDA   Subm i t  a t  6 -mon th  in te rva l s ,  a  cu r ren t  l i s t  o f  
the  name s  and  add re sse s  o f  a l l  inve s t iga to rs  
pa r t i c ipa t ing  in  the  inve s t iga t ion .  (21  CFR  
812 .150 (b ) (4 ) ) .  
P rog re ss  Repo r t s   EC / IRB  and  FDA   P rog re ss  repo r t s  w i l l  be  subm i t ted  a t  lea s t  
annua l ly .  (21  CFR  812 .150 (b ) (4 ) (5 ) ,  812 .36 ( f )   
Re ca l l  and  de v i ce  
d i spo s i t ion   In ve s t iga to rs ,  
EC / IRB ,  re levan t  
au tho r i t ie s ,  and  FDA   No t i f i ca t ion  w i th in  30  wo rk ing  day s  a f te r  the  
reque s t  i s  made  and  w i l l  inc lude  the  rea son s  
fo r  any  reque s t  tha t  an  inves t iga to r  re tu rn ,  
repa i r ,  o r  o the rw i se  d i spo se  o f  any  dev i ce s .  
(21  CFR  812 .150 (b ) (6 ) ) .  
Fa i lu re  to  ob ta in  In fo rmed  
Con sen t   FDA   In ve s t iga to r ’ s  repo r t  w i l l  be  subm i t ted  to  FDA  
w i th in  f ive  wo rk ing  day s  o f  no t i f i ca t ion .  (21  
CFR  812 .150 (b ) (8 ) ) .  
P rema tu re  te rm ina t ion  o r  
su spen s ion  o f  s tudy  In ve s t iga to rs ,  IRB ,  
and  Re le van t  
au tho r i t ie s   P ro v ide  p romp t  no t i f i ca t ion  o f  te rm ina t ion  o r  
su spen s ion  and  rea son (s ) .  (ISO  
[ZIP_CODE] :2011 ) ,  (MHLW  O rd inan ce  36 ,  A r t i c le  
32 ) .  
F ina l  Repo r t  In ve s t iga to rs ,  IRB ,  
and  regu la to ry  
au tho r i t ie s ,  whe re  
app l i cab le  and  FDA  Med t ron i c  w i l l  no t i fy  FDA  w i th in  30  wo rk ing  
day s  o f  the  comp le t ion  o r  te rm ina t ion  o f  the  
inve s t iga t ion .  A  f ina l  repo r t  w i l l  be  subm i t ted  
to  the  FDA ,  in ve s t iga to rs ,  and  IRB s  w i th in  s i x  
mon th s  a f te r  comp le t ion  o r  te rm ina t ion  o f  th i s  
s tudy .  (21  CFR  812 .150 (b ) (7 ) ) . 
S tudy  De v ia t ion s  In ve s t iga to rs   
 En su re  tha t  a l l  de v ia t ion s  f rom  the  C IP  a re  
re v iewed  w i th  the  app rop r ia te  c l in i ca l  
inve s t iga to r (s ) ,  a re  repo r ted  on  the  ca se  
repo r t  fo rms  and  the  f ina l  repo r t  o f  the  c l in i ca l  
inve s t iga t ion .   
 Re co rd  re ten t ion   
The   inve s t iga to r   mu s t   re ta in   the   Inve s t iga to r   S i te   F i le ,  sub je c t  med i ca l   f i le s  and   CRFs   in  
a cco rdan ce  w i th  lo ca l  law  and  regu la t ion s  fo r  a  m in imum  pe r iod  o f  2  yea r  (o r  longe r  i f  lo ca l  law s  
requ i re )  a f te r  ma r ke t -re lea se  in  h i s /he r  reg ion .  The  inves t iga to r  shou ld  ta ke  mea su re s  to  p re ven t  
a cc iden ta l  o r  ea r ly  de s t ru c t ion  o f  the  c l in i ca l  s tudy  re la ted  ma te r ia l s .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  53  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 I .4  M isce l laneous  
 In su ran ce  
Med t ron i c  Va scu la r  i s  a  who l ly  owned  sub s id ia ry  o f  Med t ron i c  In c . ,  wh i ch  a s  the  pa ren t  company  
o f  su ch  en t i ty  ma in ta in s  app rop r ia te  c l in i ca l  s tudy  l iab i l i ty  in su ran ce  cove rage  a s  requ i red  unde r  
app l i cab le   law s   and   regu la t ion s   and   w i l l   comp ly   w i th   app l i cab le   law   and   cu s tom   con ce rn ing  
spe c i f i c   in su ran ce   co ve rage .   I f   requ i red ,   a   C l in i ca l   T r ia l   In su ran ce   s ta temen t / ce r t i f i ca te   w i l l   be  
p ro v ided  to  the  EC / IRB .  
 Sub je c t  compen sa t ion  and  indemn i f i ca t ion  
 
Sub je c t s  w i l l  no t  re ce i ve  any  compen sa t ion  fo r  the i r  pa r t i c ipa t ion  in  th i s  s tudy  ( in c lud ing  fo l low  
up ) ;  howeve r ,  Med t ron i c  may ,  a t  i t s  op t ion ,  p rov ide  re imbu rsemen t  fo r  pa r t i c ipan ts  who  w i l l  in cu r  
e x t rao rd ina ry  t rave l  co s t s  re la ted  to  the i r  pa r t i c ipa t ion  in  the  study ,  in c lud ing  a i r fa re ,  m i leage  o r  
ho te l  e xpen se s .   Pa r t i c ipa t ing  In s t i tu t ion  w i l l  ma ke  su ch  reque s t (s )  in  w r i t ing  to  Med t ron i c  (de -
iden t i f ied  o f  pa r t i c ipan t  in fo rma t ion ) ,  de ta i l ing  the  unu sua l  c i rcums tan ce s  and  the  e xce ss i ve  co s t s  
tha t  the  pa r t i c ipan t  w i l l  in cu r .  Med t ron i c  w i l l  eva lua te  reque s t s  on  a  ca se -by -ca se  ba s i s ,  and  w i l l  
no t i fy  the  Pa r t i c ipa t ing  In s t i tu t ion  o f  i t s  de c i s ion  in  w r i t ing .  
 Sub je c t  con f iden t ia l i ty  
Sub je c t  con f iden t ia l i ty  w i l l  be  ma in ta ined  th roughou t  the  c l in i ca l  s tudy  to  the  e x ten t  pe rm i t ted  by  
[CONTACT_2371] .   Tha t   i s ,   eve ry   a t temp t   w i l l   be   made   to   remo ve   sub je c t   iden t i f ie rs   f rom   c l in i ca l   s tudy  
do cumen t s .   Fo r   th i s   pu rpose ,   a   un ique   sub je c t   iden t i f i ca t ion   code   (s i te   numbe r   and   sub je c t  
numbe r )  w i l l  be  a ss igned  and  u sed  to  a l low  iden t i f i ca t ion  o f  a l l  da ta  repo r ted  fo r  ea ch  sub je c t .  
Th i s  w i l l  a l so  en su re  tha t  the  in fo rma t ion  can  be  t ra cked  ba ck  to  the  sou rce  da ta .  
 
S tudy   da ta  may  be  made  a va i lab le  to  th i rd  pa r t ie s ,   e .g . ,  in  the  ca se  o f  an   aud i t  pe r fo rmed  by  
[CONTACT_851102] r i t ie s ,  p ro v ided  the  da ta  a re  t rea ted  con f iden t ia l ly  and  tha t  the  sub je c t ’ s  p r iva cy  
i s  gua ran teed .  The  iden t i ty  o f  a  sub je c t  w i l l  neve r  be  d i sc lo sed  in  the  even t  tha t  s tudy  da ta  a re  
pub l i shed .  
J   R ISKS  AND  BENEF ITS  
J .1  An t ic ipa ted  C l in ica l  Bene f i ts  
The  po ten t ia l  bene f i t s  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem  ha ve  no t  been  do cumen ted ;  
ne ve r the le ss ,  they  a re  e xpe c ted  to  be  s im i la r  to  tho se  a sso c ia ted  w i th  endova scu la r  s ten t  g ra f t  
sy s tems  cu r ren t ly  in  c l in i ca l  t r ia l s  o r  comme rc ia l ly  ava i lab le .   
The  m in ima l ly  in va s ive  endo lum ina l  in te rven t ion  o f fe rs  an  a l te rna t i ve  me thod  o f  t rea tmen t  tha t  i s  
po ten t ia l ly  le ss  inva s i ve ,  le ss  e xpen s ive ,  and  le ss  r i sky  than  s tanda rd  ope ra t ive  repa i r  22 .  Tho ra c i c  
ao r t i c   endo lum ina l   p ro cedu re s   a re   l i ke ly   to   ha ve   an   e ven   g rea te r   impa c t   than   tho se   o f   the  
abdom ina l  ao r ta ,  whe re  con ven t iona l  open  su rge ry  o f fe rs  a  low  mo r ta l i ty  ra te  fo r  many  pa t ien t s .  
Th i s  m in ima l ly  in va s ive  endo va scu la r  in te rven t ion  o f fe rs  an  innova t ive  t rea tmen t  s t ra tegy  fo r  a  
s ign i f i can t   numbe r   o f   pa t ien t s   w i th   se r iou s   tho ra c ic   ao r t i c   le s ion s ,   su ch   a s   aneu ry sms ,  
d i sse c t ion s ,  t rauma t i c  d i s rup t ion s ,  and  pene t ra t ing  u l ce rs .  
The  po ten t ia l  bene f i t s  o f  u s ing  s ten t  g ra f t  repa i r  in  the  t rea tmen t  o f  DTA A  a re  ba sed  on  compa r ing  
the  re su l t s  o f  endo va scu la r  repa i r  aga in s t  su rg i ca l  repa i r .   
The   mo s t   supe r io r  po ten t ia l  bene f i t   i s   tha t   s ten t   g ra f t   repa i r   p rov ide s   a   t rea tmen t   moda l i ty   fo r  
many  pa t ien t s   who  o the rw ise  wou ld  no t  be  cand ida tes  fo r  su rg i ca l  repa i r  be cause  o f  the i r  co -
mo rb id i t ie s  17 ,  23 ,  24 .   
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  54  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 O the r  po ten t ia l  bene f i t s  in c lude  a  redu c t ion  in  sho r t -te rm  and  m id -te rm  mo r ta l i ty  and  mo rb id i ty ;  a  
redu c t ion   o f   r i sk   o f   ca rd io va scu la r ,   pu lmona ry ,   neu ro log i c   and   rena l   comp l ica t ion s   a s   a  
con sequen ce   o f   sho r te r   e xpo su re   to   gene ra l   anes the s ia ,   a   le ss   inva s i ve   p ro cedu re ,   a  
p re se rva t ion   o f   the   d i s ta l   ao r t i c   p re ssu re   due   to   ma in tenan ce   o f   ao r t i c   b lood   f low ;   redu ced  
e s t ima ted  b lood  lo ss ;  lowe r  po s t -ope ra t ion  comp l i ca t ion s  su ch  a s  pa rap leg ia ;  de c rea sed  leng th  
o f  In ten s ive  Ca re  Un i t  and  ho sp i ta l  s tay ,  sho r te r  re co ve ry  t ime  and  be t te r  qua l i ty  o f  l i fe  17 ,23 ,24 ,25 ,26 .  
J .2  R isks  
Fo l low ing  i s  a  l i s t  o f  po ten t ia l  (e xpe c ted )  r i sks  tha t  may  be  a sso c ia ted  w i th  u se  o f  the  Va l ian t  Evo  
Tho ra c i c  S ten t  G ra f t  Sy s tem .  The  o ccu r ren ce  o f  the  l i s ted  comp l i ca t ion s  may  lead  to  a  repea t  
endova scu la r  in te rven t ion  and /o r  open  su rg i ca l  repa i r .  S in ce  the  Va l ian t  E vo  Tho rac i c  S ten t  G ra f t  
Sy s tem  i s  an  inve s t iga t iona l  dev i ce ,  a l l  r i sks  may  no t  be  known .   Howeve r ,  they  a re  be l ieved  to  
be   s im i la r   to   tho se   a sso c ia ted   w i th   the   e x i s t ing   endova scu la r   dev i ce s   in   c l in i ca l   u se   o r  
comme rc ia l ly   ava i lab le ,   a s   we l l   a s   the   r i sks   a sso c ia ted   w i th   s tanda rd   open   su rg i ca l   repa i r   o f  
DTAA s .   
Tab le  J -1 :  Po ten t ia l  Adve rse  Even ts /C omp l ica t ions  assoc ia ted  w i th  the  use  o f  the  
Va l ian t  Evo  Tho rac ic  S ten t  G ra f t  S ys tem  
- Ac ce s s  fa i lu re  
- Ac ce s s  s i te  comp l ica t ion s  
(e .g . ,  spa sm ,  t rauma ,  
b leed ing ,  rup tu re ,  d is se c t ion )  
- Ad ynam ic  I leu s  
- A l le rg ic  rea c t ion  ( to  con t ra s t ,  
an t ip la te le t  the rap y ,  s ten t  
g ra f t  ma te r ia l )   
- Ampu ta t ion  
- Anaph y la x is  
- Ane s the t i c  comp l i ca t ion s  
- Aneu r y sm  e xpan s ion   
- Aneu r y sm  rup tu re  
- Ang ina  
- Ao r t i c  va lve  damage  
- Ao r t i c  ve s se l  rup tu re  
- A r rh y thm ia  
- A r te r ia l  s teno s i s  
- A te le c ta s i s  
- B l indne s s  
- Bowe l  ischem ia  
- Bowe l  ne c ro s i s  
- Bowe l  ob s t ru c t ion   
- B ran ch  ve s se l  o c c lu s ion   
- B rea kage  o f  the  me ta l  
po r t ion  o f  the  de v i ce  
- Bu t to c k  c laud i ca t ion  
- Ca rd ia c  tamponade  
- Ca the te r  b rea kage  
- Ce reb ro va scu la r  a c c iden t  
(CVA ) /S t ro ke  
- Change  in  men ta l  s ta tu s  
- Coagu lopa th y  
- Conge s t ive  hea r t  fa i lu re  
- Con t ra s t  to x ic i ty  
- Con ve r s ion  t o  su rg ica l  repa i r  
- Dea th   
- Dep lo ymen t  
d i f f i cu l t ie s / fa i lu re s  
 - D isse c t ion ,  pe r fo ra t ion ,  o r  rup tu re  
o f  the  ao r t i c  ve s se l  &  su r round ing  
va scu la tu re  
- Embo l i sm   
- Endo lea k s  
- Ex ce ss ive  o r  inapp rop r ia te  
rad ia t ion  e xpo su re  
- Ex t ru s ion /e ro s ion  
- Fa i lu re  to  de l ive r  the  s ten t  g ra f t  
- Femo ra l  neu ropa th y  
- F is tu la  ( in c lud ing  ao r toen te r ic ,  
a r te r io venou s ,  and  lymp h )  
- Ga s t ro in te s t ina l  
b leed ing /comp l ica t ion s  
- Gen i tou r ina r y  comp l ica t ion s  
- Hema toma  
- Hemo r rhage /b leed ing  
- H ypo ten s ion /h ype r ten s ion  
- In fe c t ion  o r  fe ve r  
- In se r t ion  o r  remo va l  d i f f icu l ty  
- In te r co s ta l  pa in  
- In t ramu ra l  hema toma  
- Leg  edema / foo t  edema  
- L ympho ce le  
- M yo ca rd ia l  in fa r c t ion   
- Neu ropa th y  
- O cc lu s ion  -  Venou s  o r  A r te r ia l  
- Pa in / rea c t ion  a t  ca the te r  in se r t ion  
s i te  
- Pa ra ly s i s  
- Pa rapa re s is  
- Pa rap leg ia  
- Pa re s the s ia  
- Pe r iphe ra l  is chem ia  
- Pe r iphe ra l  ne r ve  in ju r y  
- Pneumon ia  
- Po s t imp lan t  synd rome  
 - Po s t -p ro cedu ra l  b leed ing  
- P ro cedu ra l  b leed ing  
- P ro s the s i s  d i la ta t ion  
- P ro s the s i s  in fe c t ion  
- P ro s the s i s  rup tu re  
- P ro s the s i s  th rombo s i s  
- Pseudoaneu r y sm  
- Pu lmona r y  edema  
- Pu lmona r y  embo l i sm   
- Rea c t ion  to  anae s the s ia  
- Rena l  f a i lu re   
- Rena l  in su f f i c ien cy  
- Reope ra t ion  
- Re sp i ra to r y  dep re ss ion  o r  
fa i lu re  
- Re t rog rade  type  A  d i s se c t ion  
- Sep s i s  
- Se roma  
- Sho c k  
- Sp ina l  neu ro log i ca l  de f ic i t  
- S ten t  g ra f t  m ig ra t ion  
- S ten t  g ra f t  m isp la cemen t  
- S ten t  g ra f t  o c c lu s ion  
- S ten t  g ra f t  tw is t ing  o r  k in k ing  
- T ran s ien t  is chem ic  a t ta c k  (T IA )  
- Th rombo s i s  
- T is sue  ne c ro s i s  
- Va s cu la r  i s chem ia  
- Va s cu la r  t rauma  
- Wound  deh i s cen ce  
- Wound  hea l ing  comp l i ca t ion s  
- Wound  in fe c t ion  
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  55  o f  73   
20 /OCT /[ADDRESS_1183339]  been  adequa te ly  t ra ined .  A l so ,  r i sk  
m in im i za t ion  a c t i v i t ie s   we re  pe r fo rmed  du r ing  de ve lopmen t  and  de s ign   ve r i f i ca t ion  te s t s  o f  the  
de v i ce .   A c t iv i t ie s  in tended  to  m in im i ze  r i sks  in c lude  the  fo l low ing .  
• In ve s t iga to r   and   s tudy   pe rsonne l   t ra in ing   w i l l   be   condu c ted   to   sha re   in fo rma t ion  
rega rd ing  the  de s ign  o f  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem ,  i t s  app l i ca t ion  and  
p re -c l in i ca l  re su l t s .  
• Adhe ren ce   to   e l ig ib i l i ty   c r i te r ia   and   sc reen ing   p ro cedu re s   w i l l   en su re   tha t   app rop r ia te  
sub je c t s  a re  en ro l led .  
• Adhe ren ce  to  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  Sy s tem  In s t ru c t ion s  fo r  Use  pa ckaged  
w i th  the  dev i ce  w i l l  en su re  the  u se  o f  va l ida ted  p ro cedu ra l  s tep s .  
• The  sub je c t s  w i l l  be  ca re fu l ly  mon i to red  th roughou t  t he  s tudy  pe r iod .  
• The  in ve s t iga to r  w i l l  e va lua te  the  sub je c t  ad ve rse  even ts  du r ing  the  cou rse  o f  the  s tudy .  
• Da ta  subm i t ted  f rom  the  in ve s t iga t ive  cen te rs  w i l l  be  mon i to red  du r ing  the  cou rse  o f  the  
s tudy .  
• Mon i to r ing  v i s i t s  w i l l  be  condu c ted  to  eva lua te  p ro to co l  comp l ian ce  and  da ta  qua l i ty .  
• Sa fe ty  and  e f fe c t i vene ss  da ta  ob ta ined  du r ing  the  cou rse  o f  the  s tudy  w i l l  be  sha red  w i th  
inve s t iga to rs   in   pe r iod i c   repo r t s   to   in c rea se   unde rs tand ing   o f   the   dev i ce   and   po ten t ia l  
ad ve rse  even t s .  
• A  da ta  mon i to r ing  comm i t tee ,  c l in i ca l  even t s  comm i t tee ,  and  co re  lab  w i l l  independen t ly  
e va lua te  sub je c t  hea l th   s ta tu s ,   dev i ce   pe r fo rman ce ,   and   iden t i fy   any   sa fe ty   conce rn s  
rega rd ing  sub je c t s ’  we l l -be ing .  
 
I f  a  woman  i s  p regnan t  o r  be come s  p regnan t ,  imp lan ta t ion  o f  the  t r ia l  de v i ce  may  in vo lve  r i sks  to  
the  emb ryo  o r  fe tu s  tha t  a re  un known  a t  th i s  t ime .  The re fo re ,  p regnan t  women  w i l l  be  e xc luded  
f rom  the  s tudy .  I f  a  fema le  sub je c t  be come s  p regnan t  du r ing  the  condu c t  o f  th i s  c l in i ca l  re sea rch  
s tudy   they   need   to   in fo rm   the   in ve s t iga t iona l   s i te   immed ia te ly .   The   r i sks   w i l l   be   con t inuou s ly  
mon i to red ,   a sse ssed   and   do cumen ted   by   [CONTACT_851103] s t iga to r .   Any   unan t i c ipa ted   o r   un fo re seen  
comp l i ca t ion s  w i l l  be  repo r ted  by  [CONTACT_851088] s t iga to r  (o r  au tho r ized  de s ignee )  to  the  IRB /  EC  and  to  
Med t ron i c .   Med t ron i c   w i l l   in   tu rn   repo r t   any   ne ce ssa ry   f ind ing s   to   the   app rop r ia te   regu la to ry  
agen c ie s  in  ea ch  o f  the  re spe c t ive  geog raph ie s .  
J .3  R isk -to -bene f i t  ra t iona le  
The  bene f i t s  and  r i sks  a sso c ia ted  w i th  Med t ron i c ’ s  tho ra c i c  s ten t  g ra f t s  a re  we l l -cha ra c te r ized  
th rough  robu s t  h i s to ry  o f  tes t ing  and  su cce ss fu l  c l in i ca l  re su l t s .  The  Va l ian t  Evo  Tho ra c i c  S ten t  
Gra f t  S y s tem  i s  Med t ron i c ’ s  th i rd  gene ra t ion  tho ra c i c  s ten t  g ra f t  wh i ch  i s  no t  on ly  de s igned  u s ing  
e s tab l i shed  de s ign  cha ra c te r i s t i cs  and  long  te rm  e xpe r ien ce  f rom  p re v iou s  gene ra t ion  Med t ron i c  
s ten t   g ra f t s   bu t   a l so   u se s   the   same   p r in c ip le s   o f   ope ra t ion   and   te chno log i ca l   cha ra c te r i s t i cs .  
Fu r the rmo re ,  i t  ha s  been  demon s t ra ted  tha t  imp lan ta t ion  o f  tho ra c i c  endova scu la r  s ten t  g ra f t s  
can  be  pe r fo rmed  sa fe ly ,  and  tha t  the se  de v i ce s  p rov ide  bene f i t s  ove r  su rg i ca l  repa i r .   
Any   po ten t ia l   r i sks   w i th   th is   s tudy   a re   m in im i zed   by   [CONTACT_851104] c t ing   qua l i f ied   inve s t iga to rs ,   ca re fu l  
a sse ssmen t   o f   ea ch   sub je c t   p r io r   to ,   du r ing   and   a f te r   imp lan ta t ion .   Med t ron ic   ha s   fu r the r  
m in im i zed  the  po ss ib i l i ty  o f  r i sks  by  [CONTACT_851105] t ing  p roduc t  te s t ing  p r io r  to  the  u se  o f  the  de v i ce  in  
th i s  c l in i ca l  s tudy ,   imp lemen t ing  qua l i ty  con t ro l  mea su re s  in to  p rodu c t ion  p ro ce sse s ,  p ro v id ing  
gu ide l ine s  fo r  sub je c t  se le c t ion  and  eva lua t ion ,  and  p rov id ing  adequa te  in s t ru c t ions  and  labe l ing .  
A l though  the re  a re  r i sks  a s so c ia ted  w i th  th i s  t r ia l ,  they  a re  no t  an t i c ipa ted  to  be  wo rse  than  the  
r i sks  no rma l ly  a sso c ia ted  w i th  the  u se  o f  the  p red i ca te  de v i ce  o r  o the r  comme r c ia l ly  ava i lab le  
de v i ce s .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  56  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 R i sk  managemen t  fo r  the  Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t  S y s tem  i s  pe r fo rmed  in  a cco rdan ce  
w i th  EN  [ZIP_CODE] :[ADDRESS_1183340] iova scu la r   Su rge ry .   J   Va sc   Su rg .  Ma r  
1991 ;13 (3 ) :452 -458 .  
2 .  Fann  J I .  De scend ing  tho rac i c  and  tho ra coabdom ina l   ao r t i c  aneu ry sms .  Co ron  A r te ry  D i s .  
Ap r  2002 ;13 (2 ) :[ADDRESS_1183341] io va sc   Su rg .   Jun  
2002 ;123 (6 ) :1060 -1066 .  
4 .  A ronbe rg  DJ ,  G laze r  HS ,  Mad sen  K ,  e t  a l .  No rma l  tho ra c i c  ao r t i c  d iame te rs  by  [CONTACT_851106] .  J  Compu t  A ss i s t  Tomog r .  Ap r  1984 ;8 (2 ) :247 -250 .  
5 .  G r iepp   RB ,   E rg in   MA ,   Ga l la   JD ,   e t   a l .  Na tu ra l   h is to ry   o f   de scend ing   tho ra c i c   and  
tho ra coabdom ina l  aneu ry sms .   Ann   Tho ra c   Su rg .   Jun   1999 ;67 (6 ) :1927 -1930 ;   d i scu ss ion  
1953 -1928 .  
6 .  C lou se   WD ,   Ha l le t t   JW ,   J r . ,   S cha f f   HV ,   e t   a l .   Imp ro ved   p rogno s i s   o f   tho rac i c   ao r t i c  
aneu ry sms :  a  popu la t ion -ba sed  s tudy .  Jama .  De c  9  1998 ;280 (22 ) :1926 -1929 .  
7 .  B i cke rs ta f f   LK ,   Pa i ro le ro   PC ,   Ho l l ie r   LH ,   e t   a l .   Tho rac i c   ao r t i c   aneu ry sms :   a   popu la t ion -
ba sed  s tudy .  Su rge ry .  De c  1982 ;92 (6 ) :1103 -1108 .  
8 .  Temudom  T ,  D 'Aya la  M ,  Ma r in  ML ,  e t  a l .  Endova scu la r  g ra f t s  in  the  t rea tmen t  o f  tho ra c i c  
ao r t i c  aneu ry sms  and  p seudoaneu ry sms .  Ann  Va sc  Su rg .  May  2000 ;14 (3 ) :230 -238 .  
9 .  P re ss le r  V ,  M cNama ra  JJ .  Tho ra c i c  ao r t i c  aneu ry sm :  na tu ra l  h i s to ry  and  t rea tmen t .  J  Tho ra c  
Ca rd io va sc  Su rg .  Ap r  1980 ;79 (4 ) :489 -498 .  
10 .  E le f te r iade s  JA .  Na tu ra l  h is to ry  o f  tho ra c i c  ao r t i c  aneu ry sms :  ind i ca t ion s  fo r  su rge ry ,  and  
su rg i ca l  ve rsu s   non su rg ica l   r i sks .   Ann   Tho ra c   Su rg .  No v   2002 ;74 (5 ) :S1877 -1880 ;  
d i scu ss ion  S1892 -1878 .  
11 .  Dean   RH   Y J ,   B rew s te r   DC (ed s ) .   Cu r ren t   D iagno s i s   and   T rea tmen t   in   Va scu la r   Su rge ry .  
No rwa l k ,  CT :  App le ton  &  Lange ;  [ADDRESS_1183342] :  App le ton  &  Lange ;  1995 .  
13 .  Chu te r   TAM ,   Donay re   CE ,   Wh i te   RA .   Endo lum ina l   va scu la r   p ro s the se s .   1 s t   ed .  Bo s ton :  
L i t t le ,  B rown ;  1995 .  
14 .  G lade  GJ ,  Vah l  AC ,  W i sse l in k  W ,  e t  a l .  M id -te rm  su rv i va l  and  co s t s  o f  t rea tmen t  o f  pa t ien t s  
w i th  de scend ing   tho ra c i c   ao r t i c   aneu ry sms ;   endova scu la r   v s .   open   repa i r :   a   ca se -con t ro l  
s tudy .  Eu r  J  Va sc  Endova sc  Su rg .  Jan  2005 ;29 (1 ) :28 -34 .  
15 .  Bo r tone   AS ,   De   C i l l i s   E ,   D 'Ago s t ino   D ,   e t   a l .  Endova scu la r   t rea tmen t   o f   tho ra c i c   ao r t i c  
d i sea se :  fou r  yea rs  o f  e xpe r ien ce .  C i rcu la t ion .  Sep  14  2004 ;110 (11  Supp l  1 ) : I I262 -267 .  
16 .  Leu rs   L J ,   Be l l   R ,   Deg r ie ck   Y ,   e t   a l .  Endo va scu la r   t rea tmen t   o f   tho ra c i c   ao r t i c   d i sea se s :  
comb ined  e xpe r ien ce   f rom   the   EUROSTAR   and   Un i ted   K ingdom   Tho ra c i c   Endog ra f t  
reg i s t r ie s .  J  Va sc  Su rg .  Oc t  2004 ;40 (4 ) :670 -679 ;  d i scuss ion  679 -680 .  
17 .  Da ke  M ,  M i l le r  C ,  Semba  CP ,  e t  a l .  T ran s lum ina l  p la cemen t  o f  endo va scu la r  s ten t  g ra f t s  fo r  
the  t rea tmen t  o f  de scend ing  tho ra c i c  ao r t i c  aneu ry sms .  N  Eng l  J  Med .  1994 ;  331 :1729 -1734 .  
18 .  C r iado  F .  TEVAR  A cce ss ,  De l i ve ry ,  and  F i xa t ion .  Endo va scu la r  Today .  Nov .  2007 :  45 -52 .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  57  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 19 .  PMA   (P100040 )   Va l ian t   Cap t iv ia   S ten t   G ra f t   Sy s tem   (Med t ron i c   in te rna l   da ta   u s ing   th e  
Va l ian t  E vo  p ropo sed  de f in i t ion ) .  
20 .  Un i ted   S ta te s   Gove rnmen t   A ccoun tab i l i ty   O f f i ce   (2010 )   Repo r t   to   Cong re ss iona l  
Reque s te rs :  FDA ’ s  Con s ide ra t ion  o f  E v iden ce  f rom  Ce r ta in  C l in i ca l  T r ia l s .  GAO -10 -798 ,  p  
17 .   
21 .  Wangge   G ,   K lunge l   OH ,   Roe s   KCB ,   de   Boe r   A ,   Hoe s   AW ,   e t   a l .   (2010 )   Room   fo r  
Imp ro vemen t  in  Condu c t ing  and  Repo r t ing  Non -In fe r io r i ty  Random ized  Con t ro l led  T r ia l s  on  
D rug s :  A  Sy s tema t i c  Re v iew .  PLoS  ONE  5 (10 ) :  e13550 .  do i :10 .1371 / jou rna l .pone .0013550  
22 .  Wh i te  RA ,  Foga r ty  TJ .  Pe r iphe ra l  endo va scu la r  in te rven t ion s .  2 nd  ed .  New  Yo rk :  Sp r inge r ;  
[ADDRESS_1183343] io tho ra c  Su rg .  Sep  2001 ;20 (3 ) :514 -519 .  
24 .  Da ke  MD ,  M i l le r  DC ,  M i t che l l  RS ,  e t  a l .  The  " f i rs t  gene ra t ion "  o f  endo va scu la r  s ten t -g ra f t s  
fo r  pa t ien t s   w i th  aneu ry sms  o f  the  de scend ing  tho ra c i c  ao r ta .  J  Tho ra c  Ca rd io va sc  Su rg .  
No v  1998 ;116 (5 ) :689 -703 ;  d i scu ss ion  703 -684 .    
25 .  Lamb re ch t s  D ,  Ca sse lman  F ,  S ch roeye rs  P ,  e t  a l .  Endova scu la r  t rea tmen t  o f  the  de scend ing  
tho ra c i c  ao r ta .  Eu r  J  Va sc  Endo va sc  Su rg .  Oc t  2003 ;26 (4 ) :437 -444 .    
26 .  O rend  KH ,  S cha r re r -Pam le r  R ,  Kap fe r  X ,  e t  a l .  Endova scu la r  t rea tmen t  in  d i sea se s  o f  the  
de scend ing  tho ra c i c  ao r ta :  6 -yea r  re su l t s  o f  a  s ing le  cen te r .  J  Va sc  Su rg .  Jan  2003 ;37 (1 ) :91 -
99 .      
27 .  E rbe l  R ,  Aboyan s  V ,  Bo i leau  C ,  e t  a l .  2014  ESC  Gu ide l ine s  on  the  d iagno s i s  and  t rea tmen t  
o f  ao r t i c  d i sea se s :  Do cumen t  cove r ing  a cu te  and  ch ron i c  ao r t i c  d i sea se s  o f  the  tho ra c i c  and  
abdom ina l   ao r ta   o f   the   adu l t .   The   Ta s k   Fo rce   fo r   the   D iagno s i s   and   T rea tmen t   o f   Ao r t i c  
D i sea se s  o f  the  Eu ropean  So c ie ty  o f  Ca rd io logy  (ESC ) .  Eu r  Hea r t  J  2014 ;35 :[ADDRESS_1183344]  Compu ted  Tomog raphy  
CVA  Ce reb ra l  Va scu la r  In c iden t  
CRO  C l in i ca l  Re sea rch  O rgan iza t ion   
DD  De v i ce  De f i c ien cy  
DMC  Da ta  Mon i to r ing  Comm i t tee  
DTA  De scend ing  Tho ra c i c  A o r ta  
DTAA  De scend ing  Tho ra c i c  Ao r t i c  Aneu ry sm  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  58  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 EC  E th i ca l  Comm i t tee   
eCRF  E le c t ron i c  Ca se  Repo r t  Fo rm  
EDC  E le c t ron i c  Da ta  Cap tu re  
FDA  Food  and  D rug  Adm in i s t ra t ion  
IB  In ve s t iga to r  B ro chu re  
ICU  In ten s i ve  Ca re  Un i t  
ICH -GCP  In te rna t iona l  Con fe ren ce  on  Ha rmon iza t ion  –  Good  C l in i ca l  P ra c t i ce  
IDE  In ve s t iga t iona l  Dev i ce  E xemp t ion  
IFU  In s t ru c t ion s  fo r  Use  
INR  In te rna t iona l  No rma l ized  Ra t io  
IPR  Independen t  phy s i c ian  rev iewe r  
IRB   In s t i tu t ion a l  Rev iew  Boa rd   
ISO  In te rna t iona l  O rgan iza t ion  fo r  S tanda rd iza t ion  
MAE  Ma jo r  Adve rse  Even t  
MDE  Ma jo r  Dev i ce  E f fe c t  
M I  Myo ca rd ia l  In fa rc t ion  
MRA  Magne t i c  Re sonan ce  Ang iog raphy  
MR I  Magne t i c  Re sonan ce  Imag ing  
PET  Po lye thy lene  te reph tha la te   
PMA  P rema r ke t  App rova l   
RA  Regu la to ry  A f fa i rs  
RAE  Regu la to ry  A f fa i rs  Eu rope  
ROP I  Repo r t  o f  P r io r  In ve s t iga t ion s  
SADE  Se r iou s  Ad ve rse  Dev i ce  E f fe c t  
SAE  Se r iou s  Ad ve rse  Even t  
SOP  S tanda rd  ope ra t ing  p ro cedu re  
TAA  Tho ra c i c  Ao r t i c  Aneu ry sm  
TEE  T ran se sophagea l  e cho ca rd iog raphy  
TEVAR  Tho ra c i c  Endova scu la r  Ao r t i c  Repa i r  
UADE  Unan t i c ipa ted  Ad ve rse  Dev i ce  E f fe c t  
[LOCATION_003]DE   Unan t i c ipa ted  Se r iou s  Adve rse  De v i ce  E f fe c t  
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  59  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 L .2  De f in i t ions  
 P r ima ry  and  Se conda ry  Endpo in ts  
Te rm  De f in i t ion  
A cce ss  fa i lu re  
 Inab i l i ty  to  in se r t  dev i ce  due  to  me chan i ca l  fa i lu re  o r  ana tom i c  
e xc lu s ion s  o f  the  femo ra l  o r  i l ia c  a r te r ie s  
Dep loymen t  Fa i lu re   
 Dep loymen t   fa i lu re   due  to   sub je c t   ana tomy   o r   me chan i ca l  
fa i lu re .  Th i s  spe c i f i ca l ly  re fe rs  to  dep loymen t  o f  the  s ten t  g ra f t  
f rom  the  de l i ve ry  sy s tem .  
Adve rse  Even t  (AE )  See  se c t ion  F .6 .1  
Se r iou s  Ad ve rse  Even t  
(SAE )  See  se c t ion  F .6 .1  
Ma jo r  Adve rse  Even t s  
(MAE s )  Ma jo r   Adve rse  even t s   in c lude   the   o ccu r ren ce   o f   any   o f   the  
fo l low ing  :  
• Re sp i ra to ry   comp l i ca t ions :   a te le c ta s i s /pneumon ia ,  
pu lmona ry   embo l i sm ,   pu lmona ry   edema ,   re sp i ra to ry  
fa i lu re .   
• Rena l  comp l i ca t ion s :  rena l  fa i lu re ,  rena l  in su f f i c ien cy .   
• Ca rd ia c   comp l i ca t ion s :   myo ca rd ia l  in fa rc t ion   (M I ) ,  
un s tab le   ang ina ,   new   a r rhy thm ia ,   e xa ce rba t ion   o f  
conge s t ive  hea r t  fa i lu re  (CHF ) .   
• Neu ro log i ca l  comp l i ca t ion s :   new   ce reb rova scu la r  
a cc iden t   (CVA ) ,  ce reb rova scu la r   embo l i c   e ven t s ,  
pa rap leg ia ,  pa rapa re s i s .   
• Ga s t ro in te s t ina l  comp l i ca t ion s :  bowe l  i schem ia .   
• Ma jo r   b leed ing   comp l i ca t ion   (p ro cedu ra l   o r   po s t -
p ro cedu ra l ) ,  coagu lopa thy .   
• Va scu la r   Comp l i ca t ion s :   ao r t i c   rup tu re ,   aneu ry sm  
rup tu re ,   hema toma   a t   a cce ss   s i te ,   p seudo   o r   fa l se  
aneu ry sm ,   a r te r io venou s   (AV )   f i s tu la ,   re t rope r i t onea l  
b leed ,  l imb  i schem ia ,  t h rombo s i s .  
See  de f in i t ion  o f  te rm s  in  se c t ion  L .2 .2  
Ma jo r  Dev i ce  E f fe c t s  
(MDE s )  Ma jo r   Dev i ce   E f fe c t s   in c lude   the   o ccu r ren ce   o f   any   o f   the  
fo l low ing :  
• De v i ce -re la ted  se conda ry  p ro cedu re s   
• De v i ce -re la ted  mo r ta l i ty  
• Conve rs ion  to  open  su rge ry  
• Tho ra c i c  Ao r t i c  Aneu ry sm  rup tu re  
De v i ce -re la ted  mo r ta l i ty  Any  dea th  re la ted  d i re c t ly  to  the  imp lan ta t ion ,  the  p re sen ce ,  o r  
ope ra t ion  o f  the  in ve s t iga t iona l  de v i ce  in  the  med i ca l  op in ion  
o f  the  C l in i ca l  Even t s  Comm i t tee  ( CEC ).    
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  60  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Te rm  De f in i t ion  
Dea th s  fo l low ing   c omp l i ca t ion s  tha t   a re  a sso c ia ted   w i th   the  
de v i ce  de s ign  a s  i t  re la te s  to  p la cemen t ,  e f f i ca cy  o r  du rab i l i ty  
(the se  may   invo l ve   the   imp lan ted   de v i ce   o r   the   de l i ve ry  
sy s tem ) ,  w i th  e ndo lea k ,  dev i ce  m ig ra t ion ,  and  fa i lu re  to  co ve r  
the  ao r t i c  in ju ry  are  in c luded  in  th i s  de f in i t ion .  
Pe r i -ope ra t i ve  mo r ta l i ty  A l l  dea th s  o ccu r r ing  in t ra -ope ra t ive ly  and  w i th in  30  day s  f rom  
the  p r ima ry  p ro cedu re   
A l l -cau se  mo r ta l i ty  Dea th  f rom  any  cau se  
Aneu ry sm -re la ted  
mo r ta l i ty  (ARM )  Any   dea th   o ccu r r ing   w i th in   30   day s   f rom   e i the r   the   in i t ia l  
p ro cedu re   o r   any   se conda ry   p ro cedu re   in tended   to   t rea t   the  
aneu ry sm  w i l l  be  con s ide red  ARM  un le ss  the re  i s  ev iden ce  to  
the  con t ra ry .  Add i t iona l ly ,  dea th s  o ccu r r ing  a s  a  con sequen ce  
o f   any   p ro cedu re  in tended   to   t rea t   the   ta rge ted   aneu ry sm ,  
aneu ry sm  rup tu re ,  o r  a  conve rs ion  to  open  repa i r  w i l l  a l so  be  
con s ide red  a s  ARM .   
U l t ima te  ad jud i ca t ion  o f  re la tedne ss  o f  dea th  w i l l  be  made  by  
[CONTACT_941]   C l in i ca l   E ven t s   Comm i t tee   (CEC ) .   E xc luded   a re  
aneu rysm s  in  ana tom i c  a rea s  o the r  than  the  ta rge ted  segmen t  
t rea ted  b y  the  Va l ian t  E vo  Tho ra c i c  S ten t  Gra f t  Sys tem .  
De v i ce -re la ted  
se conda ry  p ro cedu re  Any   se conda ry   p ro cedu re   tha t   i s   de te rm ined   by   [CONTACT_851096] s t iga to r  to  be  c lea r ly  re la ted  to  any  o f  the  imp lan ted  s ten t  
g ra f t  componen t s .   
U l t ima te   ad jud i ca t ion   o f   re la tedne ss   o f   se conda ry   p rocedu re  
w i l l  be  made  b y  the  C l in i ca l  E ven t s  Comm i t tee  (CEC ) .  
Se conda r y  p ro cedu re  Any   endova scu la r   o r   su rg ica l   p ro cedu re   pe r fo rmed   fo l low ing  
the  comp le t ion  o f  the  ope ra t ive  in i t ia l  imp lan ta t ion  p ro cedu re  
( thu s   on   sub sequen t   o cca s ion   a f te r   f ina l   c lo su re   o f   the   la s t  
a r te ry   a cce ss   s i te )   wh i ch   in vo lve s   the   ta rge ted   va scu la r  
segm en t   t rea ted   by   [CONTACT_851107] l ian t   Evo   Tho ra c i c   S ten t   G ra f t  
Sy s tem   in   wh i ch   the re   i s   e i the r   man ipu la t ion   o f   the   e x i s t ing  
Va l ian t  Evo  Tho ra c i c  S ten t  G ra f t ,  imp lan ta t ion  o f  any  add i t iona l  
s ten t  g ra f t  dev i ce s  o r  man ipu la t ion  o f  co ve red  b ran ch (e s )  by  
[CONTACT_851108]  s ten t  g ra f t s .  
Conve rs ion  to  open  
su rge ry  P r ima ry   Con ve rs ion :   Conve rs ion   f rom   endo va scu la r   to   open  
repa i r  requ i red  a t  the  t ime  o f  the  o r ig ina l  p ro cedu re ,  to  t rea t  the  
le s ion   in tended   to   be   t rea ted   w i th   the   Va l ian t   Evo  Tho ra c i c  
Sten t  Gra f t  Sy s tem .  
Se conda ry   Con ve rs ion :   Con ve rs ion   f rom   endova scu la r   to  
open  repa i r  requ i red  a t  a  t ime  beyond  the  in i t ia l  endova scu la r  
p ro cedu re ,  to  t rea t  the  le s ion  o r ig ina l ly  t rea ted  w i th  the  Va l ian t  
E vo  Tho ra c i c  S ten t  G ra f t  S y s tem .  
Tho ra c i c  Ao r t i c  
Aneu ry sm  rup tu re  Rup tu re  o r  pe r fo ra t ion  o f  the  ta rge ted  tho ra c i c  aneu ry sma l  sa c  
a s  de te c ted  by  [CONTACT_851109] ,  CT  s can ,  o r  d i re c t  ob se rva t ion  a t  
su rge ry  o r  au top sy .    
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  61  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Te rm  De f in i t ion  
Aneu rysm   rup tu re   shou ld   be   repo r ted   a s   e i the r   p rocedu re -
re la ted   aneu rysm   rup tu re   ( i .e . ,   pe r fo ra t ion   o f   the   an eu rysm  
du r ing  the  cou rse  o f  the  imp lan ta t ion  p ro cedu re )  o r  a s  a  la te  
aneu rysm  rup tu re  tha t  fo l lows  de v i ce  dep lo ymen t .   
E xc luded   a re   aneu rysm s   in   ana tom i c   a rea s   o the r   than   the  
ta rge ted   segmen t   t rea ted   b y   the   Va l ian t   E vo   Tho ra c ic   S ten t  
Gra f t  Sys tem .  
Aneu ry sm  e xpan s ion  Aneu ry sm  ma x imum  d iame te r  in c rea se  >  5  mm  a s  compa red  
to  the  1 -  mon th  con t ra s t  enhan ced  imag ing  mea su remen t s  
S ten t  g ra f t  m ig ra t ion  E v iden ce  o f  p ro x ima l  o r  d i s ta l  mo vemen t  o f  the  s ten t  g ra f t  (>10  
mm )  re la t i ve   to   f i xed   ana tom i c   landma r ks  (e .g .   sup ra   ao r t i c  
t run ks ,   coe l ia c   t run k ) ,   wh i ch   i s   no t   due   to   remode l ing   o f   the  
sub je c t ’ s  va scu la tu re .    
The   1 -mon th   imag ing   w i l l   be   u sed   a s   the   ba se l ine   fo r   th is  
de te rm ina t ion .  
Lo ss  o f  s ten t  g ra f t  
pa ten cy  De f ined  a s  a  100%  comp le te  b lo ckage  (o cc lu s ion )  o f  the  lumen  
d iame te r   o f   any   imp lan ted   s ten t   g ra f t   componen t (s )   a s  
e v iden ced  by  [CONTACT_4654] ,  ang iog raphy ,  u l t ra sound ,  o r  o the r  app rop r ia te  
imag ing  moda l i ty ,  and /o r  ope ra t ive  pa tho log i ca l  ana ly s i s .   
Endo lea k  De f ined  by  [CONTACT_941]  p re sen ce  o f  con t ra s t -enhan ced  b lood  ou t s ide  
the   lumen   o f   the   endo lum ina l   g ra f t   bu t   w i th in   the   aneu ry sm  
sa c .  Endo lea ks  a re  c la ss i f ied  a s  fo l low s :   
Type  I  a  –  Lea k  a t  the  p ro x ima l  g ra f t  a t ta chmen t  s i te  
Type  I  b  - Lea k  a t  the  d i s ta l  g ra f t  a t ta chmen t  s i te .  
Type  I  c  -  Lea k  a round  a  fene s t ra t ion ,  b ran ch  end  po in t ,  o r  
b ran ch   o cc lud ing   p lug   ( e .g . ,   p lug   o cc lud ing   a   sub c lav ian  
a r te ry  o r  i l ia c  a r te ry  to  p reven t  f low  in to  an  aneu ry sm  sa c ) .  
Type  I I  –  Re t rog rade  f low  f rom  b ran ch  a r te r ie s  a r i s ing  f rom  
the  e xc luded  segmen t .   
Type   I I I   a  –  Endo lea k   be tween   the   segmen t s   o f   the  
modu la r  g ra f t  ( jun c t iona l  endo lea k ) .   
Type   I I I   b  –  Endo lea k   in   the   m id -g ra f t   reg ion   due   to   the  
de fe c t  o f  fab r i c .  
Type  IV  –  T ran sg ra f t  lea k  due  to  fab r i c  po ro s i ty .   
Type   V  –  Aneu ry sm   en la rgemen t   in   the   ab sen ce   o f   any  
demon s t rab le  pe r fu s ion  o f  the  aneu ry sma l  sa c   
Type  unde te rm ined  - Endo lea k  o f  unde f ined  o r ig in  
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  62  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Ma jo r  Ad ve rse  E ven ts  (MAE s )  
Resp i ra to ry  comp l ica t ion s  
A te lec tas is  Co l lap se  o f  pa r t  o r  (mu ch  less  common ly )  a l l  o f  a  lung  cau sed  by  
a  b lo ckage  o f  the  a i r  pa ssage s  (b ron chu s  o r  b ron ch io le s )  o r  by  
p re ssu re  on  the  ou t s ide  o f  the  lung .  
C l in i ca l   ev iden ce   o f   a te le c ta s i s   i s   de te rm ined   by   [CONTACT_851110] s i ca l ,  
rad iog raph i c ,   and   labo ra to ry   f ind ing s   requ i r ing   t rea tmen t   w i t h  
an t ib io t i cs ,  inha la t ion  the rapy ,  in tuba t ion ,  o r  su c t ion ing .  
Pneumon ia  In f lamma t ion  o f  the  lung ,  usua l ly  cau sed  by  [CONTACT_851111] c t ion .  
C l in i ca l   e v iden ce   o f   pneumon ia   i s   de te rm ined   by   [CONTACT_851110] s i ca l ,  
rad iog raph i c ,   and   labo ra to ry   f ind ing s   requ i r ing   t rea tmen t   w i th  
an t ib io t i cs ,  inha la t ion  the rapy ,  in tuba t ion ,  o r  su c t ion ing .  
Pu lmona ry  embo l ism  Sudden  on se t  o f  p leu r i t i c  che s t  pa in ,  cough ,  hemop ty s i s ,  hypo x ia ,  
ta chy ca rd ia  and  a  po s i t i ve  ven t i la t ion /pe r fu s ion  (V /Q )  scan .  
Pu lmona ry  edema  Abno rma l  a ccumu la t ion  o f  f lu id  in  the  lung s .  
Resp i ra to ry  fa i lu re  The  need  fo r  ven t i la to ry  suppo r t  fo r  >72  hou rs  a sso c ia ted  w i th  an  
inab i l i ty  to  wean  f rom  the  re sp i ra to r  fo r  any  rea son .  
Rena l  comp l ica t ions  
Rena l  fa i lu re  Sudden   reve rs ib le   fa i lu re   o f   rena l   fun c t ion   cau sed   by   [CONTACT_851112] ,  
in te r rup t ion   o f   b lood   f low   to   the   k idney s ,   d i re c t   damage   to   the  
k idney 's  and /o r  sudden  ob s t ru c t ion  o f  u r ine  f low .  
Rena l  insu f f ic iency  S low ly  p rog re ss i ve  fa i lu re  o f  rena l  fun c t ion  re su l t ing  f rom  some  
d i sea se   (e .g . ,   d iabe te s ,   can ce r ,   hype r ten s ion ,  
g lome ru lo neph r i t i s )   tha t   cau se s   g radua l   de s t ru c t ion   o f   the  
k idney s  o r  i f  c rea t in ine  le ve l s  a re  ava i lab le ,  an  in c rea se  o f  >25%  
above  the  p re -p ro cedu re  c rea t in ine  leve l .  
Ca rd iac  comp l ica t ion s  
Myoca rd ia l  In fa rc t ion  
(M I )  • Non -Q - wa ve  M I  i s  de f ined  a s  e leva ted  CK  >  2X  the  uppe r  lab  
no rma l   w i th   the   p re sen ce   o f   e le va ted   CK -MB   (any   amoun t  
above  the  in s t i tu t ion s  uppe r  l im i t  o f  no rma l )  in  the  ab sen ce  o f  
new  pa tho log i ca l  Q  wa ve s .  
• Q   wa ve   myo ca rd ia l   in fa rc t ion   i s   de f ined   a s   de ve lopmen t   o f  
new ,  pa tho log i ca l  Q  wave s  in  2  o r  mo re  con t iguou s  lead s  (a s  
a sse ssed   by   [CONTACT_851113] )   w i th   po s t -p rocedu re  
CK   e leva t ion   >[ADDRESS_1183345] ia c  enzyme s .  
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  63  o f  73   
20 /OCT /[ADDRESS_1183346] ia c  a r re s t .  
Conges t ive  Hea r t  
Fa i lu re  (CHF )  Fa i lu re   o f   the   hea r t   to   pump   b lood   w i th   no rma l   e f f i c ien cy .  
De ve lopmen t  o f  an  a cu te  ep i sode  o f  o r  e xa ce rba t ion  o f  e x i s t ing  
low  ca rd ia c  ou tpu t  o r  f lu id   o ve r load   a ccompan ied   by   [INVESTIGATOR_5836] r iphe ra l  
and /o r  pu lmona ry  edema .  
Ce n t ra l  and  pe r iphe ra l  neu ro log ica l  comp l ica t ion s  
Ce reb rovascu la r  
acc iden t  (CVA )  /  S t roke  De f ined   a s   sudden   on se t   o f   ve r t igo ,   numbne ss ,   apha s ia ,   o r  
dy sa r th r ia   due   to   va scu la r   le s ion s   o f   the   b ra in   su ch   a s  
hemo r rhage ,  embo l i sm ,  th rombo s i s ,  o r  rup tu r ing  aneu ry sm ,  tha t  
pe rs i s ted  >24  hou rs .  
Ce reb rovascu la r  
Embo l ic  even t  The  ob s t ru c t ion  o f  a  b lood  ve sse l  f rom  the  b ra in  by  a  b lood  c lo t  
o r  fo re ign  sub s tan ce  (e .g .  a i r ,  fa t ,  ba c te r ia ) .  
Pa rap leg ia  Comp le te  lo ss  o f  mo to r  fun c t ion  in  the  lowe r  e x t rem i t ie s  and  lowe r  
po r t ion s  o f  the  t run k .  A  tho ra c i c  o r  lumba r  in ju ry  can   a f fe c t  leg ,  
bowe l  and  b ladde r  con t ro l  and  se xua l  fun c t ion .  
Pa rapa res is  M i ld  lo ss  o f  b i la te ra l  lowe r  ex t rem i ty  mo to r  fun c t ion ;  b i la te ra l  lowe r  
e x t rem i ty  wea kne ss .  
Gas t ro in tes t ina l  comp l ica t ions  
Bowe l  ischem ia  A  de c rea se  in  b lood  supp ly  to  e i the r  the  la rge  o r  sma l l  in te s t ine  
tha t   i s   a sso c ia ted   w i th   pa in ,   b leed ing ,   abdom ina l   d i s ten s ion ,  
d ia r rhea  o r  x -ray  o r  ang iog raph i c  ev iden ce  o f  redu ced  o rgan  f low .  
Ma jo r  B leed ing  comp l ica t ion s  
B leed ing ,  p rocedu ra l  A   b lood   lo ss   g rea te r   than   [ADDRESS_1183347] s  the  OR .  
Coagu lopa thy  The   de ve lopmen t   o f   an   abno rma l   b leed ing  d i so rde r   (e .g . ,  
D i ssem ina ted  In t rava scu la r  Coagu lopa thy  o r  Th rombo cy topen ia  
w i th   p la te le t   coun t s   o f   <   80 ,000 )   do cumen ted   by   [CONTACT_851114] r ia te  
labo ra to ry   s tud ie s   requ i r ing   the rapy   w i th   med i ca t ion   o r  
t ran s fu s ion .  
Vascu la r  comp lica t ion s  
Ao r t ic  rup tu re  The   tea r ing  apa r t   o f   the   ao r t i c   t i ssue .   S ign s   o f   ao r t i c   rup tu re  
in c lude   hemo tho ra x ,   un re len t ing   che s t   o r   ba ck   pa in ,   o r  
hypo ten s ion   re f ra c to ry   to   med i ca l   managemen t   fo r   a   pe r iod  
e xceed ing  two  (2 )  day s .  
Aneu rysm  rup tu re  See   de f in i t ion   o f   Tho ra c i c   Ao r t i c   Aneu ry sm   rup tu re   in   se c t ion  
L .2 .1 .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  64  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 Hema toma  a t  access  
s i te  An   abno rma l   lo ca l ized   co l le c t ion   o f   b lood   (c lo t ted   o r   pa r t ia l ly  
c lo t ted )   and   s i tua ted   a t   leve l   o f   a cce ss   s i te (s )   u sed   fo r  
endova scu la r  p ro cedu re .  
Pseudo  o r  fa lse  
aneu rysm  En la rgemen t s  o f  the  ao r ta ,  i l ia c  o r  femo ra l  a r te r ie s ,  wh ich  con ta in  
some   o r   a l l   o f   the   med ia l   laye r ,   the   adven t i t ia ,   and   pe r iao r t i c  
t i ssue ;  mo s t  common ly  a sso c ia ted  w i th  p re v iou s  ao r t i c  ope ra t ive  
p ro cedu re s ,   t rauma ,   and /o r   in fe c t ion .   P seudo -aneu ry sms  
typ i ca l ly  p re sen t  a s  a  we l l -de f ined  co l le c t ion  o f  b lood  ou t s ide  the  
ve sse l  wa l l  f rom  con ta ined  rup tu re .  
A r te r iovenous  
(AV )   f is tu la  Fo rma t ion  o f  an  abno rma l  conne c t ion  be tween  the  lumen s  o f  an  
a r te ry  and  a  ve in  a s  do cumen ted  by  [CONTACT_4654] ,  u l t ra sound ,  ang iog raphy  
o r  d i re c t  ob se rva t ion .  
Re t rope r i tonea l  b leed  B leed ing  in to  the  re t rope r i tonea l  spa ce  due  to  t rauma ,  su rge ry  o r  
pe rcu taneou s  pun c tu re  o f  an  a r te ry  o r  ve in .  
L imb  ischem ia  A   de c rea se   in   b lood   supp ly   to   e i the r   the   in fe r io r   o r   supe r io r  
l imb (s ) .  
Th rombos is  C lo t t ing   w i th in   a   b lood   vesse l   wh i ch   may   c au se   in f ra c t ion   o f  
t i ssue s  supp l ied  by  [CONTACT_851115] l ;  i t  may  be  o cc lu s ive  o r  a t ta ched  to  
the  ve sse l  o r  hea r t  wa l l  w i thou t  ob s t ru c t ing  the  lumen .  
 De v i ce  De f i c ien c ie s  
A s  de f ined  in  se c t ion  F.[ADDRESS_1183348] le ss  i t  re su l ted  in  an  Ad ve rse  Even t .  
L is t ing  o f  Dev ice  De f ic ienc ies  (DD )  ava i lab le  in  CRF  d rop  down  l is t  
Imp lan t  p ro cedu re -spe c i f i c  
DD  Inadequa te  labe l ing  
Inadequa te  pa ckag ing  
Use  E r ro r  (spe c i fy  :  No t  fo l low ing  IFU  dep loymen t  s teps ,  No t  
fo l low ing  IFU  ba i lou t  te chn ique  in s t ru c t ion s ,  Use  o f  a  de v i ce  
w i th  an  iden t i f ied  ma l fun c t ion )  
A cce ss  Fa i lu re  
In se r t ion  Fa i lu re  
De l i ve ry  D i f f i cu l ty  
De l i ve ry  Fa i lu re  
Dep loymen t  D i f f i cu l ty  
Dep loymen t  Fa i lu re  
D i f f i cu l ty  to  re lea se  t ip  cap tu re  
Fa i lu re  to  re lea se  t ip  cap tu re  
D i f f i cu l ty  to  remo ve  de l ive ry  sy s tem  
Fa i lu re  to  remo ve  de l ive ry  sy s tem  
De l i ve ry  sy s tem  componen t  b rea kage  (e .g . ,  hand le ,  shea th ,  
t ip ,  e t c . )  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  65  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 S ten t  g ra f t  In comp le te  Dep loymen t  (dev i ce  doe s  no t  fu l ly  
dep loy  in  ta rge t  a rea )  
M i sa l igned  Dep loymen t  
S ten t  g ra f t  In fo ld ing  
In comp le te  appo s i t ion /ma l -appo s i t ion  o f  p ro x ima l  s ten t  w i th  
ao r t i c  wa l l  (b i rd  bea k )  
S ten t  g ra f t  Imp rope r  p la cemen t  (M i sp la cemen t )  re la ted  to  
ma r ke r  in te rp re ta t ion ,  imp rope r  ma nu fa c tu r ing ,  phy s i c ian  
e r ro r  
Any  o the r  fa i lu re /ma l fun c t ion  o f  De l i ve ry  Sy s tem  du r ing  
p ro cedu re ,  spe c i fy :___________  
O the r  DD :  Use  E r ro r  –  Inapp rop r ia te  de v i ce  ove r  s iz ing  
Use  E r ro r  –  Inapp rop r ia te  de v i ce  ove r lap  
Use  E r ro r  –  O the r ,  spe c i fy :  _______  
In comp le te  sea l ing ,  no t  due  to  ana tomy  o r  d i sea se  
p rog re ss ion  
S ten t  gra f t  Fab r i c  po ro s i ty ,  no t  due  to  sub je c t ’ s  hepa r in iza t ion  
o r  o the r  an t i coagu lan t  med ica t ion  
S ten t  gra f t  Fab r i c  de fe c t  (spe c i fy :  s ten t  g ra f t  rup tu re ,  s ten t  
g ra f t  e x t ru s ion /  e ro s ion )  
S ten t  g ra f t  F ra c tu re  (Spe c i fy :  p ro x ima l  ba re  s ten t ,  w i re fo rm )  
S ten t  g ra f t  K in k ing *  
S ten t  g ra f t  Tw i s t ing *  
S ten t  g ra f t  D i la ta t ion  
S ten t  g ra f t  M ig ra t ion  
S ten t  g ra f t  Componen t  Sepa ra t ion  
S ten t  g ra f t  W i re  De ta chmen t  f rom  Fab r i c  (spe c i fy  lo ca t ion )  
Any  o the r  fa i lu re /ma l fun c t ion  o f  S ten t  g ra f t ,  spe c i fy :  ______  
*  No t  in ten t iona l  and  no t  due  to  ana tomy  o r  d i sea se  p rog re ss ion  
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  66  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  Add i t iona l  De f in i t ion s  
Te rm  De f in i t ion  
Land ing  zone s  o f  the  
tho ra c i c  ao r ta  
 
The  land ing  zone s  in  the  ao r ta  fo r  endova scu la r  s ten t ing  a re  
de f ined  a s  fo l low s :  
Zone   0  –  the   p ro x ima l   edge   o f   the   cove red   endog ra f t   l ie s  
p ro x ima l  to  the  d i s ta l  end  o f  the  innom ina te  a r te ry   
Zone  1  –  f rom  d i s ta l  end  o f  the  innom ina te  a r te ry  to  the  d i s ta l  
end  o f  the  le f t  common  ca ro t id  a r te ry   
Zone  2  –  f rom  the  d i s ta l  end  o f  the  le f t  common  ca ro t id  a r te ry  
to  the  d i s ta l  end  o f  the  le f t  sub c lav ian  a r te ry   
Zone  3  –  f rom  the  d i s ta l  end  o f  the  le f t  sub c lav ian  a r te ry  to  
the   end   o f   the   ao r t i c   a rch   cu rva tu re   (≤2   cm   o f   the   le f t  
sub c lav ian  a r te ry  w i thou t  co ve r ing  i t )   
Zone  4  –  p ro x ima l  e x ten t  o f  the  endog ra f t  i s  >2  cm  d i s ta l  to  
the  le f t  sub c la v ian  a r te ry  and  end s  w i th in  the  p ro x ima l  ha l f  o f  
the   de scend ing   tho ra c i c   ao r ta   (T6   app ro x ima t ing   the  
m idpo in t  o f  the  de scend ing  tho ra c i c  ao r ta )  
 
  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  67  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 L .3  Imag ing  Ma t r ix  
Ana tomy /S ten t  G ra f t  
I ssue  De te c ted  CT  w i th  
con t ra s t  CT  w i thou t  
con t ra s t  MR I  w i th  
con t ra s t  MR I  w i thou t  
con t ra s t  Ang iog ram / ,  
Ao r tog ram ,  and  
A r te r iog ram  
D iame te r  and  
Leng th  1 2 1 2 3 
S ten t  g ra f t  m ig ra t ion  1 2 1 2 2 -3  
S ten t  g ra f t  f ra c tu re  2 3 2 3 2 -3  
S ten t  g ra f t  k in k ing  2 3 2 3 2 -3  
Co l lap se  o f  s ten t  
g ra f t  2 3 2 3 2 -3  
S ten t  g ra f t  tw i s t ing  2 3 2 3 2 -3  
S ten t  g ra f t  pa ten cy  1 4 1 4 2 -3  
Endo lea ks  1 4 1 4 2 -3  
Fa l se  lumen  
pe r fu s ion  1 4 1 4 2 -3  
Occ lu s ion   1 4 1 4 2 -3  
S teno s i s  1 4 1 4 2 -3  
S ten t  G ra f t  Fab r i c  
De fe c t  1 4 1 4 2 -3  
1=  H igh ly  v i s ib le           2  =  v i s ib le             3  =  No t  ve ry  v is ib le  (p o ten t ia l  a r t i fa c t s )     4  =  Inv i s ib le  
 
L .4    Dev ice  Exp lan t  and  Re tu rned  P roduc t  Ins t ruc t ions  
EXPLANT  AND  AUTOPSY  PROCEDURE  FOR  ENDOVASCULAR  PAT IENTS  
SURGEON  AND  S ITE  RESPONS IB IL ITY  
 
NOTE :  P r io r i t y  shou ld  be  g iven  to  pa t ien t  hea l th  and  sa fe t y  a t  a l l  t ime s  du r ing  the  e xp lan t  
p ro cedu re .  
A .  I f  the  e xp lan t  i s  pa r t  o f  a  la te  conve rs ion  to  an  open -su rg i ca l  p ro cedu re ,  con s ide ra t ion  o f  
the  pa t ien t  i s  fo remo s t .  The  su rgeon  shou ld  remo ve  ONLY  the  endo va scu la r  p ro s the s i s ,  
damag ing  o r  a l te r ing  the  dev i ce  a s  l i t t le  a s  po ss ib le  ye t  p ro v id ing  op t ima l  su rg i ca l  ca re  to  
the  pa t ien t .  
B .  I f  the  e xp lan t  i s  pe r fo rmed  on  a  cadave r ,  the  su rgeon  shou ld  ca re fu l ly  v iew  the  ad ja cen t  
body  o rgan s  and  e xc i se  the  in ta c t  ao r ta  con ta in ing  the  endova scu la r  p ro s the s i s ,  inc lud ing  
1 cm  o f  t i ssue  ad ja cen t  to  the  p ro x ima l  and  d i s ta l  f i xa t ion  s i te s  to  fa c i l i ta te  h i s to log ica l  
a sse ssmen t .  
C .  I t  i s  impo r tan t  tha t  ca re  be  g iven  du r ing  the  co l le c t ion ,  hand l ing  and  e xam ina t ion  o f  the  
imp lan t  to  en su re  tha t  i t  i s  no t  damaged  o r  a l te red .  
• Pa r t i cu la r  ca re  shou ld  be  taken  to  a vo id  app ly ing  fo rce ,  t ra c t ion ,  o r  to rs ion  to  the  s ten t  
g ra f t  du r ing  the  e xp lan t .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  68  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 • Ca re  shou ld  be  e xe rc i sed  to  avo id  e xce ss i ve  man ipu la t ion  w i th  me ta l l i c  in s t rumen t s  a t  
the  p ro x ima l  and  d i s ta l  f i xa t ion  s i te s  wheneve r  po ss ib le .  
• S ten t  g ra f t  o r  po s t  mo r tem  spe c imen  shou ld  be  p la ced  in  fo rma l in  a s  i s .   Do  no t  
a t temp t  to  c lean  o r  remo ve  o rgan i c  deb r i s .  
D .  Us ing  the  E xp lan t  P ro cedu re  Ob se rva t ion  Fo rm  (UC200103088EN ) ,  the  phy s i c ian  shou ld  
a ccu ra te ly  and  fu l ly  do cumen t  the  e xp lan t  p ro cedu re  and  the  s ten t  g ra f t  e x  s i tu .  Any  
po ss ib le  t rauma  app l ied  to  the  de v i ce ,  e .g . ,  c lamp ing ,  tw i s t ing ,  to rs ion ,  o r  t ra c t ion  shou ld  
a l so  be  do cumen ted .  
• Phy s i c ian  ope ra t ion  no te s  ma y  a l so  be  u sed  to  do cumen t  the  p ro cedu re  and  the  
cha ra c te r i s t i cs  o f  the  s ten t  g ra f t  p r io r  to  and  a f te r  e xp lan t  f rom  the  body .  
• Ma rk  componen t s  tha t  sepa ra te  du r ing  e xp lan t .   A t ta ch  su tu re  o r  hemo c l ip  to  an te r io r  
s ide  and  on  the  p ro x ima l  end  fo r  p ro x ima l  cu f f s  and  d is ta l ly  fo r  d i s ta l  componen t s .  
E .  Fo l low  p ro cedu re s  f rom  E xp lan t  Re tu rn  In s t ru c t ion s  (UC200103091 )  in c luded  in  the  
e xp lan t  k i t  fo r  pa ckag ing  and  re tu rn  o f  de v i ce  to  Med t ron i c .  
EXPLANT  RETURN  INSTRUCT IONS  
1 .0  Comp le te  the  fo l low ing  fo rms :  
Exp lan t  P rocedu re  Obse rva t ion  Fo rm  (UC200103088EN )   Th i s  fo rm  i s  to  be  comp le ted  a t  
the  t ime  o f  the  e xp lan t  p ro cedu re .  
Exp lan t  Iden t i f ica t ion  Pee l -o f f  Labe ls  (UC200103089EN )   Us ing  pe rmanen t  in k ,  comp le te  
the  two  labe l s  p rov ided  in  the  k i t .   P la ce  one  comp le ted  labe l  on  the  inne r  p la s t i c  con ta ine r ,  
p la ce  the  se cond  comp le ted  labe l  on  the  ou te r  me ta l  con ta ine r .   
A i r  b i l l  (p re -p r in ted )    F i l l  in  sh ippe r  in fo rma t ion .  
2 .0  Se cu re  the  e xp lan t  in  the  exp lan t  k i t  fo r  sh ipp ing .   No te :   Med t ron ic  Mon i to rs /F ie ld  
Rep resen ta t ives  a re  no t  au tho r i zed  to  hand le  fo rma l in / fo rma ldehyde .  
• P la ce  the  e xp lan ted  dev i ce  and  any  a sso c ia ted  o rgan i c  t i ssue  in to  the  labe led  inne r  
p la s t i c  con ta ine r  in  a  10%  neu t ra l  bu f fe red  fo rma l in  (3 .7 -4%  Fo rma ldehyde )  so lu t ion  to  
ma in ta in  t i ssue  in teg r i ty .  (To  be  comp le ted  by  [CONTACT_851116] i ta l  s ta f f  on ly )  
No te :   Any  spe c imen  too  la rge  fo r  the  p rov ided  inne r  con ta ine r  may  be  sen t  in  any  
se cu re ly  c lo sed  con ta ine r  and  p la ced  w i th  p rov ided  pac k ing  in  the  me ta l  con ta ine r  and  
bo x .  
• Sea l  the  p la s t i c  con ta ine r  w i th  red  tape  (p rov ided  in  k i t ) .   The  tape  shou ld  be  s t re t ched  
c lo ckw i se  a round  the  cap  and  the  con ta ine r .   P la ce  p las t i c  con ta ine r  in to  the  ab so rben t  
bag .  
• P la ce  the  ab so rben t  bag  (w i th  p la s t i c  con ta ine r )  in s ide  the  labe led  me ta l  con ta ine r .   Fo ld  
the  top  f lap s  o f  the  ab so rben t  l in ing  o ve r  the  top  o f  the  p la s t i c  con ta ine r  and  se cu re  the  
bag  w i th  a  tw i s t  t ie  o r  cab le  t ie  (p ro v ided  in  k i t ) .   P la ce  l id  on  me ta l  can  and  sea l  w i th  the  
lo ck ing  r ing  p rov ided .   P la ce  the  can  in to  the  inne r  pa r t i t ion  o f  the  ca rdboa rd  bo x ,  and  
pu sh  in  the  co rne r  tab s  on  the  top  o f  the  pa r t i t ion  to  re ta in  the  can .  
• P la ce  the  comp le ted  Exp lan t  P rocedu re  Obse rva t ion  Fo rm ,  imp lan t  and  e xp lan t  
ope ra t i ve  repo r t s ,  and  any  rad io logy  fo l low -up  repo r t s  ( i f  a va i lab le ) ,  in s ide  the  mo i s tu re -
re s i s tan t  p la s t i c  bag  p rov ided ,  and  p la ce  in to  the  bo x .  
No te :   A  Re co rd  o f  D i sc lo su re  o f  Hea l th  In fo rma t ion  fo r  Pub l i c  Pu rpo se s  i s  in c luded  fo r  
you r  con ven ien ce  and  can  be  p la ced  in  the  pa t ien t s  f i le .  
Se cu re ly  sea l  the  bo x  w i th  c lea r  tape  (p rov ided  in  k i t ) .   A f f i x  the  sh ipp ing  a i rb i l l  to  the  
ou t s ide  o f  the  bo x .    
• A r range  fo r  p i ckup  f rom  Sh ipp ing  Company .    
I f  you  ha ve  que s t ion s  abou t  sh ipp ing  the  dev i ce ,  need  add i t iona l  in fo rma t ion ,  o r  de s i re  add i t iona l  
E xp lan t  K i t s ,  p lea se  con ta c t  the  E xp lan t  Depa r tmen t ,  a t  (707 )  591 -7672  o r  1 - 800 -465 -5533 ,  Op t ion  3 .  
Than k  you  fo r  comp le t ing  the  E xp lan t  Fo rms  and  re tu rn ing  the  dev i ce .   Med t ron i c  u se s  th i s  
in fo rma t ion  to  mee t  FDA  requ i remen t s  and  t ra ck  p roduc t  pe r fo rman ce .  
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  69  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
  EXPLANT  PROCEDURE  OBSERVAT ION  FORM  
 
PAT IENT  INFORMAT ION  
P a t i e n t  IDE /  S tu dy  ID _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
N am e :_ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
DOB  (Mon th /Day /Y ea r ) :   _ _ _ _ _ /_ _ _ _ _ /_ _ _ _ _  
  
IMPLANT  INFORMAT ION   
D a t e  o f  Imp l a n t :  _ _ _ _ _ /__ _ _ _ /_ _ _ _ _  
Imp l a n t ing  Phy s i c i a n :  _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Imp l a n t ing  H o sp i t a l  N am e :  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
C i ty  a n d  S t a t e :  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Co u n t ry :  _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
EXPLANT  INFORMAT ION  
D a t e  o f  E xp l a n t /A u to p sy :  _ _ _ _ _ /_ _ _ _ _ /_ _ _ _ _  
E xp l a n t in g  Phy s i c i a n :  _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
N am e  o f  H o sp i t a l :  _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   
A d d r e s s :  _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
C i ty  a n d  S t a t e :  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _                                
Co u n t ry :  _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _    
T e l e p h o n e :  (         ) _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
REASON  FOR  EXPLANT  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
  P l a n n e d  Su r g i c a l  Co n v e r s io n  
  Em e rg e n t  Co n v e r s i o n   
  A u to p sy  D a t e  o f  D e a th :  _ _ _ _ /_ _ _ _ /_ _ _ _   
 
R em a r k s  a b o u t  p r o c e d u r e :    
 
   
 
   
 
   
 
   
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  70  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
   E v id e n c e  o f  in f l amm a t io n      Y e s    N o 
 Comm e n t s :_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
T h r omb o s i s  p r e s e n t  in  th e  s e a l zo n e s     Y e s    N o 
 Comm e n t s :_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
C a l c i f i c a t io n  p r e s e n t  in  th e  s e a l zo n e s     Y e s    N o 
 Comm e n t s :_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
H ow  w e l l  w a s  th e  d e v i c e  a t t a c h e d  to  th e  p a t i e n t ’ s  t i s su e ?  
P r o x im a l ly :   Com e s  o u t  e a s i ly  f r om  a o r t i c  v e s s e l  
   A p p e a r s  f i rm ly  a t t a c h ed  to  a o r t i c  v e s s e l    
M id  body :    Com e s  o u t  e a s i ly  f r om  a n e u ry sm  c o n t e n t s    
   A p p e a r s  f i rm ly  a t t a c h ed  to  a n e u ry sm  c o n t e n t s  
D i s t a l ly  (L ) :    Com e s  o u t  e a s i ly  f r om  i l i a c / a o r t i c  v e s s e l  
   A p p e a r s  f i rm ly  a t t a c h ed  to  i l i a c / a o r t i c  v e s s e l    
D i s t a l ly  (R ) :   Com e s  o u t  e a s i ly  f r om  i l i a c / a o r t i c  v e s s e l  
   A p p e a r s  f i rm ly  a t t a c h ed  to  i l i a c / a o r t i c  v e s s e l  
  
Comm e n t s  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
Su c c e s s f u l  Su rg i c a l  Co nv e r s io n :     Y e s     N o  
 
P a t i e n t  O u t c om e :     A l iv e    E xp i r e d  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  71  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 EXPLANTED  DEV ICE  INFORMAT ION  
 
DEV ICE  CATALOG  NUMBER  LOT  NUMBER  
B i fu rca ted  Bod y  
       D i s ta l  Le f t  
       D i s ta l  R igh t    
Con t ra la te ra l  L imb    
 
I l ia c  E x ten s ion  
       Le f t  
       R igh t    
I l ia c  E x ten s ion  
       Le f t  
       R igh t    
I l ia c  E x ten s ion  
       Le f t  
       R igh t    
Ao r t i c  Cu f f    
 
AU I  
       D i s ta l  Le f t  
       D i s ta l  R igh t    
 
Tho ra c i c ,  P ro x ima l  Ma in    
 
Tho ra c i c ,  D i s ta l  Ma in    
 
Tho ra c i c ,  D i s ta l  Ma in    
 
Tho ra c i c ,  P ro x ima l  E x ten s ion  
   
Tho ra c i c ,  D i s ta l  E x ten s ion    
 
O the r  (Spe c i fy )    
 
Add i t iona l  Commen ts  
 
 
 
 
 
Fo rm  comp le ted  by :   ________________________  
 
T i t le :  _____________________________________  
 
Da te :  _________________  
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  72  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 L .5  In fo rmed  Consen t  Temp la te  
 
L .6  Pos t  PMA -S  app rova l  Ana lys is  
Fo l low ing  PMA -S  app rova l ,  the  po s tma r ke t  e va lua t ion  w i l l  be  condu c ted  and  re su l t s  p ro v ided  to  
the  FDA  on ce  the  la s t  sub je c t  in  the  s tudy  comp le te s  the  12 -mon th  fo l low -up  v i s i t .   
 
A  synop s i s  o f  th i s  po s t -app ro va l  p ropo sa l  a long  w i th  s ta t i s t i ca l  a ssump t ion s  i s  p re sen ted  in  Tab le  
L -1  be low .   Med t ron i c   ha s   u sed   i t s   e xpe r ien ce   w i th   Va l ian t   Cap t iv ia   in   pa t ien t s   w i th   DTAA   to  
e s tab l i sh  the  a ssump t ion s  u sed  in  the  s ta t i s t i ca l  de s ign  o f  th i s  s tudy .  The  VALOR  I I  s tudy  w i th  
the  Va l ian t  sten t  gra f t  sy s tem   e n ro l led  160  pa t ien t s   w i th  DTAA  and   wa s  a sse ssed  th rough  12  
mon th s   fo r   pu rpo se s   o f   PMA   (P100040 )   app rova l .  Th rough  1 - yea r  po s t -t rea tmen t ,   the  ra te   o f  
MDE s  comb ined  w i th  a ccess  and /o r  dep loymen t  fa i lu re s  wa s  7 .1%  (11 /153 )  (Med t ron i c  in te rna l  
da ta   u s ing   the   Va l ian t   Evo   p ropo sed   de f in i t ion ) .   The re fo re ,   fo r  the   pu rpo se  o f   po s t   app rova l  
ana ly s i s ,  the  ra te  o f  MDE s  comb ined  w i th  a cce ss  and  dep loymen t  fa i lu re s  a t  1 - yea r  w i th  Va l ian t  
E vo  i s  e s t ima ted  to  be  7 .1 %  ( re fe r  to  Tab le  L -1  be low  fo r  powe r  ana ly s i s  a ssump t ion s ) .  
Tab le  L -1 :  Powe r  Ana lys is  Assump t ions  fo r  Eva lua t ion  o f  Va l ian t  Evo  in  Pa t ien ts  w i th  
DTAA  a t  1 -yea r  
E s t ima ted  ra te  o f  MDE s  comb ined  w i th  
a cce ss  and /o r  dep loymen t  fa i lu re s  a t  1  
yea r   w i th  Va l ian t  Evo  7 .1%  
Pe r fo rman ce  Goa l  (PG )  a t  1 -yea r  20%  
S ign i f i can ce  leve l  0 .05  
S ta t i s t i ca l  te s t  One -s ided  b inom ia l  te s t  
E va luab le  samp le  s ize  N  =  [ADDRESS_1183349]  a  m in imum  o f  63  
e va luab le  sub je c t s  a t  1 -yea r  fo l low  up .  
S ta t i s t i ca l  powe r  f rom  63  o r  mo re  e va luab le  
sub je c t s  92%  (ove ra l l  s tudy  powe r  fo r  pa ss ing  bo th  
hypo the se s  i s  81% )  
 
L .7  CMS  S tudy  C r i te r ia  
Med i ca re  bene f i c ia r ie s  may  be  a f fe c ted  by  [CONTACT_851117] i ce  be cau se  in  2013  mo re  than  63%  o f  TEVAR  
ca se s  we re  pe r fo rmed  in  Med i ca re  bene f i c ia r ie s ,  and  59%  o f  c la ims  w i th  p r in c ipa l  TAA  d iagno se s  
invo lve   pa t ien t s   age   65   o r   o lde r .   S tudy   re su l t s   a re   e xpe c ted   to   be   gene ra l izab le   w i th in   the  
Med i ca re  bene f i c ia ry  popu la t ion  ba sed  on  the  p reva len ce  o f  TAA  in  pa t ien t s  age  65  and  o lde r .  
 
A l l  IRB s  shou ld  comp ly  w i th  45  CFR  pa r t  46 .  
 
 
 
 
 
 
 
  C l in ica l  Inves t iga t ion  P lan  
 
 
   
Ve rs ion  1B   1021949 8DOC  Page  73  o f  73   
20 /OCT /2017  Va l ian t  E vo  US  C l in i ca l  T r ia l  056 -F275 ,  v3 .0  C l in i ca l  
In ve s t iga t ion  P lan  Temp la te   
 Med t ron i c  Con f iden t ia l   
 M   VERS ION  H ISTORY  
Ve rs ion  Summa ry  o f  Changes  Au tho r (s ) /T i t le  
1A  • No t  App l i cab le ,  New  Do cumen t   
 
1B  • Synop s i s  upda te  w i th  schedu le  o f  e ven t s  
fo r  e x tended  fo l low -up   
•  E x tended  the  fo l low  o f  sub je c t s  f rom  12  
mon th s  to  60  mon th s  
• Adm in i s t ra t ive  change s  l i ke  co r re c t ion  o f  
typo ’ s ,  fon t  type s  and  a l ignmen t s ,  
in teg ra t ion  o f  upda ted  co rpo ra te  temp la te   
 
 